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Step into this room and dance
hoose, loose
Pull out your arsenal
And Dance
This is the floor, these are the rules, these are the moves
This is the room in which we dance
Close the floor, say you will
Dance
Madrugada, "The Nightly Disease"
Aan mijn moeder
Nijkeuter_V4.indd   5 02-05-2007   15:09:12
Nijkeuter_V4.indd   6 02-05-2007   15:09:12
Contents
Chapter 1.  General introduction and outline of this thesis
  
Chapter 2.   Diagnostic methods in pulmonary embolism
   
Chapter 3.   Effectiveness of managing suspected pulmonary embolism using an 
algorithm combining clinical probability, D-dimer testing, and computed 
tomography (the Christopher-study)
   
Chapter 4.    Excluding pulmonary embolism by non-imaging tests; the effect of varying 
cut-off levels of a clinical decision rule and D-dimer test on safety and 
clinical utility  
   
Chapter 5.    The distribution of subsegmental pulmonary emboli in multi- and single-
detector row computed tomography
  
Chapter 6.   The natural course of pulmonary embolism; clinical outcome and risk 
factors in a large prospective cohort study
   
Chapter 7.    Excluding clinically suspected recurrent pulmonary embolism: a diagnostic 
challenge
   
Chapter 8.    Resolution of thrombo-emboli in patients with acute pulmonary embolism
   
Chapter 9.   Diagnosing pulmonary embolism in pregnancy: rationalizing fetal 
radiation exposure in radiological procedures
   
Chapter 10.    Diagnostic management of deep vein thrombosis and pulmonary embolism 
in pregnancy 
 






Nijkeuter_V4.indd   7 02-05-2007   15:09:13
A pulmonary embolism (PE) comprises a sudden lodgement of a blood clot in a pulmonary 
artery with subsequent obstruction of blood supply to the lung parenchyma. Depending 
on the size and length of the embolic mass, it may occlude the main pulmonary artery, 
impact astride the bifurcation (a saddle embolus) or pass out into the progressively smaller 
branching pulmonary arteries. These pulmonary blood clots arise for more than 95% from 
thrombi within the large deep veins of the lower legs (popliteal, femoral or iliac veins). 
Hence, deep vein thrombosis (DVT) and PE are regarded as different expressions of a 
single clinical entity called venous thrombo-embolism (VTE).  
The first description of PE is attributed to Laennec in 1819 but in 1846, Virchow, a well 
known pathologist, was the first to recognize that blood clots in the pulmonary artery 
originate as venous thrombi1. He stated: “The detachment of larger or smaller fragments 
from the end of the softening thrombus which are carried along by the current of blood 
and driven into remote vessels. This gives rise to the very frequent process on which I have 
bestowed the name of Embolia”. The term “pulmonary emboli” was born. 
Pulmonary embolism is a potentially fatal disease of which early recognition and institution 
of anticoagulant treatment can prevent mortality. Due to the diversity and aspecificity of signs 
and symptoms of pulmonary embolism, varying from asymptomatic pulmonary embolism 
to haemodynamic instability and shock, clinical recognition is notoriously inaccurate. Post-
mortem studies have shown that the majority of cases of pulmonary embolism detected were 
not diagnosed prior to deatz2. Therefore, to demonstrate or refute the diagnosis, objective 
diagnostic tests are mandatory in patients with a clinical suspicion of PE. 
It has only been since forty years that a diagnosis of PE can be objectively diagnosed and 
physicians need not rely solely on their clinical judgement of the presence or absence of PE. 
In 1963, Williams and Sasahara published a landmark study of pulmonary angiography 
as a diagnostic tool in diagnosing PE3;4. The armamentarium has been expanded with the 
introduction of perfusion scintigraphy in 1964 and ventilation scintigraphy in 19685;6. 
The major concerns leading to a continued search for better diagnostic tools were the 
invasiveness and consequently complications of pulmonary angiography as well as the 
high percentage (40-60%) of non-conclusive ventilation perfusion (VQ) scans.  
A promising diagnostic tool, of which the first clinical report appeared in 1992, is helical 
computed tomography (CT)7. This method provides a series of images of the thorax in 
the transverse plane enabling to view all intra-thoracic structures. In order to visualize 
the pulmonary arteries, it requires intravenous injection of iodinated contrast agent via an 
antecubital vein during scanning. Helical CT has clear advantages, i.e. direct visualisation of 
thrombus as an intra-luminal filling defect, the possibility of making an alternative diagnosis, 
a rapid scanning time (less than 30 seconds), wide availability and excellent inter-observer 
agreement8;9. The percentage of inconclusive CT scans is low, but radiation exposure is higher 
compared to ventilation-perfusion scintigraphy. Moreover, allergic reactions to contrast agents 
occur in a small percentage of patients as well as contrast medium-induced nephropathy10. 
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Chapter 1
A diagnostic algorithm based on helical CT has gained widespread interest due to the 
common availability of helical CT. These algorithms have however often been implemented 
without appropriate assessment in clinical practice11. 
Another step forward was the development of clinical prediction rules and D-dimer tests 
in the nineties. They’re advantageous because of the possibility of limiting the requirement 
for objective diagnostic tests such as ventilation-perfusion scintigraphy or helical CT. 
Clinical prediction rules categorize patients with a clinical suspicion of pulmonary 
embolism into a low, intermediate and high pre-test probability of pulmonary embolism. 
Although implicit clinical assessment empirically has been shown to be reasonably 
accurate, the advantage of a clinical prediction rule is the rapid bedside stratification of 
likelihood of PE by a more standardized approach. 
D-dimers are degradation products of cross-linked fibrin that are released when a 
thrombus is degraded by fibrinolysis. D-dimer tests are rapid and widely available tests 
with high sensitivity and negative predictive value (97-100%). However, D-dimer tests are 
not specific (specificity of approximately 35 - 45%) due to enhanced fibrinolysis in several 
other conditions (malignancy, infection, high age, postoperative state, pregnancy). 
Several studies have demonstrated that it is safe to exclude pulmonary embolism in 
patients with a low pre-test probability of pulmonary embolism combined with a normal 
D-dimer test12-14. Using such an approach, more invasive radiological imaging tests are 
obviated in 15-47% of patients suspected of PE.
An overview of the diagnostic tools available to diagnose or exclude pulmonary embolism 
in patients with clinically suspected PE is given in Chapter 2.









Aims of the studies and outline of the thesis
Several questions remain regarding the clinical utility of the combination of a clinical 
prediction rule and D-dimer as well as regarding helical CT. A retrospective analysis 
suggested that the clinical utility of the Wells score could be further increased by using 
two, instead of three categories of clinical probability, dichotomising patients either 
into ‘unlikely’ or ‘likely’ to have pulmonary embolism. However, no large, prospective 
studies have been carried out to evaluate this dichotomization. Furthermore, it is 
currently unknown whether the diagnosis of pulmonary embolism can be excluded, and 
anticoagulant treatment withheld, on the basis of a negative helical CT alone, without 
performing additional tests. 
Our first aim was to investigate whether patients with a clinical suspicion of PE could 
be safely left untreated on the basis of a clinical decision rule indicating ‘PE unlikely’ 
combined with a normal D-dimer test. Our second aim was to evaluate whether helical 
CT could be used as a sole test to exclude PE in patients with a clinical suspicion of PE 
with either a clinical decision rule indicating ‘PE likely’ or an abnormal D-dimer test in 
patients indicated as ‘PE unlikely’. To answer these questions, the Christopher-study was 
designed, a prospective management-study performed in 12 hospitals in the Netherlands 
between November 2002 and September 2004. It evaluated a diagnostic algorithm of 
sequential application of clinical decision rule, D-dimer tests and helical CT. The results 
of the Christopher-study are described in Chapter 3. 
Due to the non-specificity of clinical signs and symptoms of PE, only 20-30% of patients 
with clinically suspected PE do have the disease. Ideally, a simple non-invasive test 
without radiation exposure and with low costs excludes a diagnosis of PE in the 70-80% 
of patients with a clinical suspicion of PE who do not have the disease. Excluding PE by 
non-invasive tests has been simplified by the introduction of the Wells clinical decision 
rules and quantitative D-dimer assays. These tests use fixed cut-off levels, i.e. a score of 4 
to categorize patients into ‘PE unlikely’ or ‘PE likely’ and a cut-off level of 500 ng/ml to 
categorize a D-dimer test as ‘normal’ or ‘abnormal’. Our third aim was to analyse whether 
the cut-off levels of the clinical decision rule as well as the D-dimer test could be varied 
to increase the clinical utility in excluding pulmonary embolism (Chapter 4). 
The safety of excluding PE on the basis of a normal helical CT has been the subject of 
debate over the past years since the accuracy of CT has been reported to be only 70%. The 
reason for the low accuracy is believed to be the limited reliability of detecting small emboli 
in subsegmental arteries. The advent of multi-row detector CT (MDCT) is thought to 
increase the detection rate at the subsegmental artery level. In the Christopher-study, we 
used single (SDCT)- as well as multi-row detector systems and therefore, our fourth aim 
was to analyse whether the prevalence of subsegmental PE differed between the two CT 
systems (Chapter 5).
Patients diagnosed with PE are treated with oral anticoagulants for a period of at least 
three months. Despite treatment, some patients experience a recurrent thrombo-embolic 
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event, while others experience side effects from treatment, i.e. major or minor bleeding 
events. Our fifth aim was to evaluate within the Christopher-study the natural course 
of hemodynamically stable patients diagnosed with PE and to assess the incidences of 
recurrent venous thrombo-embolism, bleeding and mortality. Our sixth aim was to identify 
risk factors for these events as well as the time course of these events (Chapter 6). 
In many diagnostic studies of pulmonary embolism, patients with a clinical suspicion of 
PE are eligible, without discriminating patients with or without a prior history of PE. No 
study has reported on the safety of withholding anticoagulant therapy on the basis of normal 
diagnostic tests in patients with a clinical suspicion of recurrent PE. The consequences 
of misdiagnosis of recurrent PE are major. Incorrectly concluding that recurrent PE is 
present exposes the patient to prolonged - and often life-long- anticoagulation with its 
attendant costs, inconvenience, and bleeding risks. Incorrectly concluding that recurrent 
PE is absent puts the patient at high risk of ongoing PE, which may be fatal. Our seventh 
aim was to analyse the safety of the diagnostic algorithm used in the Christopher-study to 
exclude clinically suspected recurrent PE in patients with a history of PE (Chapter 7). 
Patients diagnosed with a first episode of pulmonary embolism are usually treated for 
six months with anticoagulant therapy. It is unknown whether all pulmonary clots have 
resolved by the end of treatment. Our eighth aim was to review the literature to establish 
evidence concerning rate of resolution of pulmonary clots six months after diagnosis of 
PE (Chapter 8).    
Pregnancy is a common exclusion criterion for studies on diagnostic tests in patients 
with a suspicion of PE. It is generally thought that helical CT exposes the fetus to more 
radiation exposure than VQ scintigraphy. Our nineth aim was to investigate whether fetal 
radiation exposure is indeed higher in helical CT compared to VQ scintigraphy (Chapter 
9). Moreover, our tenth aim was to scrutiny the literature in order to evaluate the evidence 
concerning performance of diagnostic tests in pregnancy for a clinical suspicion of DVT 
and PE (Chapter 10). 
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Diagnosing pulmonary embolism is challenging since clinical signs and symptoms are 
non-specific. The diagnostic tests available for demonstrating pulmonary embolism all 
have their drawbacks and are often costly and consume considerable amounts of resources. 
Simple tools that have become available in the last several years include clinical prediction 
rules and D-dimer testing. Assessment of the clinical probability, combined with a D-
dimer test can limit the need for additional diagnostic tests by 30%. For outpatients with 
a normal, sensitive ELISA D- dimer test and a low to moderate clinical probability, PE 
can safely be ruled out. Pulmonary angiography, though still the gold standard, is rarely 
used nowadays because of its invasiveness, its high costs and limited availability, and the 
declining experience of radiologists with the technique. Two imaging techniques, i.e. lung 
scintigraphy and helical CT are the diagnostic methods of choice. A normal perfusion 
lung scan can safely exclude PE. However, 55-65 % of patients have indeterminate lung 
scan results, making additional imaging tests necessary. Helical CT is increasingly being 
used as the first-line test because it can directly visualise a thrombo-embolus, it can suggest 
an alternative diagnosis, and there is excellent inter-observer agreement. A normal helical 
CT, followed by compression ultrasonography of the leg veins, can safely rule out PE. 
Finally, the safety of withholding anticoagulant treatment from patients with a normal 
multi-row detector helical CT as the sole test has not yet been demonstrated.
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Diagnosing pulmonary embolism (PE) is challenging. Because a wide spectrum of 
symptoms is possible, the clinical diagnosis is non-specific. There is a clinical suspicion 
of PE in 1-2 per 1000 inhabitants but in only 20-30% of patients the diagnosis can be 
confirmed1;2. Because pulmonary emboli are potentially fatal, a proper diagnosis is essential 
and sensitive diagnostic testing is, therefore, mandatory. If PE is diagnosed, anticoagulant 
therapy should be started although this is associated with a chance of serious bleeding 
complications. It has been estimated that 3-4% of patients face major bleeding during 
heparin therapy3;4. In observational studies, the use of warfarin with an INR 2.0-3.0 has 
been associated with an annual incidence of major bleeding ranging from 5 to 9%5. In a 
recent randomised trial, an annual incidence of major bleeding of 3.8% was observed in 
patients receiving full dose warfarin therapy, despite careful on-site monitoring6. It has 
been estimated that less than 5% of patients will present with massive PE with circulatory 
instability.  In this situation, echocardiography is generally the most appropriate and fast 
approach and treatment will consist of intravenous thrombolytic therapy7. The diagnostic 
tests available for demonstrating pulmonary embolism in hemodynamically stable patients 
all have their drawbacks and are often costly and consume considerable resources. The aim 
of this article is to give an overview of the diagnostic tools used in patients with a clinical 
suspicion of non-massive PE.
Clinical diagnosis
A clinical suspicion of PE is raised when a patient complains of acute dyspnea without an 
apparent cause. Other symptoms are acute (pleuritic) chest pain worsening with breathing and 
less frequently cough, hemoptysis or fainting. “Classic” signs of PE on physical examination 
are tachycardia, pleuritic rub, an accentuated pulmonic component of the second heart 
sound and neck vein distention. However, all these symptoms and signs are non-specific and 
inconsistently found in patients with PE, necessitating further diagnostic work-up8. 
Measuring arterial blood gases to demonstrate hypoxaemia is of little diagnostic use in 
PE. Blood gases are normal in 15% of patients with proven PE9. Classic abnormalities 
found on an electrocardiogram include sinus tachycardia, an S wave in lead I, a Q wave 
and an inverted T wave in lead III and T-wave inversion in leads V1 to V4 indicating 
right ventricular strain. These signs are, however, also non-specific for PE. A chest X-
ray is only useful in demonstrating an alternative diagnosis (pneumonia, pneumothorax, 
heart failure) to explain the patient’s complaints. Signs found on chest x-ray in patients 
with PE that are suggestive, but not specific, include focal oligemia (Westermarks’s sign), 
a peripheral wedged-shaped density above the diaphragm indicating lung infarction 
(Hampton’s hump) or an enlarged right descending pulmonary artery (Palla’s sign). 
Clinical prediction rule 
The assessment of pre-test probability of PE allows categorization of patients suspected of 
PE in low, intermediate and high clinical probability corresponding to a prevalence of PE 
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of 10% (low clinical probability), 30-40% (intermediate probability) and 70-80% (high 
clinical probability)10. Assessment of the clinical probability, combined with a D-dimer 
test, can limit the need for additional diagnostic tests by 30%2.  Until recently, grouping 
patients into low, intermediate and high clinical probability of PE had been done with 
implicit assessment empirically. An implicit assessment of clinical probability was used in 
seven studies. In the low, moderate and high pre-test categories, the rates of PE ranged 
from 8-19%, 26 to 47% and 46 to 91%, respectively (Table 1)11. 
Table 1
Accuracy of Pretest Probability Assessment for PE using implicit diagnosis
Source No. %PE Category Est.Prob No Act.Prob%




























































Est.Prob=Estimated probability, Act.Prob=Actual probability
Although implicit evaluation yield a reasonably good accuracy, this way of categorizing 
patients is subject to inter-observer variability12;13;14. A more standardized approach to 
scoring clinical probability is the Wells’ score15. This prediction rule was derived from 
a cohort of 1260 in- and outpatients with suspected PE. Of 40 variables assessed as 
potential predictors, only 7 were found to be independently associated with the presence 
of PE (Table 2). Points for the clinical prediction rule were assigned by doubling the 
value of the regression coefficients and rounding to the nearest 0.5. Subsequently, cut-off 
points were created to classify patients into low, moderate and high probability of PE with 
corresponding rates of PE of 3%, 28% and 78%, respectively15. In the validation study, the 
corresponding rates of PE were 2%, 18.8% and 50% respectively15.  
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Heart rate > 100/min 1.5
Previous PE or DVT 1.5
Recent surgery or immobilization 1.5
Clinical signs of DVT 3
Alternative diagnosis less likely than PE 3
Clinical probability: low 0-1, intermediate 2-6, high ≥ 7 points
PE unlikely: 0-4, PE likely >4
In addition, a cut-off score was determined to be designated ‘PE unlikely’ such that a 
negative D-dimer in these patients would result in a rate of PE close to 2%. A score of ≤4 
or less in combination with a negative D-dimer resulted in a rate of PE of 1.7% (95%CI: 
0.2-6.0%)15.
Another prediction rule, the Geneva score, was developed from a database of 
1090 consecutive patients admitted to the emergency ward with suspected PE16. 
Logistic regression identified 7 variables independently associated with PE (Table 
3). Patients with a low clinical probability (score 0-4) had a prevalence of PE of 10%, 
while those with an intermediate probability (score 5-8) had a prevalence of 38% 




Previous PE or DVT 2
Heart rate > 100/min 1
Recent surgery 3
Age, y
    60-79 1
    ≥ 80 2
PaCO2*
   < 4.8 kPa 2
   4.8-5.19 kPa 1
PaO2*






Clinical probability: low 0-4, intermediate 5-8, high ≥9, * by room air
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In general, accuracy studies of the Wells and Geneva scores have confirmed their validity 
with 1.3 to 13%, 16 to 40% and 38 to 91% of the low, intermediate and high pretest 
probability groups, respectively, having pulmonary embolism (Table 4)12;15-19. Only one 
study had results that were in disagreement with these findings18. In that study, there was 
no clear discrimination between the low, moderate and high probabilities of PE18. 
The simplified Wells score is suited for out- and inpatients. An important drawback 
of this score is the highly subjective judgement of the item ‘alternative diagnosis less 
likely than PE’. The Geneva score is completely objective but it requires analysis of 
arterial blood gas by room air, which may not always be possible for patients with 
severe hypoxia. 
Table 4
Accuracy of pretest probability assessement of PE using Wells and Geneva  rules
Source No. %PE Category Act.Prob%










































ª Wells Extended Score,  ° Simplified Wells score, *Geneva Score
Wells et al studied inter-observer variability for the pretest probability using the initial 
extended score but not in the simplified score. The coefficient Kappa was excellent (K=0.86)17. 
Chagnon et al. did not document inter-observer agreement for the Geneva score or for 
the simplified Wells score, but reported that 83 patients (30%) were classified differently 
by the two scores (K=0.43)12. Extreme disagreement, defined as patients classified as low 
clinical probability by one score and high probability by the other, occurred in only 2 of 
277 patients. Leclerq et al. studied the observer variability in the assessment of clinical 
probability for patients with suspected PE20. Using the simplified Wells score, duplicate 
assessment in the categories unlikely/likely PE, resulted in a different category in 6 of 45 
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patients (K=0.66) mainly due to the subjective item "alternative diagnosis less likely than 
PE". It is concluded that reproducibility of clinical probability is moderate but comparable 
to the disagreement of clinicians in daily medical practice over patients' histories, physical 
examination and diagnostic tests, including X-rays and ECG. Clinicians should be aware 
of this when using a clinical prediction rule.  
D-dimer tests
D-dimers are degradation products of cross-linked fibrin released when a thrombus is 
degraded by fibrinolysis. For patients with acute venous thrombo-embolism, levels of D-
dimers are typically increased up to eightfold. The sensitivity of D-dimer for detecting 
venous thromboembolism is reported to be 97 to 100% at a cut-off value of 500 ng/ml21;22. 
However, D-dimer tests have a low specificity of approximately 35 to 45% since they 
are also produced in various other conditions, including malignancy, inflammation and 
infection23. D-dimer tests are therefore only useful in ruling out thrombosis. Because 
the negative predictive value lowers with increasing likelihood of PE, it is generally 
recommended to use D-dimer tests in combination with a priori assessed clinical decision 
rule and never be used as a sole diagnostic test in patients with pulmonary embolism. For 
patients with a high clinical probability of PE, the negative predictive value of D-dimer 
is too low to safely rule out PE (88.5%, 95%CI: 69.9–97.6) and additional testing is 
required13;19. 
It has been reported that the use of D-dimer testing in combination with a clinical prediction 
rule can obviate the need for objective imaging tests by 15-47% (Table 5)19;24. 
Measurement of D-dimer has become feasible with the development of monoclonal 
antibodies that bind to epitopes on D-dimer fragments. The resulting complexes are 
detected by enzyme-linked immunosorbent assay (ELISA) or agglutination techniques. 
The classic microplate ELISA-technique is considered the gold standard but this test is not 
suitable for quick diagnosis. There are quicker tests that combine the ELISA method with 
a final fluorescence (VIDAS test, result within 35 minutes(22;25)) or that make use of the 
immunofiltration (membrane ELISA) technique (Instant IA D-dimer, Nycocard D-dimer, 
test result within 2-8 minutes26;27). These have the highest sensitivity and negative predictive 
value (98-100%)22;28. These ELISA D-dimer tests can safely exclude thromboembolism but 
they do so at the expense of a relatively low diagnostic utility. Other techniques involve 
agglutination of latex beads or red blood cells and provide a semi-quantitative or qualitative 
result within a few minutes (Simpli-RED). More recently, immunoturbidimetric techniques 
have been developed that allow a quantitative estimation (TinaQuant, Liatest, MDA D-
dimer). SimpliRed, a D-dimer test with relatively low sensitivity and high specificity is 
diagnostically useful in a great proportion of patients but should be combined with a low 
clinical probability in order to safely rule out PE29. Finally, disadvantages of the visual reading 
may lead to inter-observer variability(30).  
Van der Graaf et al. compared 13 D-dimer methods in 99 outpatients suspected of deep 
venous thrombosis31. Venography was used as a reference standard and revealed DVT 
in 50.5% of patients. Of the novel quantitative D-dimer assays, VIDAS and Tinaquant 
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appeared the most sensitive (sensitivity 100%, specificity 40%). De Monye et al. compared 
the diagnostic accuracy of these same two rapid quantitative D-dimers (Tinaquant and 
VIDAS) for patients with suspected PE and validated the test results using a combination 
of objective reference tests30. Using the manufacturer’s advised cutoff values, the sensitivity 
and specificity were 88% and 52% for VIDAS and 82% and 61% for Tinaquant, respectively. 
When the sensitivities of these assays were set at 95% in order to safely replace perfusion 
scintigraphy as an initial test, the corresponding specificities then dropped to 24% for 
Tinaquant and 29% for VIDAS. Another study also evaluated two D-dimer tests (VIDAS 
and SimplyRED) to exclude PE and validated the results using pulmonary angiography32. 
VIDAS D-dimer showed a sensitivity of 97% (95%CI: 83-100%) and a specificity of 26% 
(95%CI: 18-36%) at a cut-off value of 500 ng/ml and a prevalence of PE of 25%. SimplyRED 
showed a sensitivity of 73% (95%CI: 55-87%) and a specificity of 76% (68-85%). 
Three studies have used a normal result on the D-dimer test alone to exclude PE. In the first 
study, of 444 outpatients suspected of PE, 159 (36%) had a normal result on a rapid ELISA 
D-dimer test (VIDAS) and none of these patients had a venous thromboembolic event in 
the three-month follow-up13. The prevalence of PE in this study was 23%. Another study 
showed that of 141 outpatients, 67 (47.5%) had normal results on a rapid ELISA D-dimer 
test (Vidas), of whom 42 patients had suspected PE. No false-negative D-dimer level was 
found at three months follow-up33. The prevalence of VTE in this study was however only 
10%. A recent management-study excluded PE by a normal D-dimer result (VIDAS) in 
268 of 965 patients (29%) and none experienced a thromboembolic event during 3 months 
of follow-up (failure rate 0%, 95%CI:0-1.4%)2. The prevalence of PE in this study was 23%. 
From these studies it can be concluded that ruling out PE in outpatients with a rapid and 
sensitive ELISA d-dimer test seems safe (failure rate 0%, 95%CI:0-1.8%). 
Four studies have combined normal D-dimer results with a low clinical probability of 
PE(Table 5). Wells et al. demonstrated a negative predictive value of 99.5% (1 VTE of 
437 patients, 95%CI: 99.1-100%) with the SimplyRED D-dimer test19. Ten Wolde et 
al. excluded PE by a low clinical probability and a normal D-dimer result (Tinaquant) 
in 95 of 631 patients (15%) and none had a thromboembolic event during three months 
of follow-up (failure rate 0%, 95%CI:0-3.8%)34. Another study showed also a failure rate 
of 0% in patients with a low clinical probability and normal D-dimer results(95%CI: 0-
6%)35. A fourth study excluded PE in 306 of 653 patients (47%) and 1 patient developed 
non-fatal PE during follow-up (failure rate 0.3%, 95%CI: 0-1.8%) with the prevalence of 
PE being 17%36.  
Table 5
Studies combining low clinical probability with normal D-dimer for exclusion of PE
Author D-dimer assay %PE n Failure rate
Wells et al.(19) SimplyRED 9.5% 437/930 (47%) 0.5% (0-0.9)
Ten Wolde et al.(34) Tinaquant 20% 95/631 (15%) 0 (0-3.8%)
Kruip et al.(35) VIDAS 22% 60/234 (26%) 0 (0-6%)
Anderson et al.(36) Agglutination assay 17% 306/653 (47%) 0.3% (0-1.8%)
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Only one study combined normal D-dimer levels with a low to moderate clinical 
probability of PE and no thromboembolic event was observed during follow up of 64 
patients (failure rate 0%, 95%CI: 0-5.6%)37. 
One disadvantage of the D-dimer test is the lower sensitivity when complaints are present 
for more than 10 days, while specificity is compromised in certain patient groups, i.e. 
elderly patients, or patients with infections, malignancy, sepsis, pregnancy or those in the 
postoperative state38. D-dimer tests should therefore be used by clinicians who are aware 
of the different test characteristics of the various D-dimer assays available. Moreover, 
knowledge of performance of d-dimer assays in different subgroups of patients is essential 
and should be applied to patients on an individual case-to-case basis.
Compression ultrasonography
The prevalence of (a)symptomatic deep vein thrombosis in patients with suspected and 
objectively proven PE differs in the literature varying in a meta-analysis from 18% (95%CI: 
15-20%) in suspected PE to 36-45% in proven PE39. Demonstrating a deep vein thrombosis 
by compression ultrasonography of the legs justifies treatment with anticoagulants in a patient 
with a clinical suspicion of PE. However, the sensitivity of compression ultrasonography for 
patients without clinical symptoms of a DVT is only 23 % (95%CI: 19-26)40. Moreover, when 
pulmonary embolism is not objectively diagnosed at a first episode, the diagnosis may become 
problematic when a patient returns with clinically suspected recurrent PE. 
Compression ultrasonography may be used for patients with suspected PE: 1) when 
they also have clinically suspected DVT; 2) in order to reduce the number of lung scans 
by demonstrating a DVT in patients with no symptoms of DVT and 3) after objective 
diagnostic testing (helical CT or lung scan) prove inconclusive. 
Pulmonary angiography
The traditional gold standard for diagnosing PE is contrast pulmonary angiography. 
However, this diagnostic test is rarely used nowadays because of its invasiveness, its 
high costs and limited availability, and the declining experience of radiologists with the 
technique. Because pulmonary angiography is the reference method, no formal evaluation 
of sensitivity or specificity can take place. The clinical validity of a normal pulmonary 
angiography has been studied and revealed a thromboembolic risk of 1.6% (95%CI: 0.3-
2.9) with most events occurring in the first month41. Pulmonary angiography should still 
be available when other imaging tests are inconclusive.
Ventilation/ perfusion lung scintigraphy  
Perfusion scintigraphy is a non-invasive indirect method of visualising pulmonary 
perfusion by intravenous albumin aggregates labelled with technetium 99 m. Pulmonary 
hypoperfusion is not highly specific for PE since any disease that narrows the airways or 
fills the alveoli with fluid will result in hypoxic pulmonary vasoconstriction. A perfusion 
defect corresponding to a segment is more specific for PE. The main purpose of ventilation 
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scanning, as an adjunct to perfusion lung scintigraphy in acute PE, is to allow for the 
classification of segmental perfusion defects as mismatched (perfusion defect with normal 
ventilation), which is generally accepted as proof for the presence of pulmonary embolism. 
Before scintigraphy, a chest X-ray needs to be performed to rule out abnormalities, since 
these disturb the interpretation of perfusion defects. Further, there is evidence suggesting 
that the ventilation scan may be validly replaced by chest X- ray with an overall agreement 
of 88% and a positive predictive value of 86% for a scintigraphic mismatch42.  
Lung scintigraphy is one of the methods of choice since anticoagulant therapy can be 
safely withheld from patients with a normal perfusion scan (VTE incidence 0% in 6 
months, 95%CI: 0-3.2%)43.  The positive predictive value of a high-probability VQ scan 
is approximately 90% and most physicians consider such a test result sufficient to rule 
in PE. One disadvantage of perfusion scintigraphy is that in most patients (55-65%) 
the diagnosis of PE cannot be confirmed or ruled out due to indeterminate lung scan 
results and additional imaging tests need to be performed1. Two large studies have 
attempted to combine clinical probability to lung scanning to increase the diagnostic 
yield. In 175 patients with suspected PE who were not treated on ground of a low empiric 
clinical probability and a non-diagnostic lung scan, provided that ultrasonography did 
not show a proximal DVT, the 3-month thromboembolic risk was 1,7% (95%CI: 0.4-
4.9%)44. However, this combination was found in only 21% of patients. In another study, 
anticoagulant treatment was withheld from 665 of 1239 (54%) patients who had a non-
diagnostic scan, a low or intermediate clinical probability of PE and normal serial CUS 
and the 3-month thromboembolic risk was only 0.5% (95%CI: 0.1-1.3%)17. 
Table 6
Early studies evaluating helical CT for a suspicion of PE
Year Patients(n) PE(%) Sensitivity(%) Specificity(%)
Remy-Jardin(48) 1992 42 45 95 96
Teigen(49) 1995 60 39 65 97
Goodman(50) 1995 20 55 64 89
Remy-Jardin(51) 1996 75 57 91 78
van Rossum(52) 1996 249 17 95 97
Mayo(53) 1997 139 33 89 98
Garg(54) 1998 24 25 67 100
Weighted average 609 31 86(81-91) 96(93-97)
Helical CT
Helical CT is increasingly being used as the first-line test for a clinical suspicion of 
pulmonary embolism (PE). Helical CT has clear advantages over perfusion scintigraphy, 
i.e. direct visualisation of thrombus, the possibility of providing an alternative diagnosis, 
cost effectiveness and excellent inter-observer agreement45;46. A diagnostic algorithm 
based on helical CT has gained widespread interest due to the availability of helical CT. 
These algorithms have however often been implemented without appropriate assessment 
in clinical practice. Early studies evaluating the accuracy of helical CT for a clinical 
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suspicion of PE demonstrated a sensitivity ranging from 64 to 95% with a specificity 
ranging from 78 to 100%(Table 6). These studies however did not all meet the rigorous 
methodological criteria for defining the accuracy of a diagnostic test47. Two large studies 
have been carried out evaluating single-row helical CT versus a reference method55;56. The 
first one included 299 consecutive patients at the emergency department with a clinical 
suspicion of PE and an elevated D-dimer level. PE was established by using a validated 
algorithm that included clinical assessment, lower-limb compression ultrasonography, 
lung scanning and pulmonary angiography, in comparison with single-row helical CT 
scans. Among patients with conclusive results, sensitivity of helical CT was 70% (95%CI: 
62-78%) and specificity 91% (95%CI: 86-95%)55. 
In the second study, a different algorithm was studied with all patients starting with 
perfusion scintigraphy56. All abnormal scans were followed by pulmonary angiography 
and single-row helical CT was performed in all patients with perfusion defects. Among 
the 517 patients studied, helical CT showed a sensitivity of 69% (95 CI: 63-75%) and a 
specificity of 84% (95% CI: 80-89%). Moreover, the sensitivity of helical CT was calculated 
to be 86% (95%CI: 80-92%) for detecting segmental or larger PE and only 21% (95%CI: 
14-29%) for subsegmental PE. Both studies conclude that single-row helical CT should 
not be used as the sole diagnostic test for patients with clinically suspected PE.
To demonstrate the validity of withholding anticoagulant treatment from patients with a 
normal helical CT, three large outcome studies with comparable algorithms, have appeared 
recently in the literature2;57;58.
In the first study, 1041 consecutive in- and outpatients with suspected PE were included and 
underwent helical CT and ultrasonography of the legs57. PE was diagnosed in 360 (34.6%) 
patients. Of 601 patients with negative helical CT and ultrasonography, 76 were clinically 
assessed as having a high probability of PE and lung scanning or pulmonary angiography 
followed, which showed PE in 4 (5.3%, 95%CI: 1.5-13.1). Of the 507 patients with negative 
helical CT and ultrasonography that were not treated, 9 experienced venous thromboembolism 
during the 3-month follow up period (1.8%, 95%CI: 0.8-3.3). It was concluded that 
anticoagulants could be safely withheld from patients with a low or intermediate probability 
of PE and negative findings on helical CT and compression ultrasonography. 
Van Strijen et al. evaluated single-row detector helical CT as the primary diagnostic test in 
suspected pulmonary embolism58. In this prospective, clinical outcome study, 510 consecutive 
in- and outpatients with a clinical suspicion of PE underwent helical CT. If CT scan results 
were normal or inconclusive, compression ultrasonography was performed on the same day 
and if normal, again at days 4 and 7. Anticoagulation was only started when helical CT was 
positive for the presence of PE or when compression ultrasonography was positive for the 
presence of deep vein thrombosis. Helical CT identified PE in 125 of 510 patients (24.3%), 
an alternative diagnosis in 130 patients (25.3%) and CT scans were normal in 248 patients 
(48.6%).  Compression ultrasonography revealed DVT in 2 patients, both on the initial 
examination. In the group with normal CT scans or with an alternative diagnosis 3 patients 
had a PE or DVT (0.8 %, 95 % CI 0.2-2.3 %). This study shows that single-row detector 
helical CT can be used safely as the primary diagnostic test for a clinical suspicion of PE.
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Finally, Perrier et al evaluated a diagnostic strategy for pulmonary embolism starting 
with a prediction rule combined with implicit judgement, followed by D-dimer testing, 
venous ultrasound and helical CT2. PE was considered ruled out either by a normal 
D-dimer test or in patients with a negative ultrasound and CT scan and a low to 
intermediate clinical probability. All 7 thromboembolic events occurred in the 406 
patients with a low-to-intermediate clinical probability of PE, a negative ultrasound 
and a negative helical CT scan, yielding a 3-month thromboembolic risk of 1.7% 
(95%CI: 0.8-3.5%) It can be concluded that in patients with elevated D-dimer levels, 
a strategy based on a clinical prediction rule and ultrasound combined with helical CT 
appears safe and effective.     
As is summarised in Table 7, the recurrence rate of VTE in negative helical CT varies 
considerably. This is largely due to differences in design of the studies, patient selection 
and follow up. Taking into account the three largest and best designed studies, it can be 
concluded that recurrence of VTE is 0.8-1.8% in an algorithm using helical CT combined 
with ultrasonography.   
Table 7
Outcome studies in validating helical CT
Author Year N Recurrence
Ferretti(59) 1997 164 5.4%
Garg(60) 1999 126 1.3%
Lomis(61) 1999 143 0%
Goodman(62) 2000 198 1.0%
Ost(63) 2001 103 4.2%
Gottsater(64) 2001 305 1.4%
Musset(57) 2002 525 1.8% (0.8-3.3)
van Strijen(58) 2003 512 0.8% (0.8-3.5)
Perrier(2) 2004 450 1.7% (0.8-3.5)
An issue often debated is the limitation of helical CT to accurately detect small peripheral 
emboli. Results of early studies in which single-row detector CT was compared with 
selective pulmonary angiography demonstrated the high accuracy of CT for detection 
of PE to the segmental arterial level but suggested that subsegmental pulmonary emboli 
may be overlooked on CT scans. Sensitivity of single-row detector CT for detecting 
subsegmental PE in a large accuracy study was only 21% (95%CI: 14-29%) compared to 
86% (95%CI: 80-92%) for segmental or larger PE56. CT technology is rapidly developing 
and has, in recent years, brought the advent of multi-row detector CT allowing coverage of 
the entire chest with 1-mm or submillimeter resolution within a short single breath-hold. 
Use of multi-row detector CT significantly improves pulmonary arterial visualization in 
the middle and peripheral lung zones and increases the detection rate of subsegmental 
emboli65;66. However, no clinical outcome studies have evaluated multi-row detector 
helical CT in diagnosing PE. 
Nijkeuter_V4.indd   26 02-05-2007   15:09:21
27







Another problem relating to the detection rate of small peripheral emboli, is the unknown 
relevance of these small clots that might have gone unnoticed in the past.  The percentage 
of these small peripheral emboli in subsegmental arteries has been reported to range from 
6% to 30%1;67. It is not yet known whether treatment of these small emboli results in a 
better clinical outcome for the patient. From the three outcome-studies discussed above, 
in which patients with a normal single-row detector helical CT and normal repeated 
ultrasonography did not receive anticoagulation, it may indirectly be concluded that small 
emboli that cannot be detected by CT do not need anticoagulant treatment in patients 
in stable cardiopulmonary condition at presentation, in view of the low thromboembolic 
rate at 3-month follow-up (0.8- 1.8 %, 95 % CI 0.2-2.3 %). A large, clinical outcome 
study involving more than 3000 patients is currently under way in the Netherlands. In 
this study, called Christopher study, consecutive patients with clinically suspected PE 
are being diagnosed in 12 participating hospitals, according to an algorithm involving 
clinical decision rule and D-dimer to exclude PE and multi-row helical CT to assess the 
presence of PE in patients with a high clinical probability or an abnormal D-dimertest. 
The primary endpoint is the occurrence of VTE during 3-month follow up after normal 
initial tests. Results of this study are expected in 2005.
Magnetic Resonance Angiography (MRA)
MRA is a new, rapidly evolving technique with the advantage of noninvasiveness, non-
ionizing radiation requirement, the use of safer (gadolinium) or no contrast agent and the 
versatile sequences employed to assess various tissues in the chest. The first study to compare 
MRA with pulmonary angiography obtained a sensitivity of 70% and a specificity of 100% 
in a group of 23 patients with PE68. A pioneering study investigated the performance of a 
coronal gadolinium-enhanced three-dimensional time-of-flight sequence during a single-
breath hold in 30 patients with suspected PE69. Eight patients had PE demonstrated by 
angiography. In 10% of patients the images were of insufficient quality and the sensitivity 
and specificity in the remaining patients varied between 75% and 100%, and 95% and 
100% respectively69. Another study in 36 consecutive patients with intermediate- or 
low-probability lung scan results and a high clinical suspicion, MRA was compared to 
pulmonary angiography70. A total of 19 emboli were demonstrated in 13 patients by 
angiography and MRA diagnosed 12 patients as PE (one false positive, specificity of 
96%) and missed two cases (sensitivity of 85%). Both missed PE’s were isolated and 
subsegmental. A more recent methodologically sound study compared contrast-enhanced 
pulmonary three-dimensional MRA with pulmonary angiography in 141 consecutive 
patients with an abnormal perfusion scintigraphy71. MRA was contraindicated in 13 
patients (9%) and not interpretable in 8 patients (6%). The prevalence of PE was 30%. 
MRA demonstrated 27 of 35 patients with confirmed emboli for an overall sensitivity of 
77%. The sensitivities for isolated subsegmental, segmental, and central/lobar PE were 
40%, 84%, and 100% respectively. MRA demonstrated emboli in 2 patients with normal 
angiogram for a specificity of 98%. 
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Several techniques of magnetic resonance imaging that can be applied to venous 
thromboembolic disease are rapidly evolving, i.e. MR angiography (non-gadolinium-
enhanced or gadolinium-enhanced 3D MRA), MR direct thrombus imaging, MR 
perfusion imaging and MR perfusion-ventilation imaging. A promising fairly simple 
technique is direct thrombus imaging that uses methemoglobin, a clot product, as an 
endogenous contrast. It has the advantage of potentially being able to differentiate between 
old and new clots72. However, additional prospective studies evaluating both accuracy and 
feasibility of the various MRA techniques are required before MRA can be introduced 
as a routine procedure for the diagnosis of PE. The limited availability of MRA remains 
problematic in most hospitals. 
Practical advises for diagnostic approach
In patients with clinically suspected PE, the diagnostic algorithm could start with assessing 
pre-test probability according to one of the two established rules. When there is a low 
or intermediate probability, D-dimer testing should follow. PE can be excluded when 
clinical probability is low/intermediate and quantitative D-dimer testing is normal. In 
case of a high clinical probability of PE or an abnormal D-dimer result, several algorithms 
(Figure 1) are optional in ruling out PE, depending on the logistics of the hospital.   
Compression ultrasound can be performed and when positive, treatment with 
anticoagulants is started. When compression ultrasound is negative, either helical CT 
or lung scanning should be performed. In case of an abnormal chest X-ray, helical CT is 
to be preferred since the likelihood of an indeterminate lung scan is high. If helical CT 
shows an intravascular filling defect, PE is diagnosed and treatment with anticoagulants 
is started. If helical CT is negative, PE can be considered ruled out and anticoagulants 
are withheld. In case of a normal chest X-ray, lung scanning can be performed. If the 
result is a normal scan, PE can be considered ruled out. In case of a high-probability scan, 
PE is considered ruled in and anticoagulants are started. When an inconclusive result is 
obtained, further diagnostic testing with either helical CT or pulmonary angiography 
should be performed. 
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Figure 1 
An approach to patients with clinically suspected pulmonary embolism
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Previous studies have evaluated the safety of relatively complex combinations of clinical 
decision rules and diagnostic tests in patients with suspected pulmonary embolism. 
Objective
To assess the clinical effectiveness of a simplified algorithm using a dichotomised clinical 
decision rule, D-dimer testing and computed tomography (CT) in patients with suspected 
pulmonary embolism.
Design, setting and patients
Prospective cohort study of consecutive patients with clinically suspected acute pulmonary 
embolism, conducted in 12 centres in The Netherlands from November 2002 through 
December 2004. The study population of 3306 patients included 82% outpatients and 
57% women.
Interventions
Patients were categorized as “pulmonary embolism unlikely” or “pulmonary embolism 
likely” using a dichotomised version of the Wells clinical decision rule. Patients classified 
as unlikely had D-dimer testing and pulmonary embolism was considered excluded if 
the D-dimer test result was normal. All other patients underwent CT, and pulmonary 
embolism was considered present or excluded based on the results. Anticoagulants were 
withheld from patients classified as excluded and all patients were followed up for three 
months.
Main outcome measure
Symptomatic or fatal venous thromboembolism (VTE) during the 3-month follow-up.
Results
Pulmonary embolism was classified as unlikely in 2206 patients (66.7%). The combination 
of pulmonary embolism unlikely and a normal D-dimer test occurred in 1057 patients 
(32.0%), of whom 1028 were not treated with anticoagulants; subsequent non-fatal VTE 
occurred in 5 patients (0.5 % [95% confidence interval {CI}, 0.2-1.1%]). Computed 
tomography showed pulmonary embolism in 674 patients (20.4%). Computed tomography 
excluded pulmonary embolism in 1505 patients of whom 1436 patients were not treated 
with anticoagulants; in these patients the 3-month incidence of VTE was 1.3 % (95% CI: 
0.7-2.0%). Pulmonary embolism was considered a possible cause of death in 7 patients 
after a negative CT scan (0.5%; 95% CI: 0.2-1.0%). The algorithm was completed and 
allowed a management decision in 97.9 % of patients.
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A diagnostic management strategy using a simple clinical decision rule, D-dimer testing 
and CT is effective in the evaluation and management of patients with clinically suspected 
pulmonary embolism. Its use is associated with low risk for subsequent fatal and non-fatal 
VTE. 
Introduction
The main challenge in the diagnostic work up of patients with clinically suspected 
pulmonary embolism (PE) is to accurately and rapidly distinguish the approximately 25 
percent of patients who have the disease and require anticoagulant treatment from the 
75 percent who do not 1;2. A number of new approaches have improved the diagnostic 
process for pulmonary embolism. The first is the combination of a clinical decision rule, 
such as the Wells score3, which categorizes patients as low, intermediate or high clinical 
probability of PE, with a D-dimer test. Several management studies have shown that 
pulmonary embolism can be safely ruled out without the need for additional imaging in 
patients with low clinical probability and a normal D-dimer test result, occurring in 20 
to 40% of patients3-5. In these studies 3 categories of likelihood were used. However, a 
retrospective analysis suggested that the clinical utility of the Wells score could be further 
increased by using 2 instead of 3 categories of clinical probability, dichotomizing patients 
as either likely or unlikely to have had a pulmonary embolism, but no large prospective 
studies evaluating this dichotomization have been carried out3. 
Another advancement is computed tomography (CT), which has emerged as a prominent 
imaging technique for the exclusion or confirmation of PE, as well as the detection of 
alternative diagnoses 6-10. However, a critical missing piece of information has been 
whether it is safe to withhold anticoagulation treatment after a CT that is negative for 
pulmonary embolism11;12. In a recent study13, recurrent venous thromboembolism (VTE) 
occurred in 1.7 % of patients who initially had a low or intermediate probability for 
pulmonary embolism using the Geneva score14, abnormal D-dimer test, normal bilateral 
compression ultrasound (CUS) of the leg veins and a normal multidetector-row CT. In 
that study, all patients with high probability for pulmonary embolism had to undergo 
pulmonary angiography after normal CT and normal CUS. A more efficient strategy 
would consist of an algorithm with a dichotomized decision rule, D-dimer testing and CT, 
in which pulmonary embolism is considered excluded in patients with an unlikely clinical 
probability score and a normal D-dimer test result, while CT is used in all other patients 
as the sole imaging method to make management decisions. Therefore, we performed a 
prospective study in a large cohort of consecutive patients with clinically suspected PE to 
evaluate the effectiveness of this novel management strategy. 





The Christopher Study was a prospective cohort study evaluating a diagnostic algorithm 
consisting of sequential application of a clinical decision rule, D-dimer testing and CT 
within 24 hours of presentation (Figure). All patients were followed up for a period of 3 
months after presentation to document the occurrence of subsequent symptomatic VTE.  
Patients
Consecutive patients with clinically suspected pulmonary embolism, defined as a sudden 
onset of dyspnea, sudden deterioration of existing dyspnea, or sudden onset of pleuritic 
chest pain without another apparent cause, were potentially eligible for the study. Patients 
presenting to the emergency ward (outpatients) and inpatients were eligible. Patients 
presenting to an outpatient office were directly sent to the emergency department for 
evaluation. Patients were recruited between November 2002 and September 2004. 
Exclusion criteria were treatment with therapeutic doses of unfractionated or low-
molecular-weight-heparin for more than 24 hours, life expectancy less than 3 months, 
pregnancy, geographic inaccessibility precluding follow-up, age younger than 18 years, 
allergy to intravenous contrast agents, renal insufficiency (creatinine clearance less than 30 
ml/min [<0.5 mL/s]), logistic reasons (eg, unavailability of CT, patient too ill to undergo 
CT scanning), or hemodynamic instability. Five academic and 7 general urban hospitals 
in the Netherlands participated. The Institutional Review Boards of all participating 
hospitals approved the study protocol and written or oral informed consent was obtained 
from all participants.
Clinical decision rule and D-dimer assay
Patients with clinically suspected PE were evaluated by an attending physician using a 
validated clinical decision rule (Table 1)3. Pulmonary embolism was classified as “unlikely” 
with a clinical decision rule score of 4 or less points, and “likely” with a score of more than 
4 points. This cut-off was chosen because it has been shown to give an acceptable VTE 
diagnostic failure rate of 1.7 to 2.2% in combination with a normal D-dimer test result3. 
An estimated 300 attending physicians in the participating hospitals used the clinical 
decision rule with the study participants. 
In patients with a clinical decision rule indicating pulmonary embolism unlikely, a D-
dimer concentration was measured, using either the VIDAS D-Dimer assay (Biomerieux, 
Marcy L’Etoile, France) or the Tinaquant assay (Roche Diagnostica, Mannheim, 
Germany). A D-dimer concentration of 500 ng/ml or less was defined as normal. In 
patients with pulmonary embolism unlikely and a normal D-dimer test result, the 
diagnosis of pulmonary embolism was considered excluded and anticoagulant treatment 
was withheld. Those patients who had a combination of clinical decision rule indicating 
pulmonary embolism with an abnormal D-dimer test result or who had a clinical decision 
rule indicating pulmonary embolism likely, underwent CT.   
Nijkeuter_V4.indd   40 02-05-2007   15:09:26
41
Effectiveness of Managing Suspected Pulmonary Embolism using an Algorithm combining Clinical 








Clinical decision rule according to Wells et al. 3
points
Clinical signs and symptoms of deep vein thrombosis (DVT)(minimum of leg swelling and pain with palpation of the deep veins) 3.0
Alternative diagnosis less likely than PE 3.0
Heart rate >100/minute 1.5
mmobilisation (> 3 days) or surgery in the previous 4 weeks 1.5
Previous PE or DVT 1.5
Hemoptysis 1.0
Malignancy (on treatment, treated in the last 6 months or palliative) 1.0
Clinical probability of PE unlikely ≤ 4 points, clinical probability of PE likely > 4 points.
Radiological evaluation 
Computed tomography was performed using either single-detector row or multi-detector 
row systems. Patients were examined during suspended inspiration. The single-detector 
row CT parameters were 3 mm slice thickness with a 2 mm reconstruction interval at 120 
kV/140 mAs, 120-140 mL of non-ionic contrast material containing 350 mg of iodide 
per mL with an injection speed of 3.0 mL/s and an injection delay of 16 s. Multi-detector 
row CT parameters were 1.25 mm slice thickness with a 1.2 mm reconstruction interval 
at 120 kV/120 mAs, 80-100 mL of non-ionic contrast material containing 350 mg of 
iodide per mL with an injection speed of 4.0 mL/s and bolus-tracking in the common 
pulmonary artery to get optimal contrast opacification of the pulmonary arteries. The 
pulmonary arteries were evaluated up to and including the subsegmental vessels from 
the level of the aortic arch to the lowest hemidiaphragm. Pulmonary embolism was 
diagnosed if contrast material outlined an intraluminal defect or if a vessel was totally 
occluded by low-attenuation material on at least two adjacent slices. These patients 
received low molecular weight heparin or unfractionated heparin, followed by vitamin 
K antagonists, according to local practice. In patients without pulmonary embolism, the 
presence or absence of an alternative diagnosis was recorded and anticoagulant treatment 
was withheld. The CT was considered inconclusive if the images could not be interpreted 
because of motion artefacts due to movements of the patient or the heart or if there was 
insufficient contrast enhancement of the pulmonary arteries. The management of patients 
in whom the CT could not be performed or who had an inconclusive CT scan was left to 
the discretion of the attending physician. 
The decision of the presence or absence of pulmonary embolism was made by trained 
attending radiologists, who were blinded to any specific patient clinical information. By 
protocol design they knew that a patient referred for CT either had a D-dimer level that 
was above 500 ng/ml or a clinical decision rule score that was higher than 4 points, but did 
not know which of these items was the reason for performing a CT-scan.




The primary outcome of the study was the incidence of symptomatic VTE events during 
three months follow-up, defined as fatal PE, non-fatal PE or deep vein thrombosis 
(DVT). An independent adjudication committee, whose members were unaware of the 
patient’s allocation within the diagnostic algorithm, evaluated all suspected VTE events 
and deaths. A diagnosis of PE or DVT was made based on a priori defined and generally 
accepted criteria15. Deaths were classified as due to pulmonary embolism in case of 
confirmation by autopsy, in case of an objective test positive for pulmonary embolism 
prior to death or if pulmonary embolism could not be confidently excluded as the cause 
of death.  Follow-up consisted of a scheduled outpatient visit or telephone interview at 3 
months. Patients were additionally instructed to contact the study centre or their general 
practitioner immediately in the event of symptoms suggestive of DVT or pulmonary 
embolism. At each visit, information was obtained on complaints suggestive of VTE, 
including acute onset of dyspnea, acute worsening of existing dyspnea, acute onset of chest 
pain, unilateral leg swelling and leg pain, as well as interval initiation of anticoagulants. In 
case of clinically suspected DVT or PE, objective diagnostic tests were required, including 
CUS for suspected DVT, and ventilation-perfusion scintigraphy or CT for suspected 
pulmonary embolism. In case of death, information was obtained from the general 
practitioner, from the hospital records or from autopsy.
Statistical analysis
The 2 primary analyses were incidence of symptomatic VTE during follow-up, confirmed 
by objective testing, in 1 the group of patients in whom anticoagulant treatment was 
withheld based on a classification of pulmonary embolism unlikely by clinical decision 
rule and a normal D-dimer test result, and 2) the group of patients in whom anticoagulant 
treatment was withheld based on a CT scan that excluded pulmonary embolism. 
Additional analyses were performed for fatal pulmonary embolism in these groups, as 
well as among the patients with a normal CT scan and an alternative diagnosis on CT 
separately. Sample size was based on an assumption of a 1% incidence of VTE in both 
patient groups and a goal to keep the upper limit of the 95% confidence interval below 
2.7%5,9, which has been reported as the upper limit of the range of recurrent VTE after 
a normal angiogram16. We calculated that approximately 1000 patients would have to 
be included in each group, using a 2-sided type I error of 0.05, and a type II error of 
0.20. Since we expected that approximately 30% of patients would have a classification of 
pulmonary embolism unlikely by clinical decision rule and a normal D-dimer test result5, 
a total study population of 3300 patients was needed. 
Exact 95% confidence intervals (CI) were calculated around the observed incidences 
using StatXact software, version 5 (Sytel Software corp, Cambridge, Mass). Descriptive 
parameters were calculated using SPSS software, version 11.5 (SPSS, Inc., Chicago, Ill). 
For statistical differences, the Fisher exact test was used; statistical significance was set at 
P<0.05.    
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A total of 3503 consecutive patients with clinically suspected pulmonary embolism were 
screened, of whom 184 (5.3%) were excluded because of predefined exclusion criteria: more 
than 24 hours of low molecular weight heparin (n=50), life expectancy less than 3 months 
(n=47), pregnancy (n=26), geographic inaccessibility precluding follow up (n=20), renal 
insufficiency (n=26), logistic reasons (n=10), age younger than 18 years (n=4), and allergy 
to intravenous contrast agents (n=1). In addition, 13 patients refused consent (Figure). 
The final study population of 3306 participants included 2701 (81.7 %) outpatients and 
605 (18.3 %) inpatients; the baseline demographic and clinical characteristics of the 3306 
study patients are shown in Table 2. 
Table 2
Baseline demographic and clinical characteristics of the 3306 study patients
Characteristic Value
Age in years, mean (SD+) 53.0 (18.4)
Female sex, n (%) 1897 (57.3)
Outpatients, n (%) 2701 (81.7)
Duration of complaints in days, median (IQR^) 2 (1-5)
Paralysis, n (%) 91 (2.8)
Immobilisation or recent surgery, n (%) 610 (18.4)
Previous VTE, n (%) 480 (14.5)
COPD with treatment, n (%) 341 (10.3)
Heart failure with treatment, n (%) 243 (7.3)
Malignancy, n (%) 476 (14.4)
Oestrogen use, n (%)* 438 (23.1)
Clinical symptoms of DVT, n (%) 190 (5.7)
Heart rate (beats per minute >100), n (%) 867 (26.2)
Hemoptysis, n (%) 176 (5.3)
+SD= standard deviation, ^IQR= interquartile range, *of females only 
Results of diagnostic algorithm
Of the 3306 included patients, 2206 (66.7 %) had a clinical decision rule indicating PE 
unlikely and were tested for D-dimer concentrations (Figure). The prevalence of pulmonary 
embolism in these patients was 12.1% (266/2206; 95 % CI: 10.7-13.5%) versus 37.1% 
(408/1100 patients; 95%CI: 34.2-40.0 %)) in those with a clinical decision rule indicating 
PE likely (p<0.001). Among the 1149 patients classified as unlikely but with an abnormal 
D-dimer test result, the prevalence of pulmonary embolism was 23.2% (266/1149). D-
dimer test results were normal in 1057 (32.0%) patients and in these patients pulmonary 
embolism was considered excluded. Of the 2206 patients undergoing D-dimer testing, 
968 (44 %) had a VIDAS D-dimer test performed; 1238 patients (56 %) a Tinaquant 
D-dimer test. 
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Of the 2249 patients with either abnormal D-dimer concentrations (n= 1149) or a clinical 
decision rule indicating pulmonary embolism likely (n=1100), 2199 underwent CT. In the 
other 50 patients a CT was indicated but not performed because of lack of venous access, 
extreme obesity, DVT confirmed by CUS prior to CT, or a deteriorating clinical condition 
prior to CT. Multidetector-row CT was performed in 1939 patients and single-detector-
row CT in 260 patients. Computed tomography excluded pulmonary embolism in 1505 
(45.5% of the total study population). In these patients, 702 had additional diagnostic 
information visualized on CT: pneumonia (n=212), pleural effusion (n=163), malignancy 
(n=50) and other diagnoses (n=277). Pulmonary embolism was confirmed in 674 patients 
(20.4 % of the study population). Computed tomography was inconclusive in 20 patients 
(0.9%). Hence, the diagnostic algorithm could be completed according to the protocol in 
3256 patients (98.5 %) and allowed a management decision in 3236 patients (97.9 %).
Patients with pulmonary embolism unlikely and normal D-dimer test result
Of the 1057 patients with the combination of a clinical decision rule indicating pulmonary 
embolism unlikely and normal D-dimer test result, 29 patients (2.7 %) were treated with 
oral anticoagulants during follow-up for various reasons other than VTE. Three of the 
1028 remaining patients returned with symptomatic VTE events (2 non-fatal PE, 1 
DVT) during the 3-month follow-up. In 25 patients the protocol was violated and a CT 
or a ventilation-perfusion scan was performed while not indicated. Pulmonary embolism 
was diagnosed in 2 of these 25 patients. Therefore, the incidence of VTE was 5 of 1028 
(0.5 %; 95% CI: 0.2 to 1.1%) (Table 3). Two patients were lost to follow-up (0.2%). 
In a ‘worst case’ scenario, in which these two patients would have developed VTE, the 
incidence of VTE would have been 7 of 1028 (0.7 %; 95% CI: 0.3 to 1.4 %). There were 
no fatal pulmonary embolisms. Eight (0.8 %) of the 1057 patients died of other causes. 
Of the study population, 605 were inpatients and 56 of these had a decision rule indicating 
pulmonary embolism unlikely and a normal D-dimer test result (9.3%). No VTE was 
observed at follow-up in these patients (VTE rate, 0%;95% CI: 0-6.4%). The results for 
inpatients and outpatients were comparable (VTE rate 0% (95% CI: 0-6.4%) versus 0.5% 
(95% CI: 0.2-1.2%)). The VIDAS D-dimer test had a true negative rate of 44.2 % (428/968 
patients) and the Tinaquant D-dimer assay had a true-negative rate of 50.8 % (629/1238 
patients) (p< 0.002). The negative predictive values for the VIDAS and Tinaquant assays 
were 100% (95%CI: 99.1-100%) and 99.2% (95%CI: 98.1-99.7%), respectively. 
Patients with CT excluding pulmonary embolism 
Of the 1505 patients in whom CT excluded pulmonary embolism, 69 (4.6%) received 
anticoagulants during follow-up for various reasons other than VTE. Of the 1436 patients 
who did not receive anticoagulant treatment, 18 experienced VTE events during the 3-
month follow-up (1.3 %; 95% CI: 0.7 to 2.0%). Eleven of these had non-fatal symptomatic 
thromboembolic events (3 pulmonary embolism and 8 DVT). Fatal pulmonary embolism 
was presumed to have occurred in the other 7 patients (0.5%, 95%CI: 0.2-1.0%); it was 
proven by autopsy in 2 and attributed as the cause of death in 5 (Table 4). Follow-up was 
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incomplete in one of the 1436 patients (0.1%). In a “worst-case” scenario in which this 
patient would have developed VTE, the incidence of VTE would have been 19 of 1436 
(1.3%; 95% CI: 0.8 to 2.1%). 
Rates of VTE during follow-up were comparable for inpatients and outpatients (VTE 
rate 1.4%(95 % CI 0.4 to 3.1 %) versus 1.2% (0.7-2.1%), respectively). Among the 
patients who did not receive anticoagulants, similar incidences of VTE were observed in 
those with a normal CT (9/764; 1.2% [95 % CI: 0.5 to 2.2%]) and those with additional 
diagnostic information on CT (9/672; 1.3% [95 % CI: 0.6 to 2.5%]) (Table 3). Similar 
incidences of VTE were observed in untreated patients who underwent multi-detector 
row CT (14/1266; 1.1 % [95% CI: 0.6 to 1.9%]) and single-detector-row CT (4/170; 2.4 
% [95% CI: 0.6 to 5.9%]). 
Twenty patients returned with symptoms of pulmonary embolism during follow-up. 
Computed tomography was again used as the diagnostic method in 13 of these 20 patients 
and was normal in all. No VTE was demonstrated at later follow-up. The overall mortality 
rate in patients in whom CT excluded pulmonary embolism was 8.6% (129 patients).
Table 3
Venous thromboembolic events during 3-month follow-up in untreated patients
n Total VTE n (%; 95% CI) Fatal PE n (%; 95% CI)
PE unlikely and normal D-dimer 1028 5 (0.5 %; 0.2 to 1.1 %) 0 (0 %; 0.0 to 0.3%) 
PE excluded by CT 1436 18 (1.3 %; 0.7 to 2.0%) 7 (0.5 %; 0.2 to 1.0%) 
• CT normal 764 9 (1.2%; 0.5 to 2.2%) 3 (0.4 %; 0.1 to 1.1%) 
• CT alternative diagnosis 672 9 (1.3 %; 0.6 to 2.5%) 4 (0.6 %; 0.1 to 1.5%)
VTE: Venous Thromboembolic Events
Patients with CT that was inconclusive or not performed
Of the 20 patients with an inconclusive CT, pulmonary embolism was demonstrated by 
ventilation-perfusion lung scan in 2 patients and they received anticoagulant treatment. 
During follow-up 1 of the 18 remaining patients had a non-fatal VTE event. Of the 
50 patients in whom CT was indicated but not performed, 3 had pulmonary embolism 
demonstrated by ventilation-perfusion lung scan and 2 patients had DVT demonstrated 
by CUS; during follow-up one of the remaining 45 patients had a fatal pulmonary 
embolism, while DVT occurred in 1 patient. The mortality rate for inconclusive CT was 
5% (1/20) and for CT not performed 14% (7/50). 
Patients with pulmonary embolism confirmed by CT
Of the 674 patients in whom CT had demonstrated pulmonary embolism, 20 patients 
(3.0%) had a recurrent VTE despite anticoagulant treatment. This included 11 fatal 
pulmonary embolism, 3 non-fatal pulmonary embolism and 6 DVT. One patient was lost 
to follow-up. The overall mortality in this group was 7.2% (55 patients). 




This large cohort study of 3306 consecutive patients with clinically suspected pulmonary 
embolism demonstrates that the use of a diagnostic algorithm consisting of a dichotomized 
decision rule, D-dimer testing and CT can guide treatment decisions with a low risk of 
subsequent pulmonary embolism. No further diagnostic testing was necessary in the third 
of our patients who had an unlikely clinical probability score in combination with a normal 
D-dimer test result, with a 3-month incidence of VTE of 0.5%. Computed tomography 
ruled out pulmonary embolism in all other patients without using other imaging tests 
(3-month incidence of those with a negative CT of 1.3%). The algorithm was pragmatic 
in that it could be completed in 98.5% of the eligible patients and allowed a management 
decision in 97.9%. 
Other management studies have documented the safety of a low clinical probability 
in combination with a normal D-dimer concentration for the exclusion of pulmonary 
embolism3-5, 17. In these studies, the rate of VTE during follow-up ranged from 0% to 1.5 
%. However, because the sample size was limited, upper confidence limits were as high 
as 6.0 % 3-5, 15. In contrast to our simple algorithm, a recent study13 used a more complex 
flowchart with sequential testing including clinical probability assessment, D-dimer assay, 
CUS, CT, as well as pulmonary angiography, to exclude pulmonary embolism in patients 
with a high likelihood and negative workup. As the authors pointed out, their study was 
not a true outcome study, since CUS was performed in all patients with abnormal D-
dimer level, and patients with abnormal CUS and normal CT scan were treated with 
anticoagulation. That study had a much smaller sample size (674 patients) and a higher 
rate of exclusion (25 % versus 5.6% in our study). 
To improve the simplicity and utility of their decision rule, Wells et al. proposed 
changing their model from the original 3 categories (low, moderate, high) to 2 categories 
(pulmonary embolism unlikely and pulmonary embolism likely)3. Our study is the first to 
prospectively validate the safety of the dichotomized score in combination with the D-
dimer assay. Compared with a combination using 3-category classification, this approach 
has the potential to increase the number of patients in whom pulmonary embolism can 
be excluded by approximately 50%3,17. 
Despite concerns that the sensitivity of CT for pulmonary embolism is lower than of 
pulmonary angiography18;19, the observed risk of subsequent symptomatic VTE in those 
patients in whom pulmonary embolism was excluded by CT was comparable to the risk 
reported after a normal pulmonary angiogram (3-month incidence, 1.3%; 95%CI: 0.7 
to 2.0% versus 1.7%; 95%CI: 1.0 to 2.7 %, respectively)16. In addition, in our study fatal 
pulmonary embolism occurred in 0.5 %(95 % CI 0.2-1.0 %) of patients in whom CT 
had excluded pulmonary embolism, compared with 0.3 % (95% CI 0.02-0.7 %) after 
normal pulmonary angiography16. Computed tomography has the potential advantage 
of providing additional diagnostic information for the presenting symptoms in patients 
without pulmonary embolism.
Several potential limitations in our study require comment. First, the absence of pulmonary 
embolism was not verified by pulmonary angiography. However, the clinical outcome 
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after a 3-month follow-up is widely accepted as an appropriate alternative to establish the 
safety of a diagnostic strategy, given a near-complete follow-up20.
Second, while our cohort study has the strength of minimal loss to follow-up (3 patients, 
0.1 %) and independent blinded adjudication of all outcomes, a randomised controlled 
study design would have allowed a direct comparison to other validated strategies. 
Third, CT was again used to exclude pulmonary embolism in 13 of 20 patients who 
returned during follow-up with symptoms after CT had excluded pulmonary embolism 
at baseline. Although these could represent false-negative results, these patients were not 
treated and further follow-up was uneventful, making this unlikely. 
Fourth, the use of multi-detector row CT has the potential for over-diagnosis by imaging 
very small peripheral subsegmental emboli. Because patients did not undergo confirmatory 
pulmonary angiography, our study design did not permit assessing the false-positive rate 
of CT scans. Only 10% of our patients underwent single-detector row CT, so we could 
not make a meaningful comparison of the impact of each test. However, the overall 
prevalence of pulmonary embolism in our study (20 %) is comparable to the prevalence in 
a previous multi-center study performed with single-row detector CT (24%)9 . This does 
not support a concern that multi-detector row CT technology will lead to a high number 
of false positive results.
Finally, a definitive cause of death could not be established for all patients with normal 
test results who died during follow-up. However, pulmonary embolism was assigned as 
the cause of death if it could not be confidently excluded, a conservative assumption that 
strengthens our conclusions about low risk for this strategy.
The generalizibility of our findings should be considered. The baseline clinical characteristics 
and the incidence of pulmonary embolism for our study population are  comparable with 
those observed in other population-based studies, except for a somewhat younger mean 
age5,10,12. The low proportion of patients excluded and the enrolment of consecutive patients 
who were referred to both academic and non-academic hospitals, further supports broad 
applicability of these results, as does the similar rates of VTE during follow-up between 
inpatients and outpatients. 
In conclusion, a diagnostic management strategy using a simple clinical decision rule, 
D-dimer testing and CT is as effective as other more complex diagnostic strategies in the 
evaluation and management of patients with clinically suspected pulmonary embolism. 
Its use is associated with low risk for subsequent fatal and non-fatal VTE.
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Excluding pulmonary embolism by a cut-off level of the clinical decision rule of four 
points to designate patients as “pulmonary embolism unlikely” combined with a D-dimer 
concentration of 500 ng/ml or less has been demonstrated safe.
Objective
To investigate whether varying the cut-off level of the clinical decision rule as well as the 
D-dimer test could lead to an increase in clinical utility without jeopardizing safety. 
Methods
Data were obtained from a diagnostic outcome study of patients suspected of pulmonary 
embolism.
Measurement
For each increment of clinical decision rule and D-dimer cut-off point, the number of 
patients with PE at baseline or during follow-up, the clinical utility and the 3-month 
thrombo-embolic failure rate were calculated
Results
By increasing the cut-off level of the clinical decision rule from 4 to 5 points, pulmonary 
embolism could be ruled out in an additional 4% of the study population (from 29.3 to 
33.3%) at an expense of an increased three-month thrombo-embolic failure rate of 1.5% 
(95%CI: 0.6-3.0%). By increasing the D-dimer cut-off level from 500 to 600 ng/ml, PE 
could be ruled out in an additional 3% of the study population but the three-month 
thrombo-embolic failure rate increased to 2.2% (95%CI: 1.1-4.0). 
Conclusions: 
The cut-off level of the clinical decision rule as well as the cut-off level of the D-dimer 
test should be kept at the original 4 points and 500 ng/ml respectively, in order to prevent 
exposure of patients to a 3-month thrombo-embolic failure rate exceeding that of normal 
pulmonary angiography.
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Pulmonary embolism (PE) is a potentially fatal disease and one of the leading causes of 
cardiovascular mortality. Due to the non-specificity of clinical signs and symptoms, only 
20-30% of patients with clinically suspected PE do have the disease. Excluding PE by non-
invasive tests has been simplified recent years by the introduction of standardized clinical 
decision rules (CDR) and quantitative D-dimer assays. Several management studies have 
demonstrated that the combination of a low to moderate clinical probability of PE and a 
normal D-dimer test safely rules out PE1-4. With this approach, it has been demonstrated 
that additional imaging tests including computed tomography (CT) scan and ventilation-
perfusion lung scan can be withheld in approximately 15 to 50% of patients, with a 3-month 
thrombo-embolic failure rate of less than 1%. Increasing the clinical utility, i.e. the proportion 
of patients in whom the diagnosis of PE can be safely excluded without additional imaging 
tests, would be desirable, provided that the safety of excluding PE with this approach is 
not jeopardized.  The original CDR according to Wells categorized patients with clinically 
suspected PE into three groups, i.e. patients with a low (< 2 points), intermediate (2-6 
points) and high clinical probability (>6 points) occurring in 59%, 33% and 8% of the 
study population respectively5. In comparison to patients with a low probability and normal 
D-dimer results, occurring in 29% of the study population, in a post-hoc analysis it was 
shown that PE could be confidently ruled out in an additional 20% of patients by using 
a dichotomized cut-off level of 4 points or less. The safety of using this cut-off level in 
combination with a normal quantitative D-dimer test (≤ 500 ng/ml) has recently been 
demonstrated in a large prospective cohort study in patients with clinically suspected PE 
in which the 3-month thrombo-embolic failure rate was 0.5% (95%CI: 0.2-1.1%)(6). We 
retrospectively analyzed the data of this study to evaluate 1) the safety and clinical utility of 
increasing the cut-off level of the CDR to designate patients as “PE unlikely” while the D-
dimer cut-off level remained at 500 ng/ml; and 2) the safety and clinical utility of increasing 
the cut-off level of the D-dimer test while the CDR cut-off remained at 4 points. 
Methods
Patients 
Data were obtained from a prospective cohort follow-up study performed between November 
2002 and December 2004 in the Netherlands6. In this study the safety of excluding pulmonary 
embolism by a diagnostic algorithm consisting of a CDR, a quantitative D-dimer test and 
helical CT was evaluated. In- and outpatients with a clinical suspicion of PE were eligible 
for the study. Exclusion criteria were: age under 18 years, treatment with therapeutic doses of 
unfractionated or low-molecular weight heparin for more than 24 hours prior to inclusion, a 
life expectancy of less than three months, pregnancy, allergy to intravenous contrast agents, 
renal insufficiency (creatinin clearance less than 30 ml/min), logistic reasons, geographic 
inaccessibility precluding follow up or hemodynamic instability. 
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For the present analysis, we used data from 5 of the 12 participating hospitals (1466 of 3306 
patients), since these hospitals performed D-dimer test in all included patients, while the 
other 7 hospitals only performed D-dimer tests in case of a CDR score of 4 or less. 
Diagnostic work-up 
All patients were followed for a period of three months to document the occurrence of 
symptomatic venous thromboembolic events.  PE was considered unlikely if the CDR was 
≤ 4 points, and PE was considered likely in case of a CDR > 4 points1;5. Patients with a 
CDR indicating PE unlikely underwent D-dimer testing and when normal, the diagnosis 
of PE was considered excluded. In consecutive patients from five hospitals included in this 
analysis, D-dimer tests were performed for logistic reasons in all patients irrespective of 
the score on the CDR, but the results were only communicated to the treating physician 
in case of a CDR indicating “PE unlikely”. Patients with a CDR indicating “PE unlikely” 
and an abnormal D-dimer test and patients with a CDR indicating “PE likely” underwent 
helical CT to diagnose or exclude PE. All patients in whom the diagnosis of PE was 
excluded were withheld from anticoagulant treatment and were followed for three months 
to document the occurrence of symptomatic venous thromboembolism.
The D-dimer concentration was measured using either the Vidas D-Dimer assay (Biomerieux, 
Marcy L’Etoile, France) or the Tinaquant assay (Roche Diagnostica, Mannheim, Germany). 
Three hospitals used the Vidas D-dimer and two used the Tinaquant D-dimer. A cut-off level 
below or equal to 500 ng/ml was defined as normal for both tests in the original study6. 
The Institutional Review Boards (IRB’s) of all participating hospitals approved the 
study protocol and written or oral informed consent was obtained from all participants, 
depending on the requirements of the local IRB’s.
Analysis and statistics  
D-dimer increments of 100 and 500 Fibrinogen Equivalent Units (FEU) ng/ml and 1 CDR 
score-point were used as the varying units of analysis. The reference test for calculation of 
the test characteristics sensitivity and specificity was the diagnosis of PE at baseline by 
helical CT or the occurrence of an objectively diagnosed venous thrombo-embolic event 
during the three months of follow-up. For each increment of CDR and D-dimer cut-off 
point, the number of patients with PE at baseline or during follow-up and the associated 
sensitivity, specificity, negative and positive predictive values were calculated. Exact 95% 
confidence intervals (CI) were calculated around the observed incidences using JavaStat 
software (http://hometown.aol.com/johnp71/confint.html). The number needed to test 
(NNT) for the D-dimer to rule out one patient with PE was also calculated. The NNT is the 
inverse of the proportion of true-negative D-dimer test results, i.e. a normal D-dimer test 
in patients with a CDR indicating “PE unlikely” and no venous thrombo-embolic events 
in the three-month follow-up period, divided by the total number of patients that need to 
be tested. For example, of 100 patients suspected of PE, 50 patients are designated as “PE 
unlikely” and are tested for D-dimer. Of these, 30 patients have negative D-dimer tests with 
one patient returning in the follow-up period with a venous thrombosis. The proportion of 
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true-negative tests is 29 of 50 (58%) and the NNT is 1.7 (1/0.58). The definition of clinical 
utility was chosen to be the number of patients that needed imaging tests, divided by the 
number of patients in which PE could be ruled out by a CDR indicating “PE unlikely” and 
a negative D-dimer test (CT/D-dimer index). In the aforementioned example, 70 patients 
needed imaging tests and a CDR indicating “PE unlikely” and a normal D-dimer test ruled 
out PE without imaging tests in 30 patients, resulting in a CT/DD index of 2.3 (70/30). 
Ruling out PE by a combination of a CDR score and a negative D-dimer test was 
considered safe if the negative predictive value was at least 98% and if the upper 
confidence limit of the 3-month thrombo-embolic failure rate did not exceed 2.7%, being 
the upper confidence limit of the 3-month thrombo-embolic rate of a normal pulmonary 
angiography7. 
Results 
Of 1704 eligible patients recruited in 5 hospitals, 90 were excluded because of predefined 
exclusion criteria or declined informed consent. Data regarding the CDR score were 
missing in 3 patients, D-dimer results were missing in 99 patients and 46 patients were 
treated with anticoagulants for reasons other than venous thrombo-embolism (VTE), 
resulting in a total of 1466 patients (91%) available for analysis (Table 1). The mean age 
was 54 years, 54% of patients were female and 76% were outpatients. The prevalence of 
PE was 22% (321 patients diagnosed with PE at baseline and 9 in the follow up period). 
Table 1
Baseline characteristics of the study population (n=1466)
Characteristics n (%)
Age in years 54 (19)ª
Female sex 822 (54)
Estrogen use* 168 (20)
Immobilisation > 3 days or surgery 303 (20)
History of VTE 209 (14)
COPD 156 (10)
Heart failure 138 (9)
Malignancy 238 (16)
Outpatients 1155 (76)
PE at baseline 321 (21)
ªmean (SD), *in females only
The prevalence of PE increased with increasing score on the CDR, ranging from 5% in 
patients with a score of 1 point or less, to 59% in patients with a score of more than 7 
points (Figure 1). Similarly, the prevalence of PE increased with increasing concentration 
of D-dimer, ranging from 1% in patients with D-dimer concentrations below 300 ng/ml 
to more than 60% with D-dimer concentrations above 5000 ng/ml (Figure 2). 












































Varying the cut-off level of the clinical decision rule
Table 2 demonstrates the effect of varying the cut-off level of the CDR when the D-
dimer cut-off level was kept at 500 ng/ml. A total of 960 of the 1466 patients (65.5 %) had 
a CDR score of four points or less and were tested for D-dimer according to the original 
study protocol. D-dimer was normal in 430 patients (29.3% of 1466 patients), of whom 
four had a VTE during three months follow-up (0.9%, 95%CI: 0.3-2.4). The percentage 
of true-negative D-dimer tests was 44.4% (426/960) and the number of patients needed 
to test for D-dimer in order to rule out one patient with PE was 2.3 (1/0.444). All other 
patients who either had a CDR above four points or an abnormal D-dimer test (1036 
patients) underwent a CT-scan to rule out PE. The CT/DD index was therefore 2.4 
(1036/430). The sensitivity of a normal D-dimer and a CDR cut-off level of four points 
or less was 98.8% (95%CI: 96.9-99.7), the specificity 37.5% (95%CI: 34.7-40.4) and the 
negative predictive value was 99.1% (95%CI: 97.6-99.8)(Table 3). 
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Influence of varying CDR cut-off * 




3-month VTE failure rate % TN DD NNT CT/DD index
n % (95%CI)
≤ 4 960 (65.5) 430 (29.3) 4 0.9 (0.3-2.4) 44.4 2.3 2.4
≤ 5 1213 (82.7) 488 (33.3) 7 1.5 (0.6-3.0) 39.7 2.5 2.0
≤ 6 1384 (94.4) 502 (34.2) 10 2.0 (1.0-3.7) 35.5 2.8 1.9
≤ 7 1416 (96.6) 502 (34.2) 10 2.0 (1.0-3.7) 34.7 2.9 1.9
*D-dimer cut-off remained 500 ng/ml; CDR: Clinical Decision Rule; CT/DD index: Computed Tomography/D-
dimer index; 
DD: D-dimer; NNT: Number Needed to Test for D-dimer in order to rule out one patient with PE; PE: 
Pulmonary Embolism; 
TN: True-Negative (=normal D-dimer in patients with a CDR unlikely and no VTE in follow-up); VTE: Venous 
Thrombo-Embolic events 
Table 3
Effect of varying CDR cut-off on test characteristics*
CDR score Sens (95%CI) Spec (95%CI) NPV (95%CI) PPV (95%CI)
≤ 4 98.8 (96.9-99.7) 37.5 (34.7-40.4) 99.1 (97.6-99.8) 31.5 (28.7-34.4)
≤ 5 97.9 (95.7-99.1) 42.3 (39.5-45.3) 98.6 (97.1-99.4) 33.0 (30.1-36.1)
≤ 6 97.0 (94.5-98.5) 43.3 (40.4-46.3) 98.0 (96.4-99.0) 33.2 (30.2-36.3)
≤ 7 97.0 (94.5-98.5) 43.3 (40.4-46.3) 98.0 (96.4-99.0) 33.2 (30.2-36.3)
*D-dimer cut-off level remained 500 ng/ml; CDR: Clinical Decision Rule, NPV: Negative Predicitve Value, PPV: 
Positive 
Predictive Value, Sens: Sensitivity; Spec: Specificity
Increasing the CDR cut-off level from 4 to 5 points or less would have resulted in a total 
of 1213 patients (82.7%) designated as “PE unlikely” and would have been tested for D-
dimer. D-dimer tests would have been normal in 488 patients (33.3% overall). The number 
of patients in whom the diagnosis of PE would have been ruled out without performing 
a CT scan increased from 430 at a cut-off level of 4 points or less to 488 patients at a 
cut-off level of 5 points or less, (58 patients, 4.0 % of the study population) at an expense 
of 3 additional venous thrombo-embolic events giving a three month VTE failure rate of 
1.5% (95%CI: 0.6-3.0%). The proportion of true-negative test results decreased to 39.7% 
(481/1213) at a CDR cut-off level of 5 and the corresponding number needed to test to 
rule out one PE by D-dimer test increased to 2.5 (1/0.397). The CT/DD index decreased 
to 2.0 (978/488). The sensitivity of using a cut-off level of five points while the D-dimer 
cut-off remained 500 ng/ml was 97.9% (95%CI: 95.7-99.1), the specificity 42.3% (95%CI: 
39.5-45.3) and the negative predictive value 98.6% (95%CI: 97.1-99.4)(Table 3). 
Further increasing the cut-off level of the CDR to 6 points or less would have resulted 
in 14 more patients (from 488 to 502, 0.9 % of the total study population) in whom the 
diagnosis of PE was ruled out without performing a CT scan at an expense of 3 more 
thrombo-embolic events (from 7 to 10) with a 3-month thrombo-embolic rate of 2.0% 
(95%CI: 1.0-3.7). The number needed to test for D-dimer increased to 2.8 (1/0.355) 
while the CT/DD index decreased to 1.9 (964/502).
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Varying the cut-off level of the D-dimer test
Table 4 demonstrates the effect of varying the cut-off level of the D-dimer test when the 
CDR cut-off level remained at 4 points or less to designate patients as “PE unlikely”. By 
increasing the cut-off level from 500 to 600 ng/ml, the diagnosis of PE could be ruled 
out without performing a CT scan in an additional 44 patients (from 430 to 474, 3.0% 
of the total study population) at an expense of 7 more venous thrombo-embolic events 
(from 4 to 11, 3-month VTE failure rate of 2.2% (95%CI: 1.1-4.0)). The proportion of 
true-negative test results increased to 48.2% (480/991) and the number needed to test for 
D-dimer to rule out one patient with PE decreased to 2.1 (1/0.482) while the CT/DD 
index decreased to 2.1(986/480).
By using the D-dimer cut-off level of 600 ng/ml, the sensitivity decreased to 96.7% 
(95%CI: 94.1-98.3), the specificity increased to 40.8% (95%CI: 37.9-43.7) and the 
negative predictive value decreased to 97.7% (95%CI: 95.9-98.8)(Table 5). 
Further increasing the cut-off level of the D-dimer concentration to 700 ng/ml to rule out 
PE resulted in a 3-month thrombo-embolic failure rate of 3.0% (95%CI: 1.8-4.9%).  
Table 4







3-month VTE failure rate % TN DD NNT CT/DD index
n % (95%CI)
≤ 500 960 (65.5) 430 (29.3) 4 0.9 (0.3-2.4) 44.4 2.3 2.4
≤ 600 960 (65.5) 474 (32.3) 11 2.2 (1.1-4.0) 48.2 2.1 2.1
≤ 700 960 (65.5) 507 (34.6) 16 3.0 (1.8-4.9) 51.1 2.0 1.9
≤ 800 960 (65.5) 545 (37.2) 20 3.5 (2.2-5.4) 54.7 1.8 1.7
≤ 900 960 (65.5) 576 (39.3) 23 3.9 (2.5-5.7) 57.6 1.7 1.5
≤ 1000 960 (65.5) 599 (40.9) 25 4.0 (2.6-5.9) 59.8 1.7 1.4
*Clinical Decision Rule cut-off remained ≤ 4 points; CT/DD index: computed tomography/D-dimer index; 
DD: D-dimer; NNT: Number 
Needed to Test for D-dimer; PE: Pulmonary Embolism; TN: True-Negative; VTE: Venous Thrombo-Embolic events
Table 5
Effect of varying D-dimer cut-off on test characteristics*
D-dimer
cut-off
Sens (95%CI) Spec (95%CI) NPV (95%CI) PPV (95%CI)
≤ 500 98.8 (96.9-99.7) 37.5 (34.7-40.4) 99.1 (97.6-99.8) 31.5 (28.7-34.4)
≤ 600 96.7 (94.1-98.3) 40.8 (37.9-43.7) 97.7 (95.9-98.8) 32.2 (29.3-35.2)
≤ 700 95.2 (92.3-97.2) 43.2 (40.3-46.2) 96.8 (94.9-98.2) 32.7 (29.8-35.8)
≤ 800 93.9 (90.8-96.3) 46.2 (43.3-49.2) 96.3 (94.4-97.7) 33.7 (30.6-36.8)
≤ 900 93.0 (89.7-95.5) 48.7 (45.7-51.6) 96.0 (94.1-97.5) 34.5 (31.4-37.7)
≤ 1000 92.4 (89.0-95.0) 50.5 (47.6-53.5) 95.8 (93.9-97.3) 35.2 (32.0-38.5)
*CDR cut-off level remained ≤ 4 points, NPV: Negative Predicitve Value, PPV: Positive Predictive Value, Sens: 
Sensitivity; 
Spec: Specificity
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We analysed the safety and clinical utility of varying the cut-off level of the CDR and 
D-dimer test in a large cohort study of patients suspected of pulmonary embolism. There 
are two important conclusions to be drawn from our analysis. First, our results show that 
increasing the cut-off level of the CDR while keeping the D-dimer test cut-of at 500 
ng/ml is not safe. The three-month thrombo-embolic failure rate exceeded our predefined 
upper safety limit of 2.7% even when the CDR cut-off level was only raised from 4 
to 5 points. Second, increasing the cut-off level of the D-dimer test had an even more 
profound effect on safety. By increasing the cut-off level from 500 to 600 ng/ml, the 
NPV dropped below 98% while the 3-month thrombo-embolic failure rate had an upper 
confidence limit (4.0%), which clearly exceeded our predefined upper safety limit.  
Importantly, the gain of clinical utility, i.e. the proportion of patients in whom PE could 
be ruled out without the need for additional imaging tests, was modest.  By raising the 
cut-off level of the CDR from 4 to 5 points, the CT/DD-index decreased from 2.4 to 2.0, 
reflecting only an additional 4.0% of the study population in whom PE could be ruled out. 
Similarly, by raising the D-dimer cut-off level from 500 to 600 ng/ml, the CT/DD-index 
decreased from 2.4 to 2.1 meaning that in only an additional 3.0% of the study population 
PE could be ruled out without imaging tests.  In our view this clearly demonstrates that 
using the CT/DD-index instead of the NNT (number needed to test for D-dimer) is 
clinically more meaningful because the consequences of changing cut-off levels for the 
whole population of patients with suspected PE can be directly derived from this index, 
while the NNT only describes the proportion of negative D-dimer tests in the population 
tested for D-dimer.  
This is the first study that investigated the effect of stepwise variation of both the cut-off 
level of the CDR as well as the D-dimer test. Two earlier studies have investigated the 
effect of varying the cut-off level of the D-dimer test in categories of pre-test probability 
without changing the cut-off levels to designate patients as low, intermediate or high 
clinical probability8;9. In the first study, increasing the D-dimer test cut-off level from 
500 to 600 ng/ml in patients with a low pre-test probability led to a marginal gain in 
diagnostic yield since PE could be ruled out in an additional 2.7% of the total study 
population. According to our predefined safety limit, the safety was not sacrificed since 
the 3-month thrombo-embolic failure rate increased only from 0% (95%CI:0-0.8%) to 
0.3% (95%CI: 0.01-1.4). This might be explained due to the low prevalence of PE (7%) 
in this subgroup with a low pre-test probability. Indeed, raising the D-dimer cut-off level 
from 500 to 600 ng/ml in patients with an intermediate probability (prevalence of PE 
35%) in the same study led to an unacceptably high 3-month thrombo-embolic rate of 
5.8% (95%CI: 1.9-13.1)9. 
The second study concluded that the use of three pre-test probability-specific D-dimer 
cut-off points excluded VTE in a larger proportion of patients (49.2%) than using a single 
cut-off point (36.4%) without sacrificing NPV (98%)8. However, the 3-month thrombo-
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embolic failure rate in patients with a low pre-test probability increased from 0% (upper 
95% confidence limit 1.5%) to 1.5% (upper 95% confidence limit 4.2%) and the sensitivity 
decreased dramatically from 100 to 75%. Of note, in this study the highest D-dimer cut-
off level was selected on the basis of a negative predictive value of at least 98%. The use 
of the NPV as a sole criterion of safety may be misleading since it is critically dependent 
on the prevalence of disease in the population tested. Finally, in the second study a mixed 
population of patients with clinically suspected PE and DVT was included.  
Of note, the safety of a diagnostic approach to rule out a possible fatal PE should be 
weighed against the clinical utility and costs involved in performing imaging tests. In our 
study, the increase of the CDR cut-off by one point – from 4 to 5 points- would have led 
to 0.4 less CT scans that had to be performed for every single D-dimer test that ruled out 
PE. Extrapolating this figure to the United States, with an estimated incidence of clinically 
suspected PE of 380.000 cases annually (94.000 PE cases yearly10, PE prevalence ~ 25%), 
approximately 120.000 CT scans (32%) are saved by using the original cut-off point of 
the CDR of 4 points and D-dimer cut-off level of 500 ng/ml, while an additional 15.000 
CT-scans (4%) could be saved by using the higher cut-off of the CDR of 5 points10. 
Our study could be criticized for the fact that we used data of 5 of the 12 hospitals 
participating in a large, prospective management study of a diagnostic algorithm. We do 
not think this has led to selection bias, since the prevalence of PE as well as the baseline 
characteristics of the study patients was similar to the overall population of our original 
cohort6. Second, two different D-dimer assays were used. Since there was no statistically 
significant difference in failure rate between the two tests in the original study, we have 
taken data from these D-dimer tests together.  
Strengths of our study are that we had a relatively large cohort of patients suspected of PE 
in which the diagnosis was ruled out or diagnosed by a simple algorithm and all outcome 
events were adjudicated by an independent committee.  
In conclusion, our results demonstrate that the cut-off level of the CDR to designate 
patients as “PE unlikely” and the cut-off level of the D-dimer test to designate a test 
result as “normal” should be kept at the original CDR cut-off level of 4 points and 
D-dimer concentration of 500 ng/ml, in order to prevent exposure of patients to a 3-
month thrombo-embolic failure rate exceeding that of a normal pulmonary angiography. 
The challenge for future studies is to provide algorithms, which can safely reduce the 
percentage of patients undergoing imaging tests for PE.  
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The anatomic distribution of pulmonary embolism (PE) in central, segmental and sub-
segmental arteries is understudied and an often-debated issue is the possible limitation of 
computed tomography (CT) to accurately detect peripheral emboli. Multi-detector row 
CT (MDCT) is thought to increase the detection rate of sub-segmental emboli compared 
to single-detector row CT (SDCT). We evaluated the prevalence and anatomic distribution 
of PE in consecutive patients with proven PE diagnosed by MDCT or SDCT. 
Methods
Data were obtained from a diagnostic outcome study of patients suspected of PE. An 
algorithm consisting of sequential application of a clinical decision rule, a quantitative D-
dimer test and single- or multi-detector row CT diagnosed PE. The location of PE was 
classified into three groups (central, segmental and sub-segmental PE) with emphasis on 
the largest pulmonary arterial branch involved. 
Results
A total of 3306 consecutive patients were included in the diagnostic study, of whom 674 
(20%) were diagnosed with PE. Data regarding the localisation of PE were missing in 41 
patients. Localisation of PE in MDCT was central in 160 patients (29%, 95%CI: 25-33), 
segmental in 293 patients (53%, 95%CI: 49-57) and sub-segmental in 98 patients (18%, 
95%CI: 15-21). In patients diagnosed with SDCT, PE was central in 31 patients (38%, 
95%CI: 27-49), segmental in 39 patients (48%, 95%CI: 36-59) and sub-segmental in 12 
patients (15%, 95%CI: 8-24). The percentage of detected PE did not differ significantly 
between MDCT and SDCT (31% vs. 32%, p=0.65), neither the percentage of sub-
segmental PE (18% vs. 15%, p=0.48) detected by MDCT or SDCT.  
Conclusions
The percentage of detected subsegmental PE did not differ between MDCT and SDCT. 
There seems to be no danger of over-diagnosis of small subsegmental PE using multi- 
detector row systems. 
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Over the past years the role of contrast material-enhanced computed tomography (CT) in 
the diagnosis of pulmonary emboli (PE) at the level of segmental and central pulmonary 
arteries is well established; hence this method has become the first line diagnostic test for 
the evaluation of PE in many institutions1-3.
The reliability of CT in the detection of smaller emboli in subsegmental arteries has been 
the subject of debate however4;5. Within the past years, multi-detector row CT (MDCT) 
has been introduced. The most prominent feature of MDCT is its high-speed acquisition, 
enabling quick coverage of large volumes, and improved spatial resolution. This should 
theoretically result in the visualisation of more than 90% of subsegmental arteries6 . 
Importantly, the need for diagnosing isolated subsegmental pulmonary embolism, i.e. 
PE limited to subsegmental arteries, is still uncertain7. This is reflected by the discrepancy 
between the overall sensitivity for PE for single-detector row CT (SDCT) and the 
outcome studies in which patient management was based on a normal SDCT. Thus, in 
two large prospective studies the sensitivity of SDCT for detecting all PE has been found 
to be around 70%4;8 while the same research groups observed a low 1-2% three months 
thrombo-embolic risk in patients left untreated based on a single normal SDCT and 
normal lower limb compression ultrasound3;9. It has been argued that diagnosing more 
subsegmental PE with multi-detector row CT may therefore lead to overtreatment of 
small pulmonary emboli without apparent clinical need with associated risk of bleeding. 
Contra wise, there is also expert opinion based consensus that the presence of peripheral 
emboli may be an important indicator of concurrent deep vein thrombosis and thus 
potentially heralds more severe embolic events; this would then underscore the need 
to accurately diagnose subsegmental emboli10-12. However, the need for anticoagulant 
treatment in the presence of an isolated subsegmental pulmonary embolus has never 
been studied.
In the PIOPED study, the proportion of PE limited to the subsegmental arteries using 
pulmonary angiography was 6% (95%CI: 4-9%)13. In three other studies that used 
pulmonary angiography, of which one was a retrospective study10, isolated subsegmental 
PE was observed in 10-36 % of patients10;14;15. Establishing the true prevalence of 
subsegmental PE is complicated by the 45-66% reported inter-observer variability for 
detecting emboli at the subsegmental level in pulmonary angiography16;17. Using single-
detector row CT, the prevalence of subsegmental PE was 22% (29/130)18 in one study. 
In two other studies, using multi-detector row CT, the prevalence was 7% (14/187)2 
and 15% (8/54)19. These data underline the uncertainty of establishing the prevalence 
of subsegmental PE and indicate that it is currently not established whether multi-
detector row CT is more accurate in diagnosing subsegmental PE than single-detector 
row CT.  
We analysed the distribution of central, segmental and subsegmental PE in a large cohort 
of consecutive patients diagnosed with PE by multi- or single-detector row CT as part of 
a large management study in patients presenting with clinically suspected PE1. 





This study was part of a large management study of diagnosing PE using clinical probability, 
a quantitative D-dimer test and CT1. The study was conducted in twelve Dutch hospitals 
(five academic and 7 urban hospitals), from November 2002 through September 2004. 
Approval of the Medical Ethics Committee in all participating institutions was obtained 
prior to the start of the study. All consecutive in- and outpatients with clinically suspected 
PE were considered for inclusion. Exclusion criteria were patient age under 18 years, use 
of low-molecular weight heparin (LMWH) or unfractionated heparin (UFH) more than 
24 hours prior to inclusion, pregnancy, allergy to roentgen contrast, life expectancy less 
than three months, geographic inaccessibility precluding follow-up, renal insufficiency 
(creatinine clearance < 30 mL/min [0.5 mL/sec]), logistic reasons (unavailability of CT, 
patient too ill to undergo CT-scanning) and haemodynamic instability. 
Study protocol
The study protocol is described in detail elsewhere1. In brief, a clinical probability score according 
to Wells was performed and in patients designated ‘PE unlikely’ (score ≤ 4 points), a normal 
quantitative D-dimer test (≤500 ng/ml) excluded PE. In patients designated 'PE likely' (score 
> 4 points) or with an abnormal D-dimer test, helical CT was performed. If CT demonstrated 
PE, anticoagulant therapy was initiated. Specifically, patients with PE demonstrated in 
subsegmental arteries were treated. If CT excluded PE, anticoagulation therapy was withheld. 
CT angiography was performed using either single- or multi-detector row systems as described 
before1. The pulmonary arteries were evaluated up to and including the subsegmental vessels 
from the level of the aortic arch to the lowest hemi-diaphragm. PE was diagnosed if contrast 
material outlined an intraluminal defect or if a vessel was totally occluded by low-attenuation 
material on at least two adjacent slices. The decision of the presence or absence of PE was 
made by a trained attending radiologist. The localisation of the pulmonary embolism was 
locally assessed and categorised into three classes, according to the largest pulmonary vessel in 
which PE could be seen: central (main pulmonary stem, right or left main pulmonary artery, 
lobar artery), segmental or sub-segmental artery. 
Statistical analysis
Exact 95% confidence intervals (CI) were calculated around the observed incidences 
using JavaStat software (http://statpages.org/confint.html). Descriptive parameters 
were calculated using the SPSS software, version 11 (SPSS, Inc., Chicago, Illinois). The 
univariate relation between baseline characteristics and outcome was examined by chi-
square statistics for categorical variables and t-tests for continuous variables. Fisher’s Exact 
test was used when the expected values were less than five. Non-parametric tests were 
used for continuous variables that were not normally distributed. A level of significance of 
0.05 (two-tailed) was used in all tests.  
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Age – yr* 57 (28) 59 (32) 0.50
Female sex 56 61 0.2
Duration of complaints – days* 2 (6) 3 (6) 0.33
Inpatients 25 19 0.05
Risk factors for venous thromboembolism
 Paralysis, paresis or plaster cast lower limbs‡ 4 2 0.1
 Immobilisation/bed rest > 3 days‡ 27 19 0.004
 Immobilisation due to travel by car or air‡ 5 4 0.35
 Surgery ‡ 9 6 0.21
 Previous DVT or PE 17 17 0.94
 Use of estrogen 11 13 0.47
 Heart failure with therapy 9 8 0.65
 COPD with therapy 12 13 0.50
 Malignancy 19 18 0.73
Clinical findings – %
 Signs of deep vein thrombosis 8 11 0.17
 Tachycardia (>100 beats per min) 33 38 0.09
 PE more likely than alternative diagnosis 71 74 0.35
*median (IQR), ‡ within previous month. COPD= chronic obstructive pulmonary disease, DVT= deep vein 
thrombosis, MDCT= multi-detector row computed tomography, PE= pulmonary embolism, SDCT= single-
detector row computed tomography
Results
A total of 3503 patients suspected of PE were screened and 184 met one of the exclusion 
criteria: more than 24 hours of (low molecular weight) heparin (n=50), life expectancy 
less than 3 months (n=47), pregnancy (n=26), geographic inaccessibility precluding follow 
up (n=20), and other reasons (n=41). In addition, 13 patients refused consent. A total of 
3306 patients were included into the study and a clinical decision rule indicating PE 
unlikely combined with a normal D-dimer test excluded PE in 1057 patients (32%). 
The remaining 2249 had to undergo CT scanning, but in 50 patients the protocol was 
violated and CT was not performed, while in 20 patients CT was inconclusive. A total 
of 2179 patients underwent CT scanning. Multi-detector row CT was performed in 
1921 patients (88%) and single-detector row CT in 258 patients (12%). The baseline 
characteristics of patients undergoing MDCT and SDCT are shown in Table 1. Patients 
were comparable in age (median 57 versus 59 years, p=0.5), sex (56% versus 61% female, 
p=0.2) and duration of complaints (median 2 versus 3 days, p=0.33). The percentage of 
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inpatients was higher in MDCT (25%) versus SDCT (19%, p=0.005). The presence of 
comorbidity, i.e. heart failure, COPD or malignancy was similar in both groups. All other 
risk factors for thrombosis and clinical findings were equally present in patients undergoing 
MDCT and SDCT, except for immobilisation due to bed rest, which was significantly 
more prevalent in patients undergoing MDCT (27%) than in patients undergoing SDCT 
(19%, p=0.004). 
PE was present in 31% of patients who underwent MDCT (591/1921, 95%CI: 29-
33) and in 32 of patients (83/258, 95%CI: 27-38, p=0.65) who underwent SDCT. The 
characteristics of all patients diagnosed with PE are described in Table 2.  
Table 2
Baseline characteristics of the 674 patients with PE
Characteristics PE
Age – yr* 58 (19-100)
 < 55 yr, n (%) 296 (44)
 ≥ 55 – 65 yr, n (%) 117 (17)
 > 65 yr, n (%) 261 (39)
Female sex (%) 51
Duration of complaints – days† 2 (0-90)








Risk factors for venous thromboembolism – %
 Paralysis, paresis or plaster cast lower limbs‡ 6
 Immobilisation/bed rest > 3 days‡ 17
 Immobilisation due to travel by car or air‡ 7
 Surgery‡ 10
 Previous deep vein thrombosis 9
 Previous pulmonary embolism 10
 Heart failure with therapy 6
 COPD with therapy 9
 Malignancy 19
Clinical findings – %
 Signs of deep vein thrombosis 15
 Tachycardia (>100 beats per min) 37
 Haemoptysis 8
*Mean (range), † median (range), ‡ within previous month, PE: Pulmonary Embolism, 
ƒ missing data in 41 patients
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Data regarding the localisation of PE were missing in 41 patients (6%).  
Of the remaining 633 patients, PE was central in 30% of patients (n=191), segmental 
in 52% of patients (n=332) and subsegmental in 17% of patients (n=110). MDCT had 
been performed in 551 patients with PE and SDCT in 82 patients. Localisation of PE 
detected by MDCT was central in 29% (160/551, 95%CI: 25-33), segmental in 53% 
(293/551, 95%CI: 49-57) and sub-segmental in 18% (98/551, 95%CI: 15-21) (Table 
3). Lokalisation of PE detected by SDCT was central in 38% (31/82, 95%CI: 27-49), 
segmental in 39 patients (48%, 95%CI: 36-59) and sub-segmental in 12 patients (15%, 
95%CI: 8-24). 
The percentage of detected subsegmental PE did not differ between MDCT and SDCT 
(18% vs. 15%, p=0.48), neither did the percentage of segmental PE (53% vs 48%, p=0.34). 
The percentage of central PE was non significantly higher in SDCT compared to MDCT 
(38% vs. 29%, p=0.11).
Table 3
Multi-detector row CT versus Single-detector row CT
MDCT SDCT p-value
N %(95%CI) N %(95%CI)
Percentage of PE 591/1921 31 (29-33) 83/258 32 (27-38) 0.65
Central PE 160/551 29 (25-33) 31/82 38 (27-49) 0.11
Segmental PE 293/551 53 (49-57) 39/82 48 (36-59) 0.34
Subsegmental PE 98/551 18 (15-21) 12/82 15 (8-24) 0.48
Three-month thrombo-embolic risk after a normal CT
In 1505 patients, CT excluded a diagnosis of PE. Of these, 69 patients received treatment 
with anticoagulants for other reasons than VTE and of the remaining 1436 untreated 
patients, 18 were diagnosed during follow-up with a thrombo-embolic event (1.3%, 
95%CI: 0.7-2.0). In patients in whom the diagnosis of PE was excluded by MDCT, the 
three-month thrombo-embolic risk of patients was 1.1% (14/1330, 95%CI: 0.6-1.8).  The 
14 thrombo-embolic events in patients with a normal MDCT consisted of 6 fatal PE’s, 3 
non-fatal PE’s and 5 DVT’s. 
In patients in whom PE was excluded by SDCT this risk was 2.3% (4/175, 95%CI: 0.6-
5.8; p=0.15). These events consisted of  1 fatal PE and 3 DVT’s. 




Our study shows the anatomical distribution of PE in a large cohort of consecutive in and 
outpatients with clinically suspected PE. We have shown, using multi row detection systems, 
18 % of patients to have pulmonary emboli in their subsegmental arteries as the most proximal 
location of PE. These findings are well comparable to the range of 6-30% of subsegmental 
pulmonary emboli reported in the literature (13,18). Using pulmonary angiography, in the 
largest study isolated PE was observed in 22 of 375 patients with PE (6%). In a study of 
487 consecutive patients suspected of PE, using an algorithm with VQ scanning, SDCT 
and pulmonary angiography, the prevalence of isolated subsegmental PE was 22% (29/130, 
95%CI: 16-30)18 while in two other studies, the prevalence of subsegmental PE detected by 
MDCT was 15% (8/54, 95%CI: 7-27)19 and 7% (14/187, 95%CI: 4-12)2. 
Importantly, in spite of the expected superior imaging quality of MDCT, we did not detect 
a difference in localisation of PE between single row technology and multi-row detector 
systems. Our findings offer strong support against the argument that the introduction of newer 
generations of multi row detector CT systems would lead to over-diagnosis of smaller pulmonary 
emboli in smaller subsegmental arteries and associated over treatment with anticoagulants. 
Several limitations in our study require comment. First, the localisation of the highest branch 
of pulmonary embolism was assessed locally. A central blinded reading of CT’s by a team of 
radiologists might have been more accurate and would have allowed establishing the inter-
observer agreement between radiologists. However, our study is a management study and 
reflects daily practice. Second, the number of patients that underwent single-detector row 
CT was rather small in comparison to the number of patients undergoing multi-detector row 
CT. Multi-detector row CT has been introduced rapidly in many hospitals worldwide before 
any formal evaluation of this technique could have taken place and it is therefore unlikely that 
a comparison study of single- and multi-detector row CT is going to be performed. Third, a 
diagnosis of PE was made if contrast material outlined an intraluminal defect or if a vessel was 
totally occluded by low-attenuation material on at least two adjacent slices. In the ESSEP-
study, isolated subsegmental PE was regarded as an inconclusive CT result in patients with 
a normal lower limb compression ultrasound and further tests were required9 while in two 
other studies2;20 isolated subsegmental PE was diagnosed if defects were multiple. Although 
the criteria for establishing a diagnosis of PE vary, it is a difficult task to prove the presence 
of subsegmental PE in a comparative manner. The gold standard, pulmonary angiography, is 
known to have an inter-observer agreement of only 45-66% for isolated subsegmental PE16;17 
and might therefore perform inadequately in diagnosing subsegmental PE. Moreover, in a 
porcine model, there appeared to be no difference in accuracy of detecting subsegmental PE 
between multi-detector row CT and pulmonary angiography21. 
We conclude that using MDCT the incidence of pulmonary emboli at the subsegmental 
and smaller arteries was not different when using SDCT technology. There seems to be no 
clear risk of overdiagnosis and associated over treatment using newer multi-row detector 
system CT technology in patients presenting with clinically suspected PE.
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Pulmonary embolism (PE) is a potentially fatal disease with risks of recurrent venous 
thrombotic events (VTE) and major bleeding from anticoagulant therapy. Identifying risk 
factors for recurrent VTE, bleeding and mortality may guide clinical decision-making. 
Objective: To evaluate the incidence of recurrent VTE, hemorrhagic complications and 
mortality in patients with PE and to identify risk factors and the time course of these 
events. 
Design
We evaluated consecutive patients with PE, derived from a prospective management 
study, who were followed for three months, treated with anticoagulants and underwent 
objective diagnostic testing for suspected recurrent VTE or bleeding. 
Results
Of 673 patients with complete follow-up, 20 patients (3.0%, 95%CI: 1.8-4.6) had 
recurrent VTE. Eleven of 14 patients with recurrent PE had a fatal PE (79%, 95%CI: 49-
95%), occurring mostly in the first week after diagnosis of initial PE. In 23 patients (3.4%, 
95%CI: 2.2-5.1) a hemorrhagic complication occurred, 10 of which were major bleeds 
(1.5%, 95%CI: 0.7-2.7) and two were fatal (0.3%, 95%CI: 0.04-1.1). During the three-
month follow-up, 55 patients died (8.2%, 95%CI: 6.2-10.5). Risk factors for recurrent 
VTE were immobilisation for more than 3 days; being an inpatient, having COPD or 
malignancies were risk factors for bleeding. Higher age, immobilisation, malignancy and 
being an inpatient were risk factors for mortality. 
Conclusions
Recurrent VTE occurred in a small percentage of patients treated for an acute PE and 
the majority of recurrent PE’s  were fatal. Immobilization, hospitalization, age, COPD 
and malignancies were risk factors for recurrent VTE, bleeding and mortality. Close 
monitoring may be indicated in these patients, precluding them from out of hospital start 
of treatment. 
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Pulmonary embolism (PE) is a potentially fatal disease with long-term sequelae such as 
recurrent thrombotic events and major bleeding from anticoagulant therapy. Few studies 
have investigated the clinical course of PE and varying incidences of recurrent events, 
bleeding complications and mortality have been reported1-4. During the first three months 
of anticoagulant treatment the reported rate of recurrent venous thrombo-embolism 
(VTE) in patients with PE has ranged from 2 to 6% 1-4. The rate of major bleeding during 
the first three months ranged from 2% to 4%1-4. An accurate estimate of both incidences 
of recurrent VTE and major bleeding is important but moreover, it is desirable to identify 
risk factors indicating which patients are at increased risk for an adverse clinical outcome 
of PE. Previous studies1-4 involved a relatively limited amount of patients diagnosed with 
PE precluding an accurate estimate of clinical outcomes. Further, in one study, only risk 
factors for recurrent VTE were assessed while patients diagnosed with PE as well as 
patients with deep vein thrombosis (DVT) were included, while it is known that patients 
with DVT may face a more favourable outcome than patients with PE2;5. 
We evaluated the clinical outcome during three months of a large group of consecutive 
patients with PE. We aimed to assess the incidence of recurrent venous thrombo-embolism, 
mortality and hemorrhagic complications in patients diagnosed with PE and treated with 
oral anticoagulants during this follow-up period. Second, we aimed to identify risk factors 
for recurrence, bleeding and mortality and to determine the time course of these events 
within 3 months of the start of treatment.  
Methods
Study design
Consecutive patients with PE confirmed by helical computed tomography were included. 
They were derived from a large, prospective management study using a diagnostic algorithm 
that consisted of a clinical decision rule, a D-dimer test and helical computed tomography 
(CT)6. Out- as well as inpatients were eligible. Exclusion criteria of this management-
study were: treatment with therapeutic doses of unfractionated or low-molecular-weight-
heparin for more than 24 hours, life expectancy less than 3 months, pregnancy, geographic 
inaccessibility precluding follow-up, age below 18 years, allergy to intravenous contrast 
agents or hemodynamic instability (defined as a systolic blood pressure below 90 mmHg or 
symptoms and signs of shock). The Institutional Review Boards (IRB’s) of all participating 
hospitals approved the study protocol and written or oral informed consent was obtained 
from all participants, depending on the requirements of the local IRB’s.
Before any diagnostic test was performed, demographic data of all patients were recorded. 
An inpatient was defined as a patient hospitalised for some other health problem than 
pulmonary embolism that developed symptoms possibly due to PE during hospitalisation. 
Surgery was defined as major surgery within the past month, heart-failure was defined 
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as NYHA class 2-4 for which specific therapy was given and malignancy was defined as 
active malignancy with ongoing treatment or within the past six months or in the palliative 
stages. All patients were initially treated with body-weight adjusted therapeutic doses of 
low-molecular weight heparin for at least five days or bodyweight adjusted unfractionated 
heparin aiming at an activated partial thromboplastin time between 1.5 and 2 times the 
baseline value, followed by vitamin K antagonists, aiming at an International Normalized 
Ratio (INR) of 2.0 to 3.0 for a period of six months. 
Follow-up 
Follow-up was vigorously pursued and consisted of a fixed hospital visit or telephone 
interview after three months. In addition, all patients got a detailed instruction on signs 
and symptoms of recurrent PE and DVT and they were instructed to contact the study 
centre immediately in case of complaints suggestive of DVT, PE or bleeding. At each visit, 
information was obtained on complaints suggestive for recurrent venous thrombo-embolism 
and bleeding. In case of clinically suspected DVT, PE or a hemorrhagic complication, 
appropriate objective tests were required to confirm or refute the diagnosis.
Outcome
The outcome of the study was the incidence of symptomatic recurrent venous 
thromboembolism, as well as the incidence of hemorrhagic complications and mortality in 
patients with confirmed PE during the three-month study period. Symptomatic recurrent 
venous thrombo-embolism was considered to have occurred if recurrent PE or DVT was 
documented objectively or if there was a death in which PE could not be confidently 
ruled out as a contributing cause. The objective criterion for the diagnosis of recurrent PE 
was a new intraluminal filling defect on spiral CT or pulmonary angiography; cut-off of 
contrast-material in a vessel more than 2.5 mm in diameter on pulmonary angiography; 
a new perfusion defect involving at least 75 percent of a segment, with corresponding 
normal ventilation (i.e., a high probability lung scan); a new non-diagnostic lung 
scan accompanied by documentation of deep vein thrombosis by ultrasonography or 
venography; or confirmation of a new pulmonary embolism at autopsy7;8. The objective 
criterion of a new deep vein thrombosis was a new, non-compressible venous segment 
or a substantial increase (4mm or more) in the diameter of the thrombus during full 
compression in a previously abnormal segment on ultrasonography or a new intraluminal 
filling defect on venography9;10.
Mortality was classified as death due to recurrent PE (fatal PE), fatal bleeding, cancer or 
another established diagnosis. Information about the cause of death was obtained from 
autopsy reports or from a clinical report. Hemorrhagic complications were the composite 
of major bleeding and clinically relevant bleeding. A major bleeding was defined as fatal 
bleeding, and/or symptomatic bleeding in a critical area or organ, such as intracranial, 
intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with 
compartment syndrome, and/or bleeding causing a fall in haemoglobin level of 20 g L 1 
(1.24 mmol L 1) or more, or leading to transfusion of two or more units of whole blood 
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or red cells11. Bleeding was considered clinically relevant when the episode did not qualify 
as a major bleeding but included one of the following: epistaxis requiring intervention, 
formation of a large haematoma visible on the skin or spontaneous macroscopic haematuria. 
All suspected outcome events were reviewed and classified by an independent adjudication 
committee. Deaths were classified by the committee as caused by pulmonary embolism 
if autopsy confirmed pulmonary embolism, in case of an objective test demonstrating 
pulmonary embolism prior to death, or if pulmonary embolism could not be confidently 
excluded as the cause of death. Other causes of death were classified based on autopsy 
findings or clinical reports.
Statistical analysis
The univariate relation between baseline characteristics and outcome was examined by 
chi-square statistics for categorical variables and t-tests for continuous variables. Fisher’s 
Exact test was used when the expected values were less than five. A level of significance of 
0.05 (two-tailed) was used in all tests. Multivariate stepwise logistic regression was used 
to identify independent predictors of recurrent VTE, bleeding and mortality. Variables 
were included only in the final (multivariate) analysis based on their level of significance 
(p<0.10), except for the variables age and sex that were independent of significance 
included in the analysis. The odds ratio and corresponding 95% confidence interval was 
reported for each variable in the model. The analyses were performed using SPSS software, 
version 11 (SPSS, Inc., Chicago, Illinois).     
Results
Study patients
Between November 2002 and September 2004 a total of 3503 patients with clinically 
suspected PE were screened, of whom 197 (5.6%) were excluded because of predefined 
exclusion criteria or refused informed consent: more than 24 hours of low molecular weight 
heparin (n=50), life expectancy less than 3 months (n=47), pregnancy (n=26), geographic 
inaccessibility precluding follow up (n=20), and other reasons (n=41). In addition, 13 
patients refused informed consent6. In 674 patients (20%) PE was diagnosed. The baseline 
characteristics of these patients are described in Table 1. Three-month follow-up was 
completed in 673 of the 674 patients with PE (99.9%).




Baseline characteristics of the 674 patients with PE
Characteristics PE
Age – yr* 58 (19-100)
 < 55 yr, n (%) 296 (44)
  ≥ 55 – 65 yr, n (%) 117 (17)
 > 65 yr, n (%) 261 (39)
Sex - ♀ (%) 51
Duration of complaints – days† 2 (0-90)








Risk factors for venous thromboembolism – %
 Paralysis, paresis or plaster cast lower limbs‡ 6
 Immobilisation/bed rest > 3 days‡ 17
 Immobilisation due to travel by car or air‡ 7
 Surgery‡ 10
 Previous deep vein thrombosis 9
 Previous pulmonary embolism 10
 Heart failure with therapy 6
 COPD with therapy 9
 Malignancy 19
Clinical findings – %
 Signs of deep vein thrombosis 15
 Tachycardia (>100 beats per min) 37
 Haemoptysis 8
*Mean (range), † median (range), ‡ within previous month, § in females only, PE:
Pulmonary Embolism, ƒ missing data in 41 patients
Recurrent symptomatic venous thrombo-embolism
Of the 673 patients with PE and complete follow-up, 20 patients (3.0%, 95%CI: 1.8-
4.6) had an objectively confirmed recurrent venous thrombo-embolic event during the 3-
months follow-up period. Seventy percent of patients with a recurrent venous thrombo-
embolic event (14/20) had a recurrent PE (2.1% overall) and only 30% (6/20) a DVT 
(0.9% overall). Recurrent PE was fatal in 11 of 14 patients (79%, 95%CI: 49-95%) with 
recurrent PE (1.6% overall), resulting in a case-fatality rate (number of fatal recurrences 
divided by total number of recurrences) of 55% (11/20). Recurrent thrombotic events 
occurred predominantly within the first 3 weeks after the diagnosis (14 of 20 events, 
Figure 1). Recurrent fatal PE occurred mainly in the first week (6 of 11 events) and 
significantly earlier (median 5 days, range 58 days) than recurrent non-fatal PE (median 
29 days, range 74, p=0.04). All fatal recurrent PE’s occurred during hospitalisation, while 
1 of 3 non-fatal recurrent PE’s and 2 of 6 recurrent DVT’s occurred in hospital. 
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Timing of recurrent thrombotic events
 























Risk factors for recurrent VTE in patients with pulmonary embolism
Risk factors Patients with PE 
and recurrence





Age in years* 63 (17) 57 (18) 0.15 1.02 (0.99-1.05)
Sex, female 10 (50%) 331 (51%) 0.96 0.98 (0.40-2.38)
Inpatients 6 (30%) 144 (22%) 0.39 1.52 (0.58-4.04)
Paralysis/paresis 1 (5%) 37 (6%) 1.00 0.87 (0.11-6.67)
Immobilisation > 3 days 8 (40%) 105 (16%) 0.005 3.50 (1.40-8.77)
Travel by air or car 2 (10%) 44 (7%) 0.64 1.55 (0.35-6.88)
Surgery 2 (10%) 66 (10%) 1.00 0.99 (0.23-4.36)
Previous VTE 3 (15%) 126 (19%) 0.78 0.74 (0.21-2.57)
Previous PE 2 (10%) 64 (10%) 1.00 1.02 (0.23-4.52)
Heart failure 0 40 (6%) 0.63 0.94 (0.92-0.96)
COPD 2 (10%) 60 (9%) 0.71 1.09 (0.25-4.83)
Malignancy 4 (20%) 126 (19%) 1.00 1.05 (0.34-3.18)
Signs of DVT 5 (25%) 95 (15%) 0.20 1.96 (0.70-5.51)
Tachycardia 9 (45%) 240 (37%) 0.45 1.41 (0.58-3.46)
* Mean (SD), DVT: Deep Vein Thrombosis, PE: Pulmonary Embolism, VTE: Venous Thrombo-embolic Events
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Predictors of recurrent thrombotic events 
Only one single variable, immobilisation for more than 3 days prior to the diagnosis 
of the initial PE, appeared as a significant predictor of a recurrent thrombotic event in 
univariate analysis (OR 3.50, 95%CI: 1.40-8.77) and therefore, multivariate analysis was 
not performed (Table 2). Patients with recurrences were older (a mean of 63 versus 57 
years, OR 1.02) but this risk factor did not reach significance. A separate analysis for risk 
factors of fatal recurrent PE was performed but did not show other results than for the 
whole group of recurrent events (immobilisation as a risk factor for recurrent fatal PE: 
OR 2.79, 95%CI: 1.43-5.45, other risk factors and OR’s not shown).  
Bleeding rate in patients with PE
A hemorrhagic complication of anticoagulant therapy occurred in 23 patients with PE 
(3.4%, 95%CI: 2.2-5.1). Bleeding was major in 10 patients (1.5%, 95%CI: 0.7-2.7) of 
which two were fatal (0.3%, 95%CI: 0.04-1.1). Clinically relevant bleeding occurred in 
the remaining 13 patients (1.9%, 95%CI: 1.0-3.3). The case fatality rate of bleeding was 
9% (2/23, 95%CI: 1-28). Both fatal bleeding events occurred out-of-hospital while 7 
of the 8 non-fatal major bleedings occurred in-hospital and 7 of 13 clinically relevant 
bleeding occurred in-hospital.
Table 3
Risk factors for bleeding in patients with pulmonary embolism (clinically relevant and major bleeding)
Risk factors Patients 





Univariate analysis Multivariate analysis
p-value OR (95%CI) p-value OR (95%CI)
n 23 650
Age in years* 56 (17) 58 (18) 0.66 1.00 (0.97-1.02)
Sex, female 10 (44%) 331 (51%) 0.49 0.74 (0.32-1.72)
Inpatients 11 (48%) 139 (21%) 0.003 3.39 (1.46-7.85) 0.05 2.63 (1.02-6.77)
Paralysis/paresis 1 (4%) 37 (6%) 1.0 0.75 (0.10-5.70)
Immobilisation > 3 days 4 (17%) 109 (17%) 1.0 1.05 (0.35-3.14)
Travel by air or car 0 46 (7%) 0.39 0.93 (0.91-0.95)
Surgery 6 (26%) 62 (10%) 0.02 3.34 (1.27-8.79) 0.23 1.92 (0.66-5.59)
Previous VTE 4 (17%) 125 (19%) 1.0 0.89 (0.30-2.66)
Previous PE 3 (13%) 63 (10%) 0.48 1.41 (0.41-4.86)
Heart failure 1 (4%) 39 (6%) 1.0 0.71 (0.09-5.40)
COPD 5 (22%) 57 (9%) 0.05 2.88 (1.03-8.05) 0.02 3.89 (1.22-12.4)
Malignancy 9 (39%) 121 (19%) 0.03 2.81 (1.19-6.64) 0.02 3.04 (1.16-7.97)
Hemoptysis 3 (13%) 52 (8%) 0.42 1.73 (0.50-6.01)
PE: Pulmonary Embolism, VTE: Venous Thrombo-embolic Events, *Mean (SD) 
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Table 3 shows the effect of clinical characteristics on the risk of clinically relevant or 
major bleeding using univariate and multivariate analysis. In multivariate analysis, being 
an inpatient (OR 2.63, 95%CI: 1.02-6.77), having COPD (OR 3.89, 95%CI: 1.22-12.4) 
or a malignancy (OR 3.04, 95%CI: 1.16-7.97) remained independent risk factors for 
bleeding in patients with PE. 
Mortality in patients with PE
Of 673 patients diagnosed with PE and with complete follow-up, 55 patients (8.2%, 
95%CI: 6.2-10.5) died during the three-month follow-up period. Of these 55 patients, 11 
died because of fatal recurrent PE (20%, 95%CI: 10-33). None of these fatal recurrences 
underwent autopsy to confirm the cause of death. Two patients died because of fatal 
haemorrhage (4%, 95%CI: 0.4-13). The cause of death in the remaining patients with 
PE was mainly malignancy (17 patients, 35%) or cardiovascular disease (9 patients, 16%). 











Timing of deaths in days
Predictors of mortality in patients with PE
In multivariate analysis, 4 clinical characteristics were shown to be independent risk 
factors for mortality in patients with PE (Table 4); 1) age (OR 1.04, 95%CI: 1.02-1.07); 
2) immobilisation for more than 3 days (OR 2.07, 95%CI: 1.06-4.); 3) malignancy (OR 
3.02, 95%CI: 1.65-5.52) and 4) being an inpatient (OR 2.11, 95%CI: 1.15-3.88). 









Univariate analysis Multivariate analysis
p-value OR (95%CI) p-value OR (95%CI)
n 55 618
Age in years* 69 (16) 57 (18) <0.001 1.05 (1.03-1.07) <0.001 1.04 (1.02-1.07)
Sex, female 25 (46%) 308 (50%) 0.41 0.80 (0.46-1.38)
Inpatients 25 (46%) 125 (20%) <0.001 3.31 (1.88-5.83) 0.02 2.11 (1.15-3.88)
Paralysis/paresis 2 (4%) 36 (6%) 0.49 0.60 (0.14-2.57)
Immobilisation > 3 days 17 (31%) 95 (15%) 0.004 2.41 (1.30-4.44) 0.03 2.07 (1.06-4.05)
Travel by air or car 0 45 (7%) 0.03 0.93 (0.91-0.95) 0.69 0.003 (0-5*109)
Surgery 5 (9%) 63 (10%) 0.76 0.86 (0.33-2.24)
Previous VTE 8 (15%) 116 (19%) 0.40 0.72 (0.33-1.56)
Previous PE 6 (11%) 60 (10%) 0.77 1.14 (0.47-2.77)
Heart failure 6 (11%) 32 (5%) 0.12 2.23 (0.89-5.59)
COPD 10 (18%) 48 (8%) 0.02 2.62 (1.24-5.54) 0.17 1.77 (0.79-3.97)
Malignancy 24 (44%) 104 (17%) <0.001 3.72 (2.09-6.59) <0.001 3.02 (1.65-5.52)
Clinical signs of DVT 9 (16%) 91 (15%) 0.74 1.13 (0.54-2.39)
Tachycardia 25 (46%) 224 (36%) 0.17 1.47 (0.84-2.56)
*Mean (SD), DVT: Deep Vein Thrombosis, PE= pulmonary embolism, VTE= venous thrombo-embolic events, *Mean (SD)
Table 5
Clinical outcomes during three months in patients with PE 
Patients with PE n (673) % 95%CI
Overall recurrence 20 3.0 1.8-4.6
 Fatal recurrent PE 11 1.6 0.8-2.9
 Non-fatal recurrent PE 3 0.5 0.09-1.3
 Non-fatal recurrent DVT 6 0.9 0.3-1.9
Hemorrhagic complications 23 3.4 2.2-5.1
 Fatal bleeding 2 0.3 0.04-1.1
 Major bleeding 10 1.5 0.7-2.7
 Clinically relevant bleeding 13 1.9 1.0-3.3
Overall mortality 55 8.2 6.2-10.5
DVT: Deep Vein Thrombosis, PE: Pulmonary Embolis 
Discussion
We evaluated the clinical outcome of a large prospective cohort of patients with 
symptomatic, confirmed PE and aimed to assess an accurate incidence of recurrent venous 
thrombo-embolism, mortality and hemorrhagic complications during three months of 
anticoagulant treatment (Table 5). Moreover, we aimed to identify risk factors for these 
events and to determine the time course within three months of the start of treatment. 
There are two important conclusions to be drawn from our analysis. First, a recurrent 
thrombo-embolic event presenting as a recurrent PE occurred in 2.1 % of patients with 
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PE and was fatal in the majority (79%) of these patients, occurring mostly in the first 
week of follow-up. Second, risk factors for a complicated course of PE, i.e. a recurrent 
VTE, bleeding or death, were immobilisation for more than three days prior to diagnosis 
of PE, being an inpatient, higher age and the presence of COPD or a malignancy. 
The recurrence rate of 3% that we observed is comparable to three other cohort studies 
where incidences varied between 2.1% and 3.9%1;3;4, but lower than the 6% (95%CI: 4.4 
– 7.3) recurrence rate in patients with PE in a recently published study2. The discrepancy 
with the last study might be due to a different co-morbidity profile in that study, with 
a higher prevalence of cardiovascular disease (36% vs. 6%) and older patients (mean 62 
years ± 17 SD vs. 58 years ± 18)2. Our case fatality rate of recurrent VTE is consistent 
with the findings of another study, in which a case-fatality rate of 45% was observed12. 
Moreover, the observed clustering of recurrences in the first three weeks has been described 
previously2;12  but to our knowledge, the clustering of fatal events in the first week after 
diagnosis has not been described before. 
Surprisingly, the only risk factor predicting a recurrent thrombotic event was immobilisation 
for more than three days. This finding seems to be in disagreement with an earlier study 
in which the presence of cancer, chronic cardiovascular disease, chronic respiratory disease 
and other clinically significant diseases were independent risk factors for recurrent VTE 
in patients with PE2. Immobilization due to these chronic illnesses and subsequent venous 
stasis might explain the increased risk of recurrence but immobility might as well be a 
marker for more severe comorbid conditions and these patients are subjected to a higher 
risk for recurrence2-4;13. 
The mortality rate of 8.2% during three months in patients diagnosed with PE is consistent 
with the 7.7% found in a study by Perrier et al13, but lower than the 15% mortality rate in 
the study by van Strijen and colleagues4. In addition, the incidence of fatal PE was lower 
in our study-population and in that of Perrier and colleagues (1.6% and 2.3%) compared 
to the 5.6% in the study of van Strijen et al. This latter study however had a relatively high 
percentage of inpatients (46%) compared to our study (22%) and the study of Perrier and 
colleagues (0%)13 which may have led to a high risk population. 
There are some limitations of our study that should be addressed. First, the study population 
was derived from a diagnostic management study and excluded certain patients including 
those who were treated with therapeutic doses of unfractionated or low-molecular-weight-
heparin for more than 24 hours, who had a life expectancy less than 3 months, who were 
pregnant or hemodynamically instable. Consequently, our findings may not apply to these 
patients14. However, only 5% of our screened population were excluded for abovementioned 
reasons, therefore, our findings are likely to be generalizable to most patients with PE 
who are hemodynamically stable. Second, we acknowledge that identifying risk factors for 
recurrence, bleeding and mortality was not a primary goal of our study and hence, data 
concerning the adequacy of anticoagulation were not recorded. It is possible that some 
recurrent VTE episodes were related to inadequate initial anticoagulation, however, only 
four patients with recurrent VTE had been treated initially with intravenous unfractionated 
heparin and it is unlikely to have affected our study results relating to risk factors for recurrent 
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VTE. Third, our definition of fatal recurrent PE as ‘any death in which PE could not be 
confidently ruled out as a contributing cause’ may have led to an overestimation of our 
fatality rate of recurrence. Fourth, a clear definition of a recurrent venous thrombo-embolic 
event, occurring during treatment with anticoagulants, is not available and there’s no expert 
opinion on the time limits for calling a venous thrombo-embolic event a complication of a 
first venous thrombo-embolic event or a recurrent event.  
The clinical implications of our study are two-fold. First, recurrent VTE occurs despite 
anticoagulant therapy and is most frequently encountered in the first three weeks after 
diagnosis of PE, while fatal recurrences occur predominantly in the first week after diagnosis. 
Since patients with non-massive PE are increasingly treated with LMWH instead of 
intravenous unfractionated heparin15, early discharge or even home treatment is logistically 
feasible but the safety is unclear since large comparative studies are lacking. Although it has 
been recommended to extend current organisation for outpatient management of DVT to 
stable patients with PE16, outpatient treatment of PE is not widely accepted because no 
explicit clinical criteria exist to accurately identify patients with PE at high risk of adverse 
outcomes. Our study was not designed to answer the question regarding the safety of home 
treatment. It remains to be studied whether the presence of the risk factors for an adverse 
outcome in patients with PE should guide decisions on hospital or home treatment and 
preclude early discharge from hospital in patients with these risk factors. 
Second, based on our study results, patients in whom recurrent PE occurs, face a substantial 
risk of mortality. We acknowledge that there is a potential for bias leading to overcall of 
this observation, since no autopsies were done to substantiate the clinical judgement of 
the adjudication committee. Whether awareness of this high risk and proper treatment of 
co-morbidities might decrease this risk should be studied separately. 
In summary, in patients diagnosed with PE and treated with anticoagulants, recurrent VTE 
is more likely to occur in patients who have been immobilized for more than three days while 
a major or clinically relevant bleeding is more likely to occur when patients are hospitalised 
or have COPD or a malignancy. Increasing age, immobilisation for more than three days, 
malignancy and being an inpatient increases the risk of mortality in the first three months 
after the diagnosis. In patients with these characteristics closer monitoring might be indicated, 
precluding these patients from early discharge from the hospital. Conformation of these 
variables as a risk factor for recurrence, death and bleeding needs prospective validation.
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It is unknown whether strategies validated for diagnosing pulmonary embolism (PE) are 
valid in patients with a history of PE. 
Objective
To investigate whether a diagnostic algorithm consisting of sequential application of a 
clinical decision rule (CDR), a quantitative D-dimer test and computed tomography 
(CT) safely ruled out a clinical suspicion of acute recurrent PE. 
Methods
Data were obtained from a diagnostic outcome study of patients suspected of PE. Acute 
recurrent PE was ruled out by an unlikely probability of PE (CDR score ≤ 4 points) 
combined with a normal D-dimer test (≤500 ng/ml) or by a normal CT in all other 
patients. The primary outcome was the incidence of acute recurrent venous thrombo-
embolism during three months of follow-up in patients with normal tests and not treated 
with anticoagulants. 
Results
Of 3306 patients suspected of acute PE, 259 patients (7.8%) had a history of PE of whom 
234 were not treated with anticoagulants. The probability of PE was unlikely in 82 of 234 
patients (35%) and 42 had a normal D-dimer test (18%), excluding recurrent PE. None 
of these patients had a thrombotic event during follow-up (0%, 95%CI: 0-6.9). A CT was 
indicated in all other patients (192) and ruled out recurrent PE in 127 patients (54%). 
Only one patient with a negative CT had a fatal recurrent PE during follow-up (0.8%; 
95%CI: 0.02-4.3).
Conclusions
This prospective study demonstrates the safety of ruling out a clinical suspicion of acute 
recurrent PE by a simple diagnostic algorithm in patients with a history of PE.   
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In recent years many studies have focused on improving the diagnostic management of 
patients with suspected acute pulmonary embolism (PE) by developing clinical decision 
rules and implementing computed tomography (CT)1-3. However, the management of 
patients with suspected recurrence is problematic, since it is unclear whether currently 
used strategies are valid in patients with a prior history of proven PE. In the literature there 
are no studies that investigated the diagnostic accuracy of objective tests in patients with a 
history of PE, despite the fact that it is well established that 10-20% of patients with PE 
will have a recurrence during the first two years after stopping anticoagulant treatment4;5. 
In particular, no study has reported on the safety of withholding anticoagulant therapy on 
the basis of normal diagnostic tests in patients with a clinical suspicion of recurrent PE. 
The consequences of misdiagnosis of acute recurrent PE are major. Incorrectly concluding 
that acute recurrent PE is present exposes the patient to prolonged - and often life-long- 
anticoagulation6 with its attendant costs, inconvenience, and bleeding risks. Incorrectly 
concluding that acute recurrent PE is absent puts the patient at high risk of ongoing PE, 
which may be fatal.  Objective diagnosis of acute recurrent PE in clinically suspected 
patients is relevant because in parallel it has been shown that patients clinically suspected 
of recurrent Deep Vein Thrombosis (DVT), only 20-30% have objective recurrent DVT 
demonstrated by diagnostic methods.
Moreover, the accurate diagnosis of acute recurrent PE is important because it is 
generally accepted to treat patients with two or more episodes of objectively diagnosed 
PE indefinitely with anticoagulants6. An objective diagnosis is problematic since it may 
be difficult to distinguish new from old thrombo-emboli. It has been estimated that the 
percentage of patients with residual pulmonary thrombi is 50% six months after an initial 
diagnosis of PE7. 
Recently, in a large, prospective cohort study we investigated the safety of a diagnostic 
algorithm consisting of a clinical decision rule (CDR), quantitative D-dimer test and 
CT in excluding clinically suspected PE8. The aim of the present study is to investigate 
whether this diagnostic algorithm can also be safely used to exclude the diagnosis of 
recurrent PE in patients presenting with a clinical suspicion of acute recurrent PE. 
Methods
Study design
This study was part of a large, prospective management study in 5 academic and 7 general 
hospitals in the Netherlands performed between November 2002 and December 20048. 
This study evaluated the safety of excluding PE by a diagnostic algorithm consisting of 
a CDR, a quantitative D-dimer test and CT. All patients were followed for a period 
of three months to document the occurrence of symptomatic venous thrombo-embolic 
events (VTE). 




All consecutive in- and outpatients with a clinical suspicion of recurrent PE, defined as a 
sudden onset of dyspnea, a deterioration of existing dyspnea or sudden onset of pleuritic 
chest pain without another apparent cause, were eligible for the study. All patients had 
a history of confirmed PE, with or without DVT. Previous pulmonary embolism was 
diagnosed by one of the following; a CT-scan demonstrating PE, a high-probability 
VQ-scan, an intermediate VQ-scan with CUS demonstrating DVT or pulmonary 
angiography showing PE. Patients were not systematically screened for the existence of 
chronic thrombo-embolic pulmonary arterial hypertension. 
Exclusion criteria were: age under 18 years, treatment with therapeutic doses of 
unfractionated or low-molecular weight heparin for more than 24 hours prior to inclusion, 
a life expectancy of less than three months, pregnancy, allergy to intravenous contrast 
agents, renal insufficiency (creatinine clearance less than 30 ml/min), logistic reasons, 
geographic inaccessibility precluding follow up or hemodynamic instability. Patients who 
were treated with anticoagulants at admission and/or during follow-up were excluded 
from the present analysis because the safety of withholding anticoagulants could not be 
established in these patients. The Institutional Review Boards (IRB’s) of all participating 
hospitals approved the study protocol and written or oral informed consent was obtained 
from all participants, depending on the requirements of the local IRB’s.
 
Diagnostic work-up
The dichotomized clinical decision rule according to Wells was used to determine pre-
test probability for PE (Table 1). Patients were designated as PE unlikely if the CDR 
was ≤ 4 points, and PE likely in case of a CDR > 4 points3;9. In patients with a CDR 
indicating PE unlikely, a D-dimer test was performed. In patients with a normal D-dimer 
concentration, the diagnosis of recurrent PE was considered excluded. Patients with a 
CDR indicating PE likely and patients with an abnormal D-dimer test underwent CT8. 
Single-row detector as well as multi-row detector systems were used. In case of a normal 
CT, recurrent PE was considered excluded. The criterion for the diagnosis of a recurrent 
PE was the presence of signs of acute PE, i.e. a central filling defect or complete occlusion 
of a vessel on CT. All patients in whom the diagnosis of recurrent PE was excluded were 
withheld from anticoagulant treatment and were followed for three months to document 
the occurrence of symptomatic venous thrombo-embolic events, diagnosed by objective 
imaging tests.  
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Clinical decision rule according to Wells et al. 
points
Clinical signs and symptoms of deep vein thrombosis (DVT)(minimum of leg swelling and pain with palpation of the deep veins) 3.0
Alternative diagnosis less likely than PE 3.0
Heart rate >100/minute 1.5
Immobilisation (> 3 days) or surgery in the previous 4 weeks 1.5
Previous PE or DVT 1.5
Hemoptysis 1.0
Malignancy (on treatment, treated in the last 6 months or palliative) 1.0
Clinical probability of PE unlikely ≤ 4 points, clinical probability of PE likely > 4 points.
Outcome
The primary outcome of the study was the incidence of symptomatic, recurrent venous 
thrombo-embolic events during three months follow-up in patients in whom recurrent PE 
was excluded and who were not treated with anticoagulants. Symptomatic recurrent VTE 
was considered to have occurred if recurrent PE or DVT was documented objectively 
or if there was a death in which PE was a contributing cause or could not be ruled out. 
A diagnosis of PE or DVT was made, based on a priori defined and generally accepted 
criteria10. The criteria for the objective diagnosis of DVT were a non-compressible 
venous segment during compression ultrasonography or an intraluminal filling defect on 
venography. The criteria for the objective diagnosis of recurrent PE were signs of acute 
PE, i.e. a central filling defect or complete occlusion on CT a filling defect or a cut-off of a 
vessel of more than 2.5 mm on pulmonary angiography, a new perfusion defect of at least 
75% of a segment with corresponding normal ventilation (high-probability lung scan) 
or PE confirmed by autopsy. An independent adjudication committee, whose members 
were unaware of the results of the diagnostic algorithm, evaluated all suspected venous 
thrombo-embolic events and deaths. 
Statistical analysis
The incidences of symptomatic recurrent VTE confirmed by objective testing were calculated 
for a) the group in which recurrent PE was excluded based on a CDR indicating PE unlikely 
combined with a normal D-dimer test and b) the group of patients in which recurrent PE 
was excluded based on a normal CT. Exact 95% confidence intervals (CI) were calculated 
around the observed incidences using JavaStat software (http://statpages.org/confint.html). 
Descriptive parameters were calculated using the SPSS software, version 11 (SPSS, Inc., 
Chicago, Illinois). The univariate relation between baseline characteristics and outcome 
was examined by chi-square statistics for categorical variables and t-tests for continuous 
variables. Fisher’s Exact test was used when the expected values were less than five. A level of 
significance of 0.05 (two-tailed) was used in all tests. Excluding recurrent PE was considered 
safe in case of a three-month thrombo-embolic failure rate not exceeding that of the upper 
confidence level of normal pulmonary angiography (upper 95%CI: 2.7) in patients in whom 
the diagnosis was excluded and who were not treated with anticoagulants11.  





A total of 3503 patients were eligible of which 197 were excluded because of predefined 
exclusion criteria or no informed consent (Figure 1). Of 3306 patients with a clinical 
suspicion of PE who were included in the diagnostic management study, 259 patients 
(7.8%, 95%CI: 6.9-8.8) had a history of PE. Of these, 25 patients were treated with 
anticoagulants (9.7%) and they were excluded from the present analysis. The baseline 
characteristics of the 234 remaining patients with previous PE are demonstrated in Table 
2.  Mean age was 55 years, 61% was female and the median time since the prior PE was 4 
years. The 25th percentile of time since previous PE was 1.7 years, the 75th percentile was 
7.2 years and the 90th percentile 15.1 years.
Table 2
Baseline demographic and clinical characteristics of 234 patients with a history of PE  
Characteristics n (%)
Age in years, mean (SD+) 55 (18)
Female sex 142 (61)
Outpatients 214 (91)
Duration of complaints in days, median (IQR^) 3 (1-7)
Time since previous PE in years, median (IQR^) 4 (2-7)*
Paralysis 9 (4)
Immobilisation or recent surgery 20 (9)
COPD with treatment 39 (17)
Heart failure with treatment 19 (8)
Malignancy 21 (9)
Oestrogen useª 12 (8)
Clinical symptoms of DVT 13 (6)
Heart rate (beats per minute >100) 40 (17)
Hemoptysis 12 (5)
PE at baseline 63 (27)
+SD= standard deviation, ^IQR= interquartile range, *missing 
data in 31 patients, ª of females only
Results of the diagnostic algorithm
In 63 of 234 patients, recurrent PE was diagnosed (prevalence 26.9%, 95%CI: 21.4-33.1). 
Compared to patients in whom recurrent PE was excluded, patients with recurrent PE 
were older (62 versus 52 years, p<0.001), were more often male (56% versus 33%, p=0.002) 
and had more risk factors for PE, i.e. paralysis (11% versus 1%, p=0.002), immobilization 
or surgery in last four preceding weeks (17% versus 5%, p=0.003) and malignancy (14% 
versus 7%, p=0.08).   
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Excluding recurrent PE by a CDR indicating “recurrent PE unlikely” and a 
normal D-dimer test
Of 234 patients with clinically suspected recurrent PE, 82 patients (35%) had a CDR 
indicating PE unlikely and were subsequently tested for D-dimer concentration. D-dimer 
tests were normal in 42 of 82 patients (51%) with unlikely PE, representing 18% of the 
total study population.  Recurrent PE was excluded in these patients and during the 
three-months follow-up, completed in all patients, none of the 42 patients returned with 
a symptomatic recurrent venous thrombo-embolic event (0%, 95%CI: 0-6.9) (Table 3).
Excluding recurrent PE by helical CT
Of the 234 patients with a clinical suspicion of recurrent PE, 152 patients (65%) had a 
CDR indicating PE likely and 40 patients had a CDR indicating PE unlikely but had an 
abnormal D-dimer test. Of these 192 patients, 190 underwent CT. In 63 of 190 patients, 
recurrent PE was diagnosed (prevalence 26.9%, 95%CI: 21.4-33.1). CT was normal in 89 
patients and suggested an alternative diagnosis (pneumonia, pleural effusion, malignancy 
etc.) in 38 patients (127 of 234 patients; 54% overall). During the three-month follow-
up period, one of the patients in whom PE was excluded by CT died suddenly and was 
adjudicated as a possible fatal recurrent pulmonary embolism. Therefore, the 3-month 
thrombo-embolic failure rate in patients in whom CT had excluded PE was 0.8% (1/127; 
95%CI: 0.02-4.3) (Table 3). 
In two patients the protocol was violated and a CT was not performed. During follow-up, 
an arm vein thrombosis was diagnosed in one patient and this patient was treated with 
anticoagulants. The other patient was not treated with anticoagulants and follow-up was 
uneventful. If these two patients had been included, the failure rate in patients who were 
assigned to undergo a CT would have been 1.6% (2/129; 95%CI: 0.2-5.5). 
The 3-month thrombo-embolic failure rate of the whole strategy of sequential application 
of CDR, D-dimer test and CT was 1.2% (2/171; 95%CI: 0.1-4.2)(Table 3). 
Table 3
Safety of the diagnostic algorithm in patients with previous PE
n (%) 3-m VTE failure rate
n % (95%CI)
CDR unlikely and normal D-dimer 42 (18) 0 0 (0-6.9)
PE excluded by CT 127 (54) 1 0.8 (0.02-4.3)
PE excluded by CT + protocol violations 129 (55) 2 1.6 (0.2-5.5)
Whole strategy 171 (73) 2 1.2 (0.1-4.2)
Additional observations
The prevalence of PE in patients with a CDR indicating unlikely PE was 14.6% (12/82; 
95%CI: 7.8-24.2) versus 33.6% (51/152; 95%CI: 26.1-41.7) in patients with a CDR 
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indicating likely PE. Of 168 multi-row detector CT scans, 54 patients were diagnosed 
with PE (32%; 95%CI: 25-40%). Of 21 patients with single-row detector systems, 9 
patients were diagnosed with PE (43%; 95%CI: 22-66). The diagnostic algorithm could 
be followed according to the protocol in 232 of 234 patients (99.1%). 
Discussion
A simple diagnostic algorithm consisting of sequential application of a CDR, a quantitative 
D-dimer test and a CT appears to be safe in excluding PE in patients with clinically 
suspected recurrent PE. A clinical decision rule indicating PE unlikely combined with 
a normal D-dimer test excluded recurrent PE without the need for additional CT in 
approximately one-fifth of our total study population suspected of recurrent PE. CT ruled 
out recurrent PE in all other patients. However, the relatively wide confidence intervals 
of the 3-month thrombo-embolic risk of the whole strategy (95%CI: 1.2 (0.1-4.2) do not 
permit to conclude that our approach is as safe as pulmonary angiography.
To our knowledge, this is the first prospective study assessing the value of a standardized 
diagnostic strategy in patients with clinically suspected acute recurrent pulmonary embolism. 
In two recent studies evaluating CT in patients with clinically suspected PE a history of 
venous thrombo-embolism was present in 14% and 19% of the study population respectively, 
but a separate analysis was not given either with respect to the clinical outcome after a 
normal CT1 or accuracy of CT12 in patients with a prior PE. 
We chose to limit the study to patients with a history of PE and did not allow patients 
with DVT. Patients presenting with DVT have reported scintigraphic evidence of silent 
PE in 40-50% of cases13;14. Including patients with prior DVT in our analysis would have 
led to a falsely increased feasibility of our algorithm since approximately half of those 
patients would have been patients with a first suspicion of PE. 
Our study warrants additional comment on possible limitations. First, the absence or 
presence of PE was not verified by pulmonary angiography, the gold standard. However, 
the clinical outcome after a 3-month follow-up period is widely accepted as an appropriate 
alternative to establish the safety of excluding PE by a diagnostic strategy, given a 
near complete follow-up15. Although by design, it was not the objective of our study, 
we cannot exclude the possibility of false-positive CT-scans and overdiagnosis of PE, 
especially because old thrombi may have mistakenly been judged to be new thrombi and 
consequently treated as a recurrent PE. Although we used criteria of acute PE to diagnose 
recurrent PE, the natural evolution of pulmonary clots is currently unknown and it cannot 
be excluded that signs of acute PE persist longer than is generally presumed. However, 
the observed 27% prevalence of recurrent PE is fully in line with similar observations in 
patients with clinically suspected recurrent DVT and does not suggest overdiagnosis in 
our patients16;17. 
Second, although in our study only patients presenting with an acute sudden onset of 
dyspnea, a deterioration of existing dyspnea or sudden acute onset of pleuritic chest pain 
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without another apparent cause were included, we could not fully exclude the existence 
of chronic thrombo-embolic pulmonary hypertension as an explanation for the patient’s 
symptoms because we did not systematically screen all patients on CTEPH.   
Third, the clinical decision rule consisted of the item “history of VTE” and as a consequence, 
all patients scored 1.5 points with this item. The discriminative power of the clinical 
decision rule was expected to be different in patients with prior VTE, and indeed, 35% 
of our population had a CDR indicating PE unlikely while in our overall cohort in the 
original study population 67% had a CDR indicating “PE unlikely”8. In addition, the 
combination of a CDR indicating PE unlikely and a normal D-dimer test was present 
in nearly one-fifth of patients compared to one-third in the original study population. 
Nevertheless, the prevalence of PE in patients with PE unlikely versus PE likely remained 
different, i.e. 14.6% versus 33.6%, indicating that the CDR we used is still clinically useful 
in distinguishing patients with a low and high risk for recurrent PE. Fourth, although 
our study contains the largest sample of patients with a clinical suspicion of recurrent 
PE reported, the 95% confidence limits of the three-month thrombo-embolic failure rate 
were rather wide and, exceeded that of the upper confidence limit of normal pulmonary 
angiography (2.7%)11. Finally it may be criticized that an observation period of three 
months may be too short to conclude that recurrent PE can be safely excluded. However, 
three months is a widely used period in diagnostic studies on the safety of excluding 
PE and any thrombo-embolic event occurring more than three months after a clinical 
suspicion is raised, is unlikely to be related to the first symptoms.        
In conclusion, in patients with a prior history of PE who present with a clinical suspicion 
of a recurrent PE, either a CDR indicating recurrent PE unlikely combined with a normal 
quantitative D-dimer test or either a CT in all other patients appears safe in excluding 
recurrent PE. Larger studies are needed to confirm the safety of excluding recurrent PE 
by this simple algorithm.
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Much attention has been paid in recent years to optimizing the diagnosis of acute 
pulmonary embolism (PE). However, little is known about the changes in clot burden that 
occur at the level of the pulmonary arteries after documented PE. It is often problematic 
to distinguish between a new or residual defect on lung scintigraphy or helical computed 
tomography (CT). This may lead to falsely labeling patients with residual PE as having 
recurrent PE and consequent unnecessary treatment changes. 
Design
We performed a systematic analysis of studies of imaging tests (radionuclide and 
computerized tomography) evaluating resolution rate of PE with independent assessment 
of predefined methodologic criteria by two investigators. 
Results
We identified 29 clinical studies. Of these, 25 were excluded and 4 studies were included in 
our review. Because studies differed largely in patient selection, duration of anticoagulation, 
timing of follow up etc., the studies were not pooled but briefly described. The percentage 
of patients with residual pulmonary thrombi was 87% at eight days after diagnosis, 68% 
after six weeks, 65% after three months, 57% after six months and 52% after 11 months. 
Discussion
This review shows that complete resolution of PE is not routinely achieved between 8 days 
and 11 months after diagnosis. More than 50% of patients with PE still have defects six 
months after diagnosis, after which resolution of thrombi appears to reach a plateau phase. 
Physicians should be aware of the high percentage of incomplete resolution of pulmonary 
emboli. Routine re-imaging after cessation of anticoagulant therapy in patients with PE 
to obtain a new baseline could be considered. 
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Much attention has been paid in recent years to optimizing the diagnosis of acute pulmonary 
embolism (PE). Helical computed tomography (CT) is increasingly preferred as a first-line test. 
However, little is known about the subsequent changes in clot burden that occur in pulmonary 
arteries after objectively documented PE. In patients with symptomatic objectively proven 
proximal deep vein thrombosis (DVT) of the leg veins, studies1;2 of sequential ultrasound 
examinations have demonstrated that persistent residual thrombosis is common after treatment 
with short-term anticoagulation and, according to one report3, “normalization” of the image 
is achieved in 39% at 6 months, 58% after 12 months and 74% at 36 months, while other 
studies4;5 suggest other time ranges. Information regarding the rate of resolution of pulmonary 
thrombi after diagnosis of PE is important because it may facilitate objective diagnosis when 
patients with PE return with complaints possibly due to recurrent PE. It is often clinically 
difficult to determine whether defects suggesting pulmonary emboli on lung scintigraphy or 
helical CT are residual or represent a new event. In a prospective study, it has been shown 
that 4% of first, symptomatic pulmonary embolism patients develop symptomatic chronic 
thromboembolic pulmonary hypertension (CTPH) within 2 years6. It would be desirable to 
avoid this outcome if possible and likewise to prevent the cascade of treatment consequent 
to falsely labeling patients with a recurrent PE. To better understand the natural history of 
pulmonary artery clot evolution after objectively documented PE, we performed a systematic 
analysis of published studies addressing this important clinical problem.  
Methods
Search strategy
We used electronic search strategies to identify relevant studies. The following electronic 
databases were searched: PubMed (1966 to November 2004), EMBASE (1980-nov 2004), 
Cochrane, the Library Issue 1, 2005 and Web of Science using the search terms residual 
thrombosis or incomplete recovery or incomplete resolution or (resolving AND (clots OR clot)) 
or ((Normalization OR Normalisation) AND (pulmonary arteries OR pulmonary artery)) or 
(((thrombi AND regression) or thrombus regression) AND (pulmonary embolism OR pulmonary 
embolic OR (pulmonary AND (embolism OR emboli OR embolus))) or (Scintigraphic AND 
control AND pulmonary embolism). We augmented our search by reviewing the reference 
lists of retrieved articles. Studies published in any language were used.
Study selection
We attempted to identify all published clinical studies that evaluated patients with 
pulmonary embolism and the rate of resolution of pulmonary emboli visualized by 
follow up objective imaging tests. Of potential articles, abstracts were read to determine 
eligibility and in case of doubt, full-text articles were retrieved. To be included, a study had 
to 1) be prospective and involve consecutive patients; 2) objectively diagnose symptomatic 
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pulmonary embolism (pulmonary angiography or helical CT, high-probability ventilation/
perfusion (VQ) lung scintigraphy or intermediate probability VQ scan with positive 
compression ultrasonography or venography); 3) use objective imaging tests at follow up; 
4) describe the duration and type of treatment of PE with a minimum administration of 
anticoagulant therapy of 6 weeks and no allowance of vena cava ligation, femoral ligation 
or pulmonary embolectomy; 5) identify whether there was a prior history of venous 
thromboembolism; 6) provide a description of the method of follow-up.
Data extraction
Two investigators independently assessed studies for inclusion according to the predefined 
methodological criteria. Investigator disagreements were resolved by majority opinion of a 
third investigator. Study authors were contacted as required to retrieve missing information.
Table 1
Excluded studies
Author (Ref) Year Diagnosis N Reason for 
exclusion
Time of FU 
scan
Follow up result
Sautter (16) 1964 PA 2 2,5 25 d, 128 d 100% normalisation
Fred (7) 1966 PA 7 1,2,5 7-19 d 6/7 normalisation
Poe (17) 1967 PA/VQ 20 2,3 7 d- 16 m 40% normalisation
Murphy (18) 1968 PA/VQ 25 2,3,5,6 1-20 w 60% normalization
Dalen (19) 1969 PA 15 2,5 1-34 d 3/15 normalisation
Paraskos (8) 1969 PA 43 1,5 1-7 y 65% normalisation
Mounts (20) 1969 PA 4 2,5 4 w – 3 m 0% normalisation
Sutton (9) 1969 PA/embolect 38 1,5 3-5 y (1-8) 45% normalisation
Tow (21) 1969 clinic/PA 69 2,3,5 4-120 d 48% normalisation
McDonald (22) 1970 PA 9 2 17-48 h 0% normalisation
Walker (10) 1970 VQ 74 1,2,3,5,6 3-277d 32.5% normalisation
Winebright (23) 1970 VQ 70 2,5,6 3m- 1y 27% normalisation
UPET (24) 1973 PA+ VQ 105 2,5,6 1-14d, 3,6,12m 77% normalisation
Hall (11) 1977 PA/embolect 88 1,2,5 5 y (1-9 y) 42% normalisation
Fredin (25) 1982 VQ 23 2,4,5 10-14 d Partial/compl norm. 22/23
Riedel (12) 1982 PA, VQ/+CUS 76 1,2,7 1-15 y 22/49 normalisation
Schwarz (26) 1985 PA 7 2 6 d + 15 m 6/7 normalisation
Palla (30) 1986 VQ 69 3 7,30,180 d 0% normalisation
Prediletto (27) 1990 VQ/PA 33 2 7, 30 d, 6 m 28% normalisation
Pacho (28) 1996 VQ 13 2,7 4 w, 5 m 18% normalisation
Nauffal (13) 1997 VQ/+VA 116 1,2 7,10 d, 6 m 28% normalisation
Otero (29) 1997 VQ, PA, VA 70 2,5,7 6 m 23% normalisation
Menendez (14) 1998 PA, VQ/+VA 96 1 7-10 d, 6 m 68% normalisation
Ribeiro (31) 1999 VQ 67 5 6 w, 1 y 34% normalisation
Gotthardt (15) 2002 VQ 129 1 0-10 y 70% normalisation
PA: pulmonary angiography; VQ: lung scintigraphy; VA: venography of the legs; CT: computed tomography; 1: 
retrospective study; 2: non-consecutive patients; 3:no objective diagnosis; 4: asymptomatic patients; 5: impro-
per treatment (embolectomy or vena cava or femoral ligation or no treatment); 6: anticoagulant therapy < six 
weeks; 7: no description of history of VTE; h: hours; d:days, w: weeks; m: months; y: years
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We identified 29 clinical studies. Of these, 25 were excluded because of 1) retrospective 
design7-15; 2) non-consecutive patients7;10-13;16-29; 3) lack of objective verification of the 
diagnosis10;17;18;21;30; 4) asymptomatic patients25; 5) treatment with inferior vena cava ligation 
or femoral ligation, embolectomy or no treatment in some patients7-11;16;18-21;23-25;29;31; 6) 
anticoagulant therapy for less than 6 weeks10;18;23;24; and 7) no description of history of 
VTE12;28;29. The excluded studies and reason for exclusion are listed in table 1. Four studies 
remained for inclusion in our review of rate of resolution of thrombi in patients with PE 
(table 2)32-35. Two studies used VQ lung scintigraphy as the follow up test and two studies 
used helical CT. The included studies differ not only in objective diagnostic tests used 
at follow up, but also in duration of follow up and duration of treatment. Therefore, we 
decided not to pool data statistically, but to describe the studies briefly. 
Table 2
Included studies






Therapy FU scan Follow up result
32 VQ VQ 30 No OAT 3 m 6 m 43% normalization 
33 VQ VQ 157 43 OAT 3 m 8 d, 3 m 13% d8, 35% 3 m normalization 
34 PA/CT CT 62 3 OAT ≥6 m/filter/FT mean 10.5 m 48% normalization
35 PA/VQ CT 19 No OAT 6 w 6 w 32% normalization
PA: pulmonary angiography; VQ: ventilation/perfusion lung scintigraphy; CT: computed tomography; VA: venography 
of the legs; FU: follow up; FT: fibrinolytic therapy; OAT: (oral) anticoagulant therapy; d: days, w: weeks; m: months
Studies using VQ scintigraphy at follow up 
Hvid-Jacobsen et al. re-examined 30 consecutive patients 6 months after diagnosis of PE32. 
All had repeat V/Q scans and chest X-rays and all had been treated for 3 months. Six months 
after diagnosis, 13 patients (43%) had normalized scans, 9 (30%) had minor defects, 6 (20%) 
had persistent defects and 2 had new defects. None of the patients had developed symptoms 
of recurrent PE. In this early study, the authors concluded that defects could not be assumed to 
have resolved 6 months after diagnosis of PE and that re-scanning after treatment should be 
done to obtain a new baseline. A limitation of this study is the 3-month time interval between 
cessation of anticoagulant treatment and follow-up scan. The time course of natural resolution 
of pulmonary thrombi with anticoagulant therapy in this study may be confounded by the 
asymptomatic recurrence of pulmonary embolism in the 3-month period without treatment. 
Wartski et al.33 included 157 patients from the THESEE study, a multicenter, randomized, 
comparison of continuous, adjusted-dose intravenous heparin versus once-daily, subcutaneous, 
low-molecular weight heparin followed by oral anticoagulants for 3 months in 612 patients 
with acute pulmonary embolism33;36. The results of THESEE showed both initial therapies to 
be equally effective. The 2 treatment groups did not significantly differ in age, sex, weight or 
percentage of vascular obstruction (PVO) and were therefore pooled. Of 157 patients at study 
entry, 145 had high-probability lung scans and 12 had intermediate lung scans with deep vein 
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thrombosis confirmed by venography or compression ultrasonography. In all patients, routine 
follow-up perfusion lung scintigraphy was obtained after eight days and after three months. 
The degree of PVO was calculated for each scan by assigning a weight to each lobe, based 
on regional blood flow distribution, and subsequently estimating a quantitative score from 
0 (no perfusion) to 1 (normal perfusion) on the basis of gamma count defects seen in each 
lobe. Lobar perfusion score was calculated by multiplying the assigned weight of each lobe by 
the perfusion score. The overall score is the sum of the six separate lobar scores (the lingula is 
counted as a separate lobe) and PVO (%) is calculated as follows: (1- total perfusion score) × 
100%. Three months after diagnosis, fifty-three patients (34%) had normalized perfusion lung 
scans; 21 of these (13% of the total) had already normalized perfusion by day 8. Of the 157-
patient cohort, 16 (10%) had no resolution of perfusion defects whatsoever after 3 months. 
An additional 28 (18%) of the total cohort had some improvement by day 8 but no further 
resolution by 3 months. These authors also concluded that follow-up scintigraphy serves as 
a new baseline for the diagnosis of recurrent PE33. Furthermore, they suggest that a follow-
up scan may help to identify patients who are likely to progress to chronic thromboembolic 
pulmonary hypertension on the basis of extensive residual defects.
Studies using helical CT at follow up
Remy-Jardin et al. were among the first to use helical CT as a follow-up test to evaluate the 
resolution of acute pulmonary embolism34. In 62 consecutive patients who had been referred 
to an intensive care unit with massive acute PE, a follow up CT scan was performed a mean 
of 11 months after onset to analyze the outcome of endoluminal clots after at least 6 months 
of anticoagulation therapy. The diagnosis of acute PE was made with pulmonary angiography 
(n=43) or helical CT (n=19). For 59 of the 62 patients, the massive acute PE was their first 
episode of thromboembolism; three of 62 had a history of chronic thrombo-embolic disease. 
Complete resolution of thrombi at a mean of 11 months (range, 1-53 months) was shown in 
48% of patients and endovascular abnormalities were present in 52%34. Within this follow-up 
period there were no clinical episodes of recurrent PE. Follow-up scans were categorized as 
showing resolution of thrombi (group 1) or endovascular abnormalities (group 2). Group 1 
patients showed no cardiopulmonary symptoms or echocardiographic abnormalities, while 6 
of 32 (9,7% overall) group 2 patients had dyspnea on exertion and 5 group 2 patients (8,1% 
overall) had echocardiographic findings of pulmonary hypertension. Furthermore, group 2 
patients were categorized into a) patients with partial resolution of initial thrombi (n=24) and 
b) patients with CT features of chronic PE, defined as severe arterial narrowing of more than 
50% of the arterial diameter developing between the time of the initial diagnosis and the post-
therapeutic follow-up. A striking finding was that 8 patients (13%) had CT signs of chronic PE 
over a median follow-up of 8.5 months (range 2-30 months) despite an anticoagulant course 
of at least six months and no symptomatic recurrences. The authors conclude that helical CT 
might help in understanding changes within central pulmonary arteries after massive acute 
PE, enabling not only the in vivo surveillance of organized and recanalized clots, but also of 
arterial narrowing (a sign of chronic PE) in asymptomatic patients.  
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Van Rossum et al. described the helical CT appearance of clots 6 weeks after acute PE35. 
Clots on the initial and follow-up scan were divided into five categories; (1) central filling 
defect or complete occlusion (the established CT criteria for acute PE); (2) eccentric clot 
contiguous with the vessel wall at the site of acute PE on the initial scan; (3) filling defect with 
central contrast material indicating recanalization;  (4) severe arterial luminal narrowing or 
vessel occlusion of a stenosed artery (the established criteria for chronic PE); and (5) normally 
enhancing vessels at follow-up indicating complete resolution of clots. At the initial CT scan, 
all patients (n=19) had type (1) clots, signs of acute PE. Normalization of pulmonary arteries 
at 6-week follow-up was seen in 6 patients (32%). Of the 13 (68%) patients with residual 
abnormalities, two patients still had solely type (1) clots. In the 11 remaining patients, most 
emboli had disappeared but some residual emboli were present as eccentric emboli contiguous 
with the vessel wall (22% of initial 153 clots) or filling defects with central contrast material 
(3% of initial 153 clots) representing recanalization (i.e., type 2 and 3 clots). In one of these 
patients, signs of chronic PE at the initial scan remained unchanged at follow-up. The authors 
of this study wondered whether existing CT criteria for chronic PE are as specific as assumed 
since this study showed that eccentric emboli contiguous with the vessel wall and evidence of 
recanalization are already present at six weeks follow-up in 22% and 3% of clots, respectively. 
No vascular narrowing or stenosis with occlusion was found, which may be more specific 
criteria for chronic PE.  
Figure 1 summarizes our findings regarding the percentage of patients with residual thrombi 
in patients who presented with acute PE in the four studies described.
Figure 1
Residual thrombi in patients with PE
95% Confidence Intervals of the percentage of residual PE are depicted by the y error bars

































This review shows that complete resolution of pulmonary thrombo-embolism is not 
routinely achieved between 8 days and 11 months after acute PE. Overall, more than 
50% of patients with PE have persistent defects at their follow up scan six months after 
diagnosis (figure 1). Afterward, resolution of thrombi seems to reach a plateau phase since 
complete resolution is found in 43% of patients after six months and in nearly the same 
percentage of patients (48%) after eleven months. Of interest is the wide variation in 
resolution of thrombi in individual patients. Complete resolution of pulmonary thrombi 
was already present in 13% of patients 8 days after diagnosis of PE while in 10% of patients 
no change in thrombotic occlusion was seen after three months. The pathophysiological 
mechanisms of resolution of thrombi and the risk factors and clinical consequences of 
partial resolution remain largely unknown. 
There are several methodological issues within the included studies in our review. First, 
the timing of follow-up was not standardized between the studies, varying from 8 days to 
6 months. In the study of Remy-Jardin there was no pre-specified timing of follow-up and 
hence follow-up ranged from 1 to 53 months34. Similarly, the duration of anticoagulation 
therapy differed in length and in timing related to the follow up scan, varying from 6 
weeks to more than 6 months. Also, there is no current standard technique for imaging 
resolution of PE. Two studies used VQ scintigraphy and two used CT as a follow up 
diagnostic method, but it is apparent that these two techniques are not interchangeable. 
Perfusion scintigraphy is a functional test but is reported to underestimate the presence 
of thromboembolic disease and also the severity of angiographic and hemodynamic 
compromise in CTPH37;38. Helical CT depicts the morphology of the pulmonary arteries 
but contains no information regarding pulmonary functional status. Moreover, no uniform 
criteria are used in defining chronic imaging defects, even when similar l imaging methods 
were used. Last, a confounding but unavoidable fact in prior or future studies is that for 
patients diagnosed with a first PE, it cannot be confidently ruled out that imaging defects 
were already present before the diagnosis since the majority of patients have no scan 
before their first thromboembolic event. With radionuclide scans, physicians cannot be 
certain, even with the aid of concomitant chest CT scans, that persistent defects represent 
residual thrombi rather than other defects responsible for decreased perfusion.
What are the implications of our findings for the future management of PE? First, 
physicians should be aware that complete resolution of pulmonary thrombi is not achieved 
in more than 50% of patients six months after diagnosis of PE and that this fact may 
complicate the objective and accurate diagnosis of recurrent pulmonary embolism. Second, 
an attempt should be made to generate an international consensus among physicians 
caring for PE patients, including radiologists and nuclear medicine physicians, regarding 
the optimal way of imaging, interpreting and reporting of resolution of pulmonary emboli 
and diagnosing chronic PE. Third, routine re-imaging after cessation of anticoagulant 
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treatment in patients with PE to obtain a new baseline could be considered39. Finally, in 
patients with persisting thrombo-embolic obstruction or with persisting cardiopulmonary 
complaints, one should be alert for chronic PE and the development of chronic 
thromboembolic pulmonary hypertension6.     
In conclusion, resolution of pulmonary thrombi is not routinely achieved after an acute 
PE. The pathophysiologic mechanisms, risk factors and clinical implications of incomplete 
resolution are not well established. There is a clear need for prospective well-designed 
follow-up studies to more accurately define the resolution rate after documented PE and 
related prognostic factors. 
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In pregnancy, the diagnosis of pulmonary embolism (PE) is problematic. There is doubt as 
to whether objective diagnostic tests are needed and confusion as to what objective test is 
the safest with respect to fetal radiation exposure. A recent study has reported a very low 
(1·8%) prevalence of high-probability ventilation-perfusion (VQ) lung scans in pregnant 
women suspected of PE.1 From this study it is apparent that the clinical diagnosis of PE 
is inaccurate and therefore objective diagnostic tests are mandatory, in order to avoid 
treatment of women that do not have PE. 
Currently, helical computerised tomography (CT) and VQ scintigraphy are the most 
common diagnostic tests used in non-pregnant patients with suspected PE. Physicians are 
reluctant to perform helical CT in pregnant women because of potential adverse effects of 
radiation exposure to the fetus. VQ scintigraphy has been assumed to be associated with 
less radiation exposure than helical CT. To compare the relative amounts of radiation 
exposure to the fetus, we calculated fetal radiation exposure when single- and multi-
detector row helical CT and VQ scintigraphy were performed using our local hospital 
protocols. Further, we compared our data with data of the literature.
Since there are no established methods for calculating fetal radiation exposure in 
diagnostic radiological procedures, we used a pragmatic approach. The amount of 
radiation absorbed by the fetus was assumed to be equal to that absorbed by the uterus 
of a non-pregnant woman. Assessment of the uterus dose was achieved by measurement 
of the computed tomography dose index and the application of organ dose conversion 
factors.2 The following CT protocols were used for fetal dose assessment: 120kV, 250 
mAs, slice thickness 3 mm and pitch factor 1·7 for single-detector row helical CT 
(Philips AVE) and 120 kV, 85 mAs, slice thickness 16 × 0·5 mm and pitch factor 1·4 
for multi-detector row helical CT (Toshiba Aquilion 16). The scanned range extends 
from the dorsal lung sinus to the top of the lung. Since fetal radiation exposure was 
calculated, physical measures (eg. abdominal shielding with lead) to reduce radiation 
exposure were not taken into account.
For the perfusion scintigraphy protocol we used 40 MBq of Technetium-labelled albumin 
aggregates. In our institution, ventilation scintigraphy is performed with Krypton-81m, 
which is inhaled for two minutes per image. The Rubidium-Krypton generator generates 
450-750 MBq per minute.
Our calculated data of CT radiation exposure were compared with doses in nuclear 
medicine and doses calculated by the International Commission on Radiological Protection 
(ICRP) and the National Radiological Protection Board (NRPB) of the UK.3,4
The calculated dose of radiation absorbed by the fetus for a single-detector row helical CT 
was 0·026 mSv. An even lower dose (0·013 mSv) was calculated for the multi-detector 
row helical CT. In comparison, the calculated dose of fetal radiation with perfusion 
scintigraphy was 0·11-0·20 mSv. In comparison with doses given by the ICRP and NRPB 
(table 1), our calculated doses of helical CT were low.  
Our study suggests that performing a helical CT according to our local protocol, 
whether single- or multi-detector row, exposes the fetus to less radiation than perfusion 
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scintigraphy. Our findings are clearly contradictive to the general idea that helical CT is 
more hazardous to the fetus than perfusion scintigraphy. 
Table 1
Radiation dose to the fetus by radiological examination
LUMC(mSv) ICRP(mSv) NRPB(mSv) 
Single-detector row helical CT 0·026 0·06 0·06
Multi-detector row helical CT 0·013 n.d. n.d.
Perfusion scintigraphy(99mTc MAA, 200 MBq) n.a. 0·4-0·6 0·2-0·4
Perfusion scintigraphy (99mTc MAA, 40 MBq) 0·11-0·20 n.d. n.d.
Ventilation scintigraphy (99mTc aerosol) n.a. 0·1-0·3 0·3-1·2
Ventilation scintigraphy (81mKr, 600MBq) 0·0001 n.d. n.d.
n.a.= not applicable, n.d.= not determined
LUMC= University Medical Centre Leiden
ICRP= International Commission on Radiological Protection
NRPB= National Radiological Protection Board 
Regarding the generalizability of our data, it is apparent that our calculated fetal 
radiation dose for CT is well within the range of that found by others. It has been 
documented that radiation exposure to the patient for a given radiological procedure can 
vary considerably between different institutions and even within the same institution. 
There are several factors that affect radiation dose from CT, e.g. (beam energy, tube-
current time product, pitch, collimation, patient size and dose reduction options). Each 
institution should therefore carefully scrutinize its protocol for performing helical 
CT and define the optimal balance between minimal patient radiation exposure and 
maximal diagnostic CT image quality. 
Calculating patient radiation exposure with a computerized model beholds accepting certain 
assumptions, which possibly differ from an exact measurement. An exact measurement 
is however, impossible to perform, both in helical CT as well as in scintigraphy. Due to 
lack of more appropriate measurements it is commonly assumed that radiation dose to 
the uterus is a good approximation of the radiation dose to the fetus in early pregnancy. 
This period of early pregnancy is the most important period, since the fetus is considered 
to be most vulnerable to radiation effects in the period of organogenesis (in the 3rd until 
the 15th week). The main issue following in-utero exposure at typical diagnostic levels 
is induction of malignancies. The number of excess malignancy cases up to age 15 years 
following irradiation in utero is considered to be 1 in 16000 per mSv.5 
We conclude that when a clinical suspicion of pulmonary embolism is raised in a pregnant 
patient, only objective diagnostic testing can rule out the disease. Our calculation of fetal 
radiation dose in helical CT justifies performing this objective diagnostic method as a first line 
test in pregnancy. It is hoped that increased awareness of the risks and benefits of imaging in 
pregnant patients suspected of pulmonary embolism will result in a more rational management 
to this patient group.  
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Diagnosing deep vein thrombosis (DVT) and pulmonary embolism (PE) in pregnancy is 
challenging. Many of the common diagnostic tests, including compression ultrasonography 
(CUS), ventilation-perfusion scintigraphy (VQ scan) and helical computed tomography 
(hCT) that have been extensively investigated in non-pregnant patients, have not been 
appropriately validated in pregnancy. Extrapolating results of diagnostic studies of DVT 
and PE in non-pregnant patients to those who are pregnant may not be correct because 
during pregnancy, physiologic and anatomic changes may affect diagnostic test results, 
presentation and natural history of VTE.
Methods
We performed a systematic analysis of published studies addressing accurate diagnostic 
testing for DVT and PE in pregnancy to determine the accuracy of these tests in 
pregnancy. 
Results
Our initial search yielded 530 articles of which four remained for inclusion, three studies 
investigating diagnostic testing in patients with a clinical suspicion of DVT and one study 
in patients with a clinical suspicion of PE. 
Conclusions
From our systematic analysis of published studies investigating diagnostic testing for a 
clinical suspicion of DVT or PE in pregnancy we conclude that; 1) two studies support 
withholding anticoagulant therapy in pregnant women with a clinical suspicion of DVT 
and normal results on serial IPG (impedance plethysmography), however, IPG is no 
longer used; 2) one study demonstrated that a normal CUS at presentation combined with 
a normal D-dimer test or an abnormal D-dimer test combined with normal serial CUS 
appears promising for safely excluding DVT in pregnant patients, but too few patients 
were included in this pilot-study to draw firm conclusions; and 3) one study investigated 
pregnant patients with a clinical suspicion of PE and this study concluded that in patients 
with normal or non-diagnostic VQ scans, withholding anticoagulant therapy might be 
safe, but this needs confirmation in larger studies. Recommendations on diagnostic testing 
of pregnant patients with a clinically suspected DVT or PE are provided. 
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Diagnosing deep vein thrombosis (DVT) or pulmonary embolism (PE) in pregnancy 
presents challenges to clinicians. Non-thrombotic leg or respiratory symptoms are 
commonly experienced in pregnancy and are often clinically indistinguishable from those 
found in patients with DVT and PE. Hence, the clinical diagnosis is inaccurate and accurate 
diagnostic testing is essential to exclude or diagnose venous thromboembolism (VTE). 
However, many of the common diagnostic tests including compression ultrasonography 
(CUS), ventilation-perfusion scintigraphy (VQ scan) and helical computed tomography 
(hCT), that have been extensively investigated in non-pregnant patients, have not been 
appropriately validated in pregnancy. Extrapolating results of diagnostic studies of 
DVT and PE in non-pregnant patients to those who are pregnant may not be correct 
because of physiologic changes during pregnancy and the possibility of differences in 
pathophysiology and presentation of VTE in pregnancy. Also, studies of non-pregnant 
patients invariably report on subjects who are, on average, older and are more likely to 
have co-morbid cardio-respiratory conditions that can result in an abnormal VQ scans.  
The purpose of this review is to establish the evidence concerning the accuracy of diagnostic 
tests performed for a clinical suspicion of PE and DVT during pregnancy. Therefore, we 
undertook a systematic analysis of published studies addressing diagnostic testing for 
DVT and PE in pregnancy. Further, recommendations for diagnostic testing are made for 
clinicians when they evaluate pregnant patients with clinically suspected DVT or PE. 
Methods
Search strategy
We used electronic search strategies to identify relevant studies. The following electronic 
databases were searched: PubMed (1966 to November 2004), EMBASE (1980-nov 2004), 
Cochrane, the Library Issue 1, 2005 and Web of Science using the search terms pregnancy, 
gestational period, pulmonary embolism, venous thrombosis, deep vein thrombosis, radiological 
tests, diagnosis, pulmonary angiography, helical or spiral computed tomography, ventilation-
perfusion lung scintigraphy, magnetic resonance imaging, compression ultrasound, impedance 
plethysmography and venography. We augmented our search by reviewing the reference lists 
of retrieved articles. Studies published in any language were used.
Study selection
We attempted to identify all published clinical studies that evaluated pregnant patients with 
a clinical suspicion of deep vein thrombosis or pulmonary embolism. Of potentially eligible 
articles, abstracts were read to determine eligibility and in case of doubt, full-text articles 
were retrieved. To be included, a study had to 1) involve consecutive pregnant patients with 
a clinical suspicion of DVT or PE; 2) use validated diagnostic tests to diagnose DVT (CUS 
or impedance plethysmography (IPG) or venography for a suspicion of DVT or magnetic 
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resonance imaging for a suspicion of iliac vein thrombosis) and PE (pulmonary angiography 
or hCT, or VQ lung scanning); 3) use validated diagnostic testing in patients with suspected 
VTE in follow up; 4) describe a pre-specified duration of follow-up of patients with negative 
tests; and 5) withhold anticoagulant treatment in patients with negative tests.
Data extraction
Two investigators independently assessed studies for inclusion according to the predefined 
methodological criteria. Investigator disagreements were resolved by majority opinion of 
a third investigator. 
Results
Our initial search identified 530 articles, of which 14 were potentially eligible for analysis1-
14. According to the predefined inclusion criteria, 10 of the 14 studies were excluded (Table 
1). Reasons for exclusion were: consecutive patients were not evaluated5;6;10, only patients 
with confirmed instead of suspected DVT were included 1;2;7;8, objective testing was not 
performed in all patients2;10 and no pre-specified duration of follow-up of patients with 
negative tests was stated 2-6;9;10. Therefore, four studies were included in the primary analysis, 
three studies investigating diagnostic testing in patients with a clinical suspicion of DVT 
and one study investigating diagnostic testing in patients with a clinical suspicion of PE11-14. 
As there were so few studies, each study is briefly discussed.
Table 1
Excluded studies 
Ref Test(s) used Patients Nr of 
patients
no DVT/PE Duration of follow-up and nr. of events in 
patients with normal tests
(1) Venography, plethysmography, 
thermography











(3) Venography Suspicion of DVT 29 17 not described
(4) CUS Suspicion of DVT 28 21 not described
(5) Doppler US Suspicion of VTE 58 4 not described
(6) Venography + color Doppler 
ultrasound
Suspicion of VTE 59 9 not described
(7) Duplex, Venography or autopsy Confirmed DVT or PE 32 0 not described
(8) Doppler, IPG, venography, CT/MRI, 
VQ, PA
Confirmed DVT or PE 165 0 not described
(9) MRI Suspicion of Iliac thrombosis 10 7 not described, no VTE
(10) VQ scintigraphy Suspicion of PE 82 64 median 25 months (range 3-60 months), 
2 events with IP VQ scan
CUS: Compression UltraSound, DVT: Deep Vein Thrombosis, IP: intermediate probability, IPG: Impedance 
Plethysmography, MRI: Magnetic Resonance Imaging, PE: Pulmonary Embolism, US: UltraSound, VQ: (ventila-
tion) perfusion lung scintigraphy, VTE: Venous Thrombo-Embolism 
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Studies investigating diagnostic testing for a clinical suspicion of DVT in 
pregnancy
Two studies evaluated the clinical validity of negative results by serial IPG in pregnant 
patients with a clinical suspicion of DVT11;12. In the study of Hull et al, patients had serial 
testing on the day of presentation and days 3, 5 or 7, 10 and 14 when IPG remained 
normal12. Of 152 patients, 139 had normal results on serial IPG and none had VTE 
during follow-up (3 months postpartum, 0%; 95% confidence interval (CI), 0-2.6%). In 
the second study, of 77 obstetric patients (47 pregnant, 30 postpartum) with suspected 
DVT, 45 had normal serial IPG and none had VTE during a 6-month follow-up period 
(0%; 95%CI, 0-6%)11. 
One pilot study evaluated CUS in the diagnosis of DVT in pregnancy13. Two hypotheses 
were tested: 1) a normal CUS on the day of presentation combined with a normal 
SimpliRed D-dimer (SRDD) test and 2) an abnormal SRDD at presentation but with 
normal serial CUS would both reliably exclude DVT in symptomatic pregnant women. 
Based on the initial CUS and SRDD result, women were categorized into one of four 
groups and managed accordingly; 1) CUS normal, SRDD normal; clinical follow up 
until 6 weeks postpartum; 2) CUS normal, SRDD abnormal; CUS was repeated 3 and 7 
days later and those with normal serial CUS were followed until 6 weeks postpartum; 3) 
CUS equivocal; venography was performed; 4) CUS positive; DVT was diagnosed. Of 
53 included patients, 7 were diagnosed with DVT (13%, 95%CI: 5.5-25.3%). Group 1 
comprised 31 patients and none of them developed objectively diagnosed VTE during 
follow-up (0%, 95%CI: 0-9.2%). Four of the 18 women in group 2 were diagnosed with 
DVT on serial CUS and of the remaining 14 patients, none developed VTE during follow-
up (0%, 95%CI: 0.7-26.8%). The authors conclude that a normal CUS at presentation 
combined with a normal SRDD or an abnormal SRDD combined with normal serial 
CUS appears to safely exclude DVT in pregnant patients, but larger confirmatory studies 
are needed. 
Based upon the results of our systematic review of published studies investigating 
diagnostic testing for a clinical suspicion of DVT, there is clearly a huge need for large 
prospective studies evaluating currently available and new tests for the diagnosis of DVT 
in pregnant women. Unfortunately, 2 of 3 studies involved evaluation of IPG, a test that 
is no longer performed. The use of CUS with or without D-dimer testing merits further 
evaluation. 
Studies investigating diagnostic testing for a clinical suspicion of PE in pregnancy
Chan et al. retrospectively studied the distribution of lung scan results and safety of 
withholding anticoagulation therapy following a normal or non-diagnostic scan in 
pregnant women14. Eight of 121 cases (6.6%) were already receiving treatment for venous 
thromboembolism prior to VQ scanning. In the remaining 113, 83 (73.5%) scans were 
interpreted as normal, 28 (24.8%) as non-diagnostic and 2 (1.8%) as high probability. In 
the 104 women who did not receive anticoagulation therapy following lung scanning (80 
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normal and 24 non-diagnostic), no venous thromboembolic events were reported during 
a mean follow-up period of over 20 months (0%, 95%CI: 0.0-1.0%). The authors conclude 
that the prevalence of high-probability VQ scans in pregnant women with suspected PE 
is very low. Withholding anticoagulation in pregnant women with normal perfusion scans 
is safe. Unfortunately, the small number of patients with non-diagnostic VQ scans and the 
fact that in non-pregnant patients, as many as 25% of patients with such scans have PE, 
do not allow us to conclude that PE can be excluded in a pregnant women with a non-
diagnostic scan. Large prospective studies are needed to evaluate diagnostic strategies for 
pregnant women with suspected PE.
Based on the results of our systematic analysis of studies investigating diagnostic tests for 
a clinical suspicion of DVT or PE in pregnancy, there is dire need for properly designed 
studies of pregnant women with suspected DVT or PE. Consequently, the following 
recommendations for clinical practice regarding the diagnostic approach of a pregnant 
patient with a clinical suspicion of DVT or PE are partly driven by the personal opinion 
of the authors.
Recommended diagnostic testing of a clinical suspicion of deep vein throm-
bosis in a pregnant patient
Although there are no large, prospective studies evaluating CUS in pregnant patients for a 
clinical suspicion of DVT, there is no biologic reason why a clearly abnormal CUS wouldn’t 
make a firm diagnosis of DVT. Therefore, compression ultrasonography should be performed 
as a first test in a pregnant patient with a clinical suspicion of DVT (Figure 1). Patients with 
an abnormal CUS, defined as a non-compressible segment of the popliteal or a more proximal 
vein can be diagnosed with DVT and should be treated appropriately with unfractionated or 
low molecular weight heparin. However, a normal CUS might not be as safe reassuring in non-
pregnant patients since isolated iliac DVT is thought to be more common in pregnant than in 
non-pregnant patients and such thrombi are difficult to detect by CUS. Patients with a normal 
CUS should undergo serial CUS testing after day 6-8, or sooner – days 2 to 3 - when clinical 
suspicion is strong, to detect proximal extension of distal thrombi. If CUS becomes abnormal, 
DVT can be diagnosed. If doubt about the presence of DVT persists, limited venography 
with abdominal shielding should be considered. The amount of fetal radiation exposure with 
venography and abdominal shielding is less than 0.5 mSv (Table 2)15. This amount is much 
lower than the threshold dose for induction of malignancies (100 mSv) and justifies the use 
of diagnostic testing involving radiation in pregnancy for the exclusion of potentially fatal 
VTE16;17. If iliac or pelvic vein thrombosis is suspected, duplex Doppler ultrasound or full 
venography can be performed. In centres with availability of, and experience with MRI, MR 
venography is a reasonable alternative test to venography in demonstrating iliac or pelvic vein 
thrombosis. However, the safety of excluding DVT when MR venography is normal has not 
been demonstrated. The roles of pre-test probability assessment and D-dimer testing in the 
diagnosis of suspected DVT in pregnancy have yet to be defined.  
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Clinical suspicion of iliac vein thrombosis? DVT diagnosed
Yes No
Consider duplex Doppler serial CUS
flow present absent flow abnormal normal
no duplex
available
Consider venography DVT diagnosed DVT absent
or MRI
Legend
DVT: Deep Vein Thrombosis, CUS: Compression UltraSonography, MRI: Magnetic Resonance Imaging
Figure 1
Algorithm for a clinical suspicion of DVT in pregnancy
DVT: Deep Vein Thrombosis, CUS: Compression UltraSonography, MRI: Magnetic Resonance Imaging
Table 2
Radiation dose to the fetus by radiological examination
Diagnostic test Radiation (mSv)
Unilateral venography without shielding 3.14
Unilateral venography with shielding < 0.5
Pulmonary angiography via femoral route 2.21-3.74
Pulmonary angiography via brachial route < 0.5
Perfusion scintigraphy(99mTc MAA, 200 MBq) 0.2-0.6
Perfusion scintigraphy (99mTc MAA, 40 MBq) 0·11-0·20
Ventilation scintigraphy (99mTc aerosol) 0.1-0.3
Ventilation scintigraphy (81mKr, 600MBq) 0·0001
Single-detector row helical CT 0·026
Multi-detector row helical CT 0·013
Estimates of radiation exposure are derived from McMaster University and University Medical Centre 
Leiden(15,17) 
To convert mSv to rads: 1 mSv ∼ 0,1 rad.    
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Recommended diagnostic testing of a clinical suspicion of pulmonary embo-
lism in a pregnant patient
High quality evidence from prospective studies of the safety of ruling out PE by VQ 
scintigraphy or CT scan is lacking. Although there are no strong reasons to believe 
that VQ scintigraphy and CT scan results should be interpreted differently in pregnant 
compared to non-pregnant patients, there is a theoretical possibility of compression of 
the lung bases by the uterus in late pregnancy that may result in an abnormal VQ scan, 
the evidence of which however is lacking. Therefore, when confronted with a clinical 
suspicion of PE in a pregnant patient, one should start with VQ scan, a helical CT, or 
bilateral CUS, depending on local availability and expertise (Figure 2). Helical CT has 
the advantage of low fetal radiation exposure (Table 2), a low number of non-diagnostic 
results and the ability to make an alternative diagnosis that can explain the patient’s 
complaints. The visualisation of an arterial filling defect is diagnostic for PE.  The safety 
of using helical CT as a stand-alone test has been argued18. Two studies have shown DVT 
on CUS in 6 to 8% of (non-pregnant) patients with a suspicion of PE despite a negative 
helical CT19;20. These results contrast with another study in which CUS revealed DVT 
in only 2 of 378 (0.5%) patients with no PE on helical CT21. This discrepancy might be 
explained by the timing of CUS; in the first two studies CUS was performed before or 
concomitant with helical CT while in the latter study, CUS was performed after helical 
CT revealed no PE. 
Ventilation-perfusion scintigraphy is to be considered a first line diagnostic test and 
rules out the diagnosis of PE when the result of the perfusion scan is normal. When a 
high probability scan is obtained, the diagnosis of PE can be considered confirmed. All 
other abnormal VQ-scan results are non-diagnostic and the diagnosis of PE needs to be 
confirmed or excluded by additional testing with a hCT scan or alternatively shielded 
pulmonary angiography. Ultrasonography can be used as a first line test to demonstrate 
DVT or as an additional test when VQ scanning is non-diagnostic. When CUS 
demonstrates DVT, further testing is not necessary and the patient can be considered 
to have a VTE. A normal CUS is always to be followed by additional tests to rule out 
PE. The roles of pre-test probability assessment and D-dimer testing in the diagnosis of 
suspected PE in pregnancy have yet to be defined.  
Future perspectives
Although guidelines can be given for objective DVT and PE diagnosis in pregnant patients, 
there is a clear need for prospective studies. Two large prospective management studies in 
the diagnosis of pulmonary embolism in pregnancy have been started recently. In the first 
study in Canada a decision tree with clinical risk factors, CUS and VQ-scanning is being 
evaluated. In another study in the Netherlands helical CT as a first line and sole test for 
the diagnosis of PE is evaluated by studying the safety of withholding anticoagulants in 
pregnant women with clinically suspected PE and a normal CT-scan.
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Figure 2 Algorithms for a clinical suspicion of PE in pregnancy
Suspected PE Suspected PE
hCT VQ scan
PE Normal/Alt. Inconclusive High Probability Non-diagnostic* Normal
PE diagnosed No PE Consider repeat hCT, PE diagnosed PE excluded
VQ-scan or PA
bilateral CUS
DVT present DVT absent
diagnose DVT hCT
and clinical PE (see diagram hCT)
Legenda
PE: Pulmonary Embolism, hCT: helical Computed Tomography, VQ scan: VentilationPerfusion scan, PA:
Pulmonary Angiography, CUS: Compression UltraSonography, DVT: Deep Vein Thrombosis, *Non-diagnostic=
no high-probability and no normal result on VQ scan.
Figure 2
Algorithms for a clinical suspicion of PE in pregnancy
PE: Pulmonary Embolism, hCT: helical Computed Tomography, VQ scan: VentilationPerfusion scan, PA: Pulmonary Angiography, CUS: Compression UltraSo-
nography, DVT: Deep Vein Thrombosis, *Non-diagnostic=
no high-probability and no n rmal result on VQ scan.
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Pulmonary embolism is a potentially fatal disease in which early recognition and institution 
of anticoagulant treatment can prevent mortality. The diagnostic tools available to establish 
whether a patient has a pulmonary embolism were limited to pulmonary angiography and 
ventilation-perfusion scintigraphy. Both tests have considerable limitations. Helical CT 
evolved as a new technique in diagnosing PE and gained widespread interest but has been 
implemented rapidly, without appropriate assessment in clinical practice. Two accuracy 
studies, comparing helical CT to the golden standard pulmonary angiography, showed a 
disappointing sensitivity of only 70%, but management studies showed a 3-month thrombo-
embolic failure rate (the risk of developing DVT or PE despite negative tests) of less than 
2% after a negative helical CT combined with other techniques. These diagnostic algorithms 
were usually complicated and therefore not easily implemented in clinical practice. 
The Christopher-study was performed to investigate whether a dichotomization of the Wells 
clinical decision rule, classifying patients into ‘PE unlikely’ and ‘PE likely’ in combination 
with a D-dimer test is safe to rule out pulmonary embolism in patients with a clinical 
suspicion. Furthermore, the study was designed to investigate whether helical CT is safe to 
rule out PE without performing any additional diagnostic tests. 
In Chapter 3, the results of this prospective management-study are described in 3306 
consecutive patients suspected of PE. The Wells clinical decision rule classified patients as 
‘PE unlikely’ in 2206 (66.7%) of patients. These patients underwent D-dimer testing and 
1057 (32.0%) had a negative D-dimer result (≤500 ng/ml). PE was considered excluded 
in these patients. All other patients, i.e. those classified as ‘PE likely’ or those classified as 
‘PE unlikely’ but with an abnormal D-dimer test, underwent helical CT. PE was diagnosed 
in 674 (20.4%) patients and these were consequently treated with anticoagulants. In 1505 
patients (45.5%), CT excluded PE. In 50 patients (1.5%) the protocol was violated and 
CT was not performed and in 20 (0.9%) patients the CT was inconclusive. Hence, the 
diagnostic algorithm could be completed according to the protocol in 3256 (98.5%) patients 
and allowed a management decision in 3236 patients (97.9%). In patients in whom PE was 
excluded by a clinical decision rule indicating ‘PE unlikely’ combined with a negative D-
dimer and were not treated with anticoagulants, during three months of follow-up venous 
thrombo-embolism was diagnosed in 5 out of 1028 untreated patients (0.5%, 95%CI: 0.2-
1.1). In patients in whom CT had ruled out PE and were not treated with anticoagulants 
during three months follow-up 18 of 1446 untreated patients experienced a venous thrombo-
embolic event (1.3%, 95%CI: 0.7-2.0). In conclusion, the Christopher-study demonstrates 
that a simple diagnostic algorithm consisting of a dichotomised clinical decision rule, D-
dimer and helical CT can guide treatment decisions with a low risk of subsequent venous 
thrombo-embolism.  
Chapter 4 discusses whether varying the cut-off level of the clinical decision rule as well as the 
cut-off level of the D-dimer test could lead to an increase in clinical utility (i.e. the proportion 
of patients in whom the diagnosis of PE can be safely excluded without additional imaging 
tests) without jeopardizing safety. For each increment of clinical decision rule and D-dimer 









cut-off point, the number of patients with PE at baseline or during follow-up, the clinical 
utility and the 3-month thrombo-embolic failure rate were recalculated. By increasing the 
cut-off level of the clinical decision rule from 4 to 5 points, pulmonary embolism could be 
ruled out in an additional 4% of the study population (from 29.3 to 33.3%) at an expense 
of an increased three-month thrombo-embolic failure rate of 1.5% (95%CI: 0.6-3.0%) in 
comparison to 0.9% (95%CI: 0.3-2.4) for patients who had a clinical decision rule cut off at 
4 points. By increasing the D-dimer cut-off level from 500 to 600 ng/ml, PE could be ruled 
out in an additional 3% (from 29.3% to 32.3%) of the study population but the three-month 
thrombo-embolic failure rate increased 0.9 (95%CI: 0.3-2.4) to 2.2% (95%CI: 1.1-4.0). This 
sub-study concluded that at the prevalence of 29.3%, the cut-off level of the clinical decision 
rule as well as the cut-off level of the D-dimer test should be kept at the original 4 points 
and 500 ng/ml respectively, in order to prevent exposure of patients to a 3-month thrombo-
embolic failure rate exceeding that of a normal pulmonary angiography.
The anatomic distribution of pulmonary embolism in central, segmental and sub-segmental 
arteries is understudied and an often-debated issue is the possible limitation of computed 
tomography to accurately detect peripheral emboli. Multi-detector row CT is thought to 
increase the detection rate of sub-segmental emboli compared to single-detector row CT. 
In Chapter 5, we evaluate the prevalence and anatomic distribution of PE in consecutive 
patients with proven PE diagnosed by MDCT or SDCT. The location of PE was classified 
into three groups (central, segmental and sub-segmental PE) with emphasis on the largest 
pulmonary arterial branch involved. A total of 3306 consecutive patients were included 
in the diagnostic study, of whom 674 (20%) were diagnosed with PE. Data regarding the 
localisation of PE were missing in 41 patients. Localisation of PE in MDCT was central 
in 160 patients (29%, 95%CI: 25-33), segmental in 293 patients (53%, 95%CI: 49-57) and 
sub-segmental in 98 patients (18%, 95%CI: 15-21). In patients diagnosed with SDCT, PE 
was central in 31 patients (38%, 95%CI: 27-49), segmental in 39 patients (48%, 95%CI: 
36-59) and sub-segmental in 12 patients (15%, 95%CI: 8-24). The percentage of detected 
PE did not differ significantly between MDCT and SDCT (31% vs. 32%, p=0.65), neither 
the percentage of sub-segmental PE (18% vs. 15%, p=0.48) detected by MDCT or SDCT. 
In conclusion, based on these data there seems to be no danger of over-diagnosis of small 
subsegmental PE using multi-detector row systems. 
In Chapter 6, the natural course of patients diagnosed with PE is described in terms of 
incidence of recurrent venous thrombo-embolism, bleeding and mortality. Moreover, risk 
factors for these events were identified as well as the time course of these events. Of 673 
patients with complete follow-up, 20 patients (3.0%, 95%CI: 1.8-4.6) had recurrent VTE. 
Eleven of 14 patients with recurrent PE had a fatal PE (79%, 95%CI: 49-95%), occurring 
mostly in the first week after diagnosis of initial PE. In 23 patients (3.4%, 95%CI: 2.2-5.1) a 
hemorrhagic complication occurred of whom 10 were major bleeds (1.5%, 95%CI: 0.7-2.7) 
and two were fatal (0.3%, 95%CI: 0.04-1.1). During the three-month follow-up, 55 patients 
died (8.2%, 95%CI: 6.2-10.5). Risk factors for recurrent VTE were immobilisation for more 
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than 3 days, while being an inpatient, having COPD or malignancies were risk factors 
for bleeding. Age, immobilisation, malignancy and being an inpatient were risk factors for 
mortality. In conclusion, recurrent VTE occurred despite anticoagulant therapy in 3 % of 
patients with PE and the majority of recurrent PE’s (79%) were fatal. Also, patients with 
PE have a high mortality rate, 8.2% during three months of follow-up. Immobilization, 
hospitalization, age, COPD and malignancies were risk factors for complications of PE. 
Close monitoring may be indicated in these patients, precluding them from out of hospital 
start of treatment. 
It is unknown whether strategies validated for diagnosing pulmonary embolism are valid 
in patients with a history of PE. Chapter 7 describes whether the Christopher-algorithm, 
consisting of sequential application of a clinical decision rule (CDR), a quantitative D-
dimer test and helical computed tomography, could safely rule out a clinical suspicion of 
recurrent PE. All patients of the Christopher-study who had a history of PE were included 
in this sub-study. Recurrent PE was ruled out by an unlikely probability of PE (CDR score 
≤ 4 points) combined with a normal D-dimer test (≤500 ng/ml) or by a normal CT in 
all other patients. The primary outcome was the incidence of recurrent venous thrombo-
embolism during three months of follow-up in patients with normal tests and not treated 
with anticoagulants. Of 3306 patients suspected of PE, 259 patients (7.8%) had a history 
of PE. Of these, 25 (9.7%) were treated with anticoagulants and excluded. The probability 
of PE was unlikely in 82 of 234 patients (35%) and 42 had a normal D-dimer test (18%), 
excluding recurrent PE. None of these patients had a venous thrombotic event during 
follow-up (0%, 95%CI: 0-6.9). A CT was indicated in all other patients (n=192) and ruled 
out recurrent PE in 127 patients (54%). One patient had a fatal recurrent PE during follow-
up (0.8%; 95%CI: 0.02-4.3). This is the first prospective study that demonstrated the safety 
of ruling out a clinical suspicion of recurrent PE by a simple diagnostic algorithm in patients 
with a history of PE.  
Much attention has been paid in recent years to optimizing the diagnosis of acute pulmonary 
embolism. However, little is known about the changes in clot burden that occur at the 
level of the pulmonary arteries after documented PE. It is often problematic to distinguish 
between a new or residual defect on lung scintigraphy or helical computed tomography. 
This may lead to falsely labeling patients with residual PE as having recurrent PE and 
consequent unnecessary treatment changes. 
In Chapter 8 a systematic analysis is shown of studies of imaging tests (radionuclide and 
computerized tomography) evaluating resolution rate of PE with independent assessment 
of predefined methodological criteria by two investigators. We identified 29 clinical studies. 
Of these, 25 were excluded and 4 studies were included in our review.. The percentage of 
patients with residual pulmonary thrombi was 87% at eight days after diagnosis, 68% after six 
weeks, 65% after three months, 57% after six months and 52% after 11 months. No definite 
conclusions can be made on the resolution of PE beyond 11 months after diagnosis. 









This review shows that complete resolution of PE is not routinely achieved between 8 days 
and 11 months after diagnosis. More than 50% of patients with PE still have defects six 
months after diagnosis, after which resolution of thrombi appears to reach a plateau phase. 
In pregnancy, the diagnosis of pulmonary embolism is problematic. There is doubt as to 
whether objective diagnostic tests are needed and confusion as to what objective test is the 
safest with respect to fetal radiation exposure. However, pulmonary embolism is still one of 
the leading causes of maternal mortality and it is critically important to objectively diagnose 
pulmonary embolism since a clinical diagnosis is notoriously inaccurate. However, physicians 
are reluctant to perform helical CT in pregnant women because it is assumed that helical 
CT exposes the fetus to a higher radiation dose than VQ scintigraphy. In Chapter 9 we 
describe the results of a calculation of fetal radiation dose by helical CT and compare these 
to VQ scintigraphy. Our calculation of fetal radiation dose in helical CT was based on the 
assumption that radiation dose to the uterus is a good approximation of the radiation dose 
to the fetus in early pregnancy. This early period is the most important period since the fetus 
is considered to be most vulnerable to radiation exposure. The calculated dose of radiation 
absorbed by the fetus for a single-detector row helical CT was 0·026 mSv. An even lower 
dose (0·013 mSv) was calculated for the multi-detector row helical CT. In comparison, the 
calculated dose of fetal radiation with perfusion scintigraphy was 0·11-0·20 mSv. 
Diagnosing deep vein thrombosis and pulmonary embolism in pregnancy is challenging. Many 
of the common diagnostic tests, including compression ultrasonography (CUS), ventilation-
perfusion scintigraphy and helical computed tomography that have been extensively 
investigated in non-pregnant patients, have not been appropriately validated in pregnancy. 
Extrapolating results of diagnostic studies of DVT and PE in non-pregnant patients to 
those who are pregnant may not be correct because of differences in pathophysiology and 
presentation of DVT and PE in pregnancy. In Chapter 10 a systematic analysis is shown of 
published studies addressing diagnostic testing for DVT and PE in pregnancy to determine 
the accuracy of these tests in pregnancy. According to our predefined inclusion criteria, 
only four studies remained for inclusion, three studies investigating diagnostic testing in 
patients with a clinical suspicion of DVT and one study in patients with a clinical suspicion 
of PE. From our systematic analysis of published studies investigating diagnostic testing for 
a clinical suspicion of DVT or PE in pregnancy we conclude that; 1) two studies support 
withholding anticoagulant therapy in pregnant women with a clinical suspicion of DVT 
and normal results on serial IPG (impedance plethysmography), however, IPG is no longer 
used; 2) only one study demonstrated that a normal CUS at presentation combined with 
a normal D-dimer test or an abnormal D-dimer test combined with normal serial CUS 
appears promising for safely excluding DVT in pregnant patients, but too few patients 
were included in this pilot-study to draw firm conclusions; 3) only one study investigated 
pregnant patients with a clinical suspicion of PE and this study concluded that in case of 
normal or non-diagnostic VQ scans, withholding anticoagulant therapy might be safe, but 
this needs confirmation in larger studies. 




The Christopher-study demonstrates that a simple diagnostic algorithm consisting of a 
dichotomised clinical decision rule according to Wells, D-dimer test and helical CT is 
safe in excluding pulmonary embolism with a low risk of subsequent venous thrombo-
embolism. In one-third of the study population, PE could be ruled out without using 
imaging tests. In all other patients, a helical CT demonstrating no PE turned out to be 
safe in excluding PE without performing additional tests. Furthermore, the algorithm of 
the Christopher-study is easily implemented in daily clinical practice since 98% of the 
patients could be managed according to our protocol. In order to prevent exposure of 
patients to a 3-month thrombo-embolic failure rate exceeding that of a normal pulmonary 
angiography, the cut-off level of the clinical decision rule as well as the cut-off level of 
the D-dimer test should be strictly adhered to at the original 4 points and 500 ng/ml 
respectively. As regards to the type of CT-scanner, i.e. multi- or single-detector row CT, 
we did not find a significant difference in the percentage of detected PE between MDCT 
and SDCT, neither in the percentage of sub-segmental PE. Based on these data, there 
seems to be no danger of over-diagnosis of small subsegmental PE using multi-detector 
row systems. 
In patients diagnosed with PE and treated with anticoagulants, recurrent VTE occurred 
despite anticoagulant therapy in a small percentage of patients and the majority of recurrent 
PE’s were fatal, occurring mostly in the first week after diagnosis of PE. Also, patients 
with PE have a high mortality rate during three months of follow-up. Immobilization, 
hospitalization, age, COPD and malignancies were risk factors for complications of PE, 
i.e. recurrent venous thrombo-embolic events, bleeding or mortality. Close monitoring may 
be indicated in these patients, precluding them from out of hospital start of treatment.
In patients with a clinical suspicion of recurrent PE, the Christopher-design appeared 
to rule out recurrent PE safely, although confidence limits of the three-month thrombo-
embolic risk were rather wide and do not permit to conclude that our approach is as 
safe as pulmonary angiography. The proportion of patients with a clinical suspicion of 
recurrent PE that could be ruled out without using imaging tests was one-fifth compared 
to one-third in patients without a history of PE. The less discriminative power of the 
clinical decision rule in patients with a history of PE is due to the item “history of VTE” 
on which all patients score 1.5 points. 
A complicating factor in diagnosing recurrent PE, is that it is currently unknown 
whether pulmonary emboli resolve completely. There seems to be a wide variation in 
resolution of thrombi in individual patients and the pathophysiologic mechanisms and 
clinical consequences remain largely unknown. Physicians should be aware that complete 
resolution of pulmonary thrombi may not be achieved and it may complicate the objective 
and accurate diagnosis of recurrent PE.  
Another group of patients that need major concern in diagnosing pulmonary embolism 
are pregnant patients. Despite the fact that pulmonary embolism is still one of the leading 
causes of maternal mortality, there’s a major lack of evidence concerning the accuracy 









of diagnostic tests in pregnant women. One complicating factor is fear of radiation 
exposure. Based on our calculation with a computerized model, taking into account 
certain assumptions, we conclude that helical CT exposes the fetus to less radiation than 
perfusion scintigraphy. The main issue following in-utero exposure at typical diagnostic 
levels of radiation is induction of malignancies with a number of excess malignancies 
cases up to age 15 years following in-utero exposure is considered to be 1 in 16.000 per 
mSv. Fear of radiation exposure is therefore not an argument to withhold objective tests 
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Een longembolie is een potentieel fatale aandoening waarbij vroege herkenning en 
het starten van behandeling met anticoagulantia mortaliteit kan doen voorkomen. De 
diagnostische testen die beschikbaar zijn om aan te tonen dat een patiënt een longembolie 
heeft waren tot voor kort beperkt tot pulmonalis angiografie en ventilatie-perfusie 
scintigrafie. Beide testen hebben aanzienlijke beperkingen. Spiraal CT is opgekomen 
als een nieuwe techniek in het diagnosticeren van longembolieën en heeft een brede 
belangstelling verkregen maar is echter snel in de praktijk geïmplementeerd zonder een 
adequate evaluatie. Twee studies hebben de accuraatheid van spiraal CT vergeleken met 
die van de gouden standaard, de pulmonalis angiografie. Zij lieten een teleurstellende 
sensitiviteit van slechts 70% zien. Echter, management studies toonden dat de kans op het 
alsnog krijgen van een DVT of longembolie ondanks negatieve testen, minder dan 2% is 
gedurende drie maanden follow-up na een normale spiraal CT gecombineerd met andere 
technieken. Deze diagnostische algoritmes zijn veelal gecompliceerd en daardoor moeilijk 
te implementeren in de dagelijkse klinische praktijk. Dit heeft geleid tot het ontstaan van 
de Christopher-studie.  
De Christopher-studie is uitgevoerd om te onderzoeken of een dichotomisatie van de klinische 
beslisregel volgens Wells, die patiënten classificeert in ‘longembolie onwaarschijnlijk’ en 
‘longembolie waarschijnlijk’, in combinatie met een D-dimeer test, veilig is in het uitsluiten 
van de diagnose longembolie bij patiënten met een klinische verdenking. Daarnaast is de 
studie ontworpen om te onderzoeken of spiraal CT veilig is in het uitsluiten van de diagnose 
longembolie zonder het verrichten van additionele diagnostische testen. 
In Hoofdstuk 3 zijn de resultaten van deze prospectieve management studie beschreven 
bij 3306 opeenvolgende patiënten. De klinische beslisregel volgens Wells classificeerde 
patiënten als ‘longembolie onwaarschijnlijk’ in 2206 (66.7%) van de patiënten. Deze 
patiënten ondergingen een D-dimeer test en 1057 (32.0%) patiënten hadden een negatief 
resultaat (≤500 ng/ml). De diagnose longembolie werd uitgesloten geacht bij deze 
patiënten. Alle andere patiënten, die geclassificeerd waren als ‘longembolie waarschijnlijk’ 
of die geclassificeerd waren als ‘longembolie onwaarschijnlijk’ maar met een abnormale 
D-dimeer test, ondergingen spiraal CT. De diagnose longembolie werd gesteld bij 674 
(20.4%) patiënten en zij werden vervolgens behandeld met anticoagulantia. In 1505 
patiënten (45.5%) sloot CT de diagnose longembolie uit. In 50 patiënten (1.5%) was er 
sprake van een protocol violation en CT werd niet verricht. In 20 (0.9%) patiënten bleek de 
CT inconclusief en kon de diagnose longembolie niet worden gesteld of verworpen. Het 
diagnostisch algoritme kon volgens protocol worden gevolgd in 3256 (98.5%) patiënten 
en leidde tot een management beslissing bij 3236 patiënten (97.9%). 
Van alle 1028 patiënten waarbij een longembolie was uitgesloten middels een klinische 
beslisregel ‘longembolie onwaarschijnlijk’ gecombineerd met een normale D-dimeer test en 
die niet werden behandeld met anticoagulantia, werden 5 patiënten alsnog gediagnosticeerd 
met een veneuze trombose gedurende de follow-up van drie maanden (0.5%, 95%CI: 0.2-
1.1). Van alle patiënten waarbij een CT scan de diagnose longembolie had uitgesloten en 
die niet werden behandeld met anticoagulantia, kregen 18 patiënten van de 1446 alsnog 










een veneuze trombose gedurende de drie maanden follow-up (1.3%, 95%CI: 0.7-2.0). 
Concluderend, de Christopher-studie toont aan dat een simpel diagnostisch algoritme 
bestaand uit een gedichotomiseerde klinische beslisregel, D-dimeer test en spiraal CT, 
veilig en efficiënt is in het uitsluiten van de diagnose longembolie met een lage kans op 
het alsnog ontstaan van een veneuze trombose in de drie volgende maanden.   
Bij de huidige afkappunten van de klinische beslisregel (kleiner of gelijk aan 4) en de D-
dimeer test (≤500 ng/ml) kan bij 32% van alle patiënten de diagnose longembolie worden 
uitgesloten zonder het verrichten van beeldvormende diagnostiek. In hoofdstuk 4 wordt 
beschreven of door het variëren van de afkappunten van de klinische beslisregel en de D-
dimeer test, er meer patiënten beeldvormende diagnostiek kan worden onthouden zonder 
daarbij de veiligheid op het spel te zetten. Indien het afkappunt van de klinische beslisregel 
van 4 naar 5 punten werd opgehoogd, kon de diagnose longembolie bij een additionele 
4% van alle patiënten worden uitgesloten, echter ten koste van een verminderde veiligheid 
(1.5% kans op veneuze trombose tegenover 0.9% bij een afkappunt van 4). Door het 
ophogen van het afkappunt van de D-dimeer test van 500 naar 600 ng/ml, kon in een 
additionele 3% van alle patiënten de diagnose longembolie worden uitgesloten tegenover 
een verhoogde kans op het krijgen van alsnog een veneuze trombose gedurende de volgende 
drie maanden (2.2% ipv 0.9%). Als veiligheidsgrens wordt aangehouden de bovenste limiet 
van het 95% betrouwbaarheidsinterval van een normale pulmonalis angiografie (=2.7%). 
Om patiënten niet bloot te stellen aan een groter veiligheidsrisico dan bij een normale 
pulmonalis angiografie, dienen de afkappunten van zowel de klinische beslisregel als de 
D-dimeer test te worden gehandhaafd op respectievelijk 4 punten en 500 ng/ml. 
Een vaak terugkerend debat is de mogelijke beperking van CT om accuraat perifere, kleine 
embolieën te detecteren. Multi-detector row CT zou beter subsegmentele longembolieën 
kunnen detecteren in vergelijking met single-detector row CT. Echter,  of deze kleine 
embolieën klinisch relevant zijn, en dus behandeld moeten worden is vooralsnog 
onbekend. Hoofdstuk 5 beschrijft de prevalentie en anatomische distributie van 
longembolieën bij patiënten die MDCT of SDCT hebben ondergaan. De lokalisatie van 
de longembolie bij patiënten die MDCT ondergingen was centraal in 29%, segmentaal in 
53% en subsegmentaal in 18%. Bij patiënten die SDCT ondergingen was de longembolie 
lokalisatie centraal in 38%, segmentaal in 48% en subsegmentaal in 15%. Het percentage 
gedetecteerde longembolieën (31% vs. 32%, p=0.65), en het percentage subsegmentele 
longembolieen (18% vs. 15%, p=0.48) was niet significant verschillend tussen MDCT 
en SDCT. Hiermee lijkt er geen gevaar te bestaan dat MDCT kleine subsegmentele 
longembolieën overdiagnosticeert. 
In Hoofdstuk 6 wordt het natuurlijk beloop gedurende drie maanden van patiënten 
waarbij de diagnose longembolie is gesteld, beschreven. Van 673 patiënten ontwikkelden 
20 patiënten (3.0%, 95%CI: 1.8-4.6) een recidief trombose tijdens behandeling met 
anticoagulantia (14 longembolie, 6 DVT). Van de 14 patiënten met een recidief 
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longembolie, bleken 11 fataal (79%, 95%CI: 49-95%), meestal optredend in de eerste 
week na de initiële diagnose longembolie. In 23 patiënten (3.4%, 95%CI: 2.2-5.1) trad een 
bloedings-complicatie op waarvan 10 werden geclassificeerd als belangrijk (1.5%, 95%CI: 
0.7-2.7) en twee fatale bloedingen (0.3%, 95%CI: 0.04-1.1). De all-cause mortaliteit 
gedurende drie maanden follow-up was 8.2%. Risicofactoren voor een complicatie 
(recidief trombose, bloeding of mortaliteit) waren immobilisatie langer dan drie dagen, 
hogere leeftijd, hospitalisatie, COPD en maligniteiten. Het nauwgezet monitoren van 
deze patiënten is mogelijk geïndiceerd, waarbij deze patiënten niet in aanmerkingen 
komen voor thuisbehandeling. 
Het is onbekend of strategieën die gevalideerd zijn voor het uitsluiten van longembolieën 
ook veilig zijn bij patiënten met een voorgeschiedenis van longembolieën. Hoofdstuk 7 
beschrijft de resultaten van de Christopher-studie bij patiënten met een eerdere longembolie. 
Een recidief longembolie was uitgesloten geacht bij patiënten met een klinische beslisregel 
‘longembolie onwaarschijnlijk’in combinatie met een normale D-dimeer test, of, in alle 
andere gevallen, door een normale spiraal CT. Van alle 3306 patienten geincludeerd in de 
Christopher-studie, hadden 259 patiënten (7.8%) al eerder een longembolie gehad. Hiervan 
werden 25 (9.7%) behandeld met anticoagulantia en daarom geëxcludeerd. Een longembolie 
was onwaarschijnlijk volgens de klinische beslisregel in 82 van de 234 patiënten (35%) 
en hiervan hadden 42 een normale D-dimeer test (18%), waardoor de diagnose recidief 
longembolie kon worden uitgesloten. Geen van deze patiënten ontwikkelde een veneuze 
trombose in de drie maanden follow-up (0%, 95%CI: 0-6.9). Alle andere 192 patiënten 
ondergingen een spiraal CT, die een recidief longembolie uitsloot in 127 patiënten (54%). 
Eén patiënt uit deze groep had een fataal recidief longembolie tijdens de follow-up (0.8%; 
95%CI: 0.02-4.3). Dit is de eerste prospectieve studie die aantoont dat ook bij patiënten 
met een eerdere longembolie, het diagnostisch algoritme waarschijnlijk veilig kan worden 
gebruikt in het uitsluiten van een recidief longembolie.   
Er is veel aandacht in de laatste jaren geweest voor het optimaliseren van de diagnostiek 
naar een acute longembolie. Echter, er is weinig bekend over de veranderingen die optreden 
in de stolsels in het pulmonale vaatbed als de diagnose longembolie eenmaal is gesteld. Het 
is vaak ook problematisch om het onderscheid tussen een oude en een nieuwe trombus 
te maken. Dit zou kunnen leiden tot het misdiagnosticeren van een recidief longembolie 
terwijl er sprake is van residuale longembolie, met vervolgens onnodige behandeling met 
anticoagulantia. In Hoofdstuk 8 wordt een systematische analyse gepresenteerd van 
studies naar beelvormende diagnostiek die het aanwezig zijn van residuale stolsels na 
een diagnose longembolie hebben geëvalueerd. Van 29 gevonden studies zijn 25 volgens 
vantevoren vastgestelde criteria geëxcludeerd. Het percentage patiënten met residuale 
pulmonale trombi was 87% acht dagen na diagnose, 68% na zes weken, 65% na drie 
maanden, 57% na zes maanden en 52% na 11 maanden. Dit review toont aan dat het 
compleet oplossen van pulmonale stolsels na de diagnose longembolie niet altijd wordt 
bereikt in een tijdsbestek van 8 dagen tot 11 maanden na de diagnose longembolie. 










Een longembolie is een van de meest frequente doodsoorzaken in de zwangerschap. 
Echter, diagnostiek naar een longembolie in de zwangerschap is problematisch. Er is 
twijfel over het belang van verrichten van objectieve diagnostische testen en verwarring ten 
aanzien van welke test het meest veilig is wat betreft foetale stralingsbelasting. Aangezien 
een klinische diagnose aspecifiek is, het missen  van een longembolie potentieel fataal 
is en behandeling significante risico’s met zich mee brengt, is objectieve diagnostiek 
noodzakelijk. Artsen zijn vaak weerhoudend in het verrichten van een spiral CT in de 
zwangerschap omdat het wordt aangenomen dat een CT meer stralenbelasting oplevert 
dan een perfusiescan. In Hoofdstuk 9 beschrijven we de resultaten van een mathematisch 
model waarin de foetale stralingsbelasting wordt berekend voor zowel CT als perfusie-
scan. Hierin is gebruik gemaakt van de aanname dat stralingsbelasting op de uterus een 
goede benadering is van de stralingsbelasting van de foetus in d vroege zwangerschap. 
Juist deze vroege periode in de zwangerschap is het meest belangrijk aangezien de foetus 
het meest kwetsbaar is voor stralenbelasting. De berekende stralingsdosis voor een single-
detector row CT is 0·026 mSv en een zelfs lagere dosis voor de multi-detector row CT 
(0·013 mSv). Ter vergelijking, de foetale stralingsdosis voor een perfusiescan is 0.11-0·20 
mSv. Concluderend, in de vroege en meest kwetsbare periode van de zwangerschap is de 
foetale stralenbelasting minder met een spiraal CT dan met een perfusiescan. 
Vele van de diagnostische testen, zoals compressie echografie, ventilatie-perfusie scintigrafie 
en spiraal CT, die uitgebreid zijn gevalideerd bij niet-zwangere patiënten met een verdenking 
longembolie of DVT, zijn niet onderzocht bij zwangere patiënten. Het extrapoleren van de 
data van diagnostische studies bij niet-zwangeren naar zwangere vrouwen, zou niet correct 
kunnen zijn vanwege verschillen in pathofysiologie en presentatie van een trombosebeen 
of longembolie in de zwangerschap. Om de diagnostische accuraatheid van verschillende 
testen gebruikt ter uitsluiting van een longembolie danwel DVT in de zwangerschap 
aan te tonen, hebben we een systematische analyse verricht naar gepubliceerde studies 
over dit onderwerp (Hoofdstuk 10). Volgens vantevoren opgestelde inclusie criteria, 
kwamen slechts 4 studies in aanmerking voor inclusie. Hieruit kan worden geconcludeerd 
dat; 1) twee studies ondersteunen het niet starten van behandeling met anticoagulantia 
bij zwangere vrouwen met een klinische verdenking op een trombosebeen indien er 
normale resultaten zijn van seriële impedantie plethysmografie, echter deze techniek 
wordt hedendaags niet meer gebruikt; 2) slechts 1 studie toonde aan dat een normale 
compressie echografie gecombineerd met een normale D-dimeer test of een abnormale 
D-dimeer test gecombineerd met een normale seriële echo, veilig lijkt in het uitsluiten 
van een DVT bij zwangere vrouwen, echter er waren te weinig patiënten in de studie 
geïncludeerd om harde conclusies te trekken; 3) slechts 1 studie betrof zwangere vrouwen 
met een klinische verdenking longembolie en concludeerde dat bij een normale of niet-
diagnostische ventilatie-perfusiescan het onthouden van anticoagulantia waarschijnlijk 
veilig is, maar dat dit bevestiging vereist in grotere, prospectieve studies. 
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